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The immune system can be manipulated to recognize and eliminate cancerous 
cells. Many of these manipulations aim to increase the proliferation and activation of 
tumor-targeting cytotoxic CD8+ T cells through direct stimulation or attenuation of 
immuno-inhibitory checkpoint pathways. Here, I use nanotechnology to develop 
platforms that can enhance and/or target immuno-stimulatory properties by controlling 
the kinetics, costimulation, and nanoscale delivery of immunotherapies. 
I first developed a nanoparticle that converts inhibitory signals in the tumor 
microenvironment to T cell stimulatory signals. By tethering checkpoint blockade and co-
stimulatory molecules to a single platform, I made particles that physically link tumor 
cells and T cells while inhibiting checkpoint activity and activating T cells. These 
particles delayed or eliminated tumor growth in several murine models at doses 10-100x 
less than soluble inhibitory and co-stimulatory molecules and resulted in a systemic 
memory immune response while localizing the nanoparticles to the tumor 
microenvironment. 
Next, I developed a modified type of artificial antigen presenting cell (aAPC) that 
boosts CD8+ T cell activation for adoptive cell transfer. T cell signaling components 
were separated onto distinct superparamagnetic nanoparticles and activation was induced 
by clustering the particles with a magnetic field. This platform streamlined the 
application of various combinations of co-stimulatory molecules together with a single 
antigen-specific receptor to increase the expansion of antigen-specific T cells and extend 
their persistence in vivo. 
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Finally, I developed more effective biodegradable aAPC by modifying the 
particle material and through combination with checkpoint blockade. Biodegradable 
aAPC synergized with anti-PD-1 checkpoint blockade to delay the growth of established 
murine melanoma. A new type of polymeric aAPC also activated antigen-specific CD8+ 
























Jonathan P. Schneck, M.D. Ph.D. (primary adviser, reader) 
Professor, Department of Pathology 
Johns Hopkins University School of Medicine 
 
Jordan J. Green, Ph.D. 
Associate Professor, Department of Biomedical Engineering 
Johns Hopkins University School of Medicine 
 
Andrea Cox, M.D. Ph.D. 
Professor, Department of Medicine 
Johns Hopkins University School of Medicine 
 
Michael Edidin, Ph.D. (reader) 
Professor Emeritus, Department of Biology 










I would like to thank Dr. Jonathan Schneck for being a supportive adviser. I met 
with him shortly after taking the medical school immunology course and explained that I 
knew very little immunology but that I found it fascinating and was eager to learn more. 
He welcomed me into the lab and gave me the freedom to pursue many different projects 
while learning a new subject. Over the course of the next five years, he maintained that 
open-minded and honest mentoring style which gave me plenty of opportunities to 
succeed, fail, and learn from my own mistakes. 
I also need to thank Joanie Bieler and Karlo Perica, the lab “mom” and my 
original mentor, respectively. Without Joanie’s comprehensive knowledge and five star 
baked goods, I would have never made it as long as I did. Karlo, my graduate student 
mentor, taught me more than I thought possible in the ten short months we overlapped 
before he graduated from the lab with his PhD. And of course, all of the other members 
of the Schneck lab, especially Ami Bessell and John Hickey, who helped with both 
science and sanity throughout the years and inspired me as they brought new children 
into the world while working hard towards graduate degrees.  
I need to thank my thesis committee and close collaborators for all of their 
attentive time and valuable feedback – Drs. Jordan Green, Michael Edidin, Andrea Cox, 
as well as fellow graduate student Randall Meyer. I am thankful to have had guidance 
from such a diverse group of intelligent people.  
Finally, I need to thank my family and friends. My fiancé, Joe Galaro, never 
stopped encouraging me even while also struggling through the ups and downs of his 
own PhD. I am thankful for my parents, four siblings, grandparents, aunts, uncles, and 
vi 
 
cousins who continued to support me even when they were confused why I was “still” in 
school, and all of the old and new friendships that I kept and made in Baltimore that I 




















Table of Contents 
 
Abstract ......................................................................................................................................................... ii 
Acknowledgements ......................................................................................................................................... v 
Table of Contents ......................................................................................................................................... vii 
List of Figures ................................................................................................................................................xi 
Chapter 1. Summary of the Dissertation ..................................................................................................... 1 
Chapter 2. The Cancer-Immunity Cycle ..................................................................................................... 3 
2.1  T cell activation .................................................................................................................................... 3 
2.2  Blockades allow cancer progression .................................................................................................... 5 
Chapter 3. Immunoengineering Approaches for T Cell Modulation ........................................................ 8 
3.1 Properties to consider when designing a platform ................................................................................ 8 
3.1.1 Ligand choice and arrangement ..................................................................................................... 8 
3.1.2 Particle size .................................................................................................................................. 11 
3.1.3 Particle shape ............................................................................................................................... 12 
3.2 Particle-based approaches ................................................................................................................... 13 
3.2.1 Artificial antigen presenting cells ................................................................................................ 14 
3.2.2 Drug-carrier particles ................................................................................................................... 18 
3.2.3 Non-T cell interacting particles ................................................................................................... 22 
3.2 Protein engineering ............................................................................................................................. 25 
3.2.1 Engineered cytokines ................................................................................................................... 26 
3.2.2 Antibody Engineering .................................................................................................................. 29 
3.3 Combination immunotherapies ........................................................................................................... 33 
Chapter 4. Dual Targeting Nanoparticle Stimulates the Immune System to Inhibit Tumor Growth . 38 
4.1 Introduction ......................................................................................................................................... 38 
4.2 Methods .............................................................................................................................................. 40 
viii 
 
4.2.1 Mice ............................................................................................................................................. 40 
4.2.2 Reagents and cell lines................................................................................................................. 41 
4.2.3 Immunoswitch particle synthesis and characterization ................................................................ 41 
4.2.4 In vitro CD8+ T cell activation model ......................................................................................... 42 
4.2.5 B16 in vivo tumor growth experiments ........................................................................................ 43 
4.2.6 B16-SIY tumor infiltrating lymphocyte analysis ......................................................................... 44 
4.2.7 T cell receptor sequencing analysis ............................................................................................. 45 
4.2.8 MC38-OVA in vivo tumor models .............................................................................................. 46 
4.2.9 Immunoswitch biodistribution ..................................................................................................... 47 
4.2.10 Conjugation assay ...................................................................................................................... 48 
4.2.11 In vivo killing assay ................................................................................................................... 49 
4.2.11 Statistics ..................................................................................................................................... 50 
4.3 Results ................................................................................................................................................. 51 
4.3.1 Immunoswitch particles activate T cells in vitro ......................................................................... 51 
4.3.2 Enhanced T cell-tumor cell conjugation ...................................................................................... 56 
4.3.3 Immunoswitch particles inhibit tumor growth in vivo ................................................................. 58 
4.3.4 Endogenous T cell activation ....................................................................................................... 62 
4.3.5 Changes in the T cell receptor repertoire ..................................................................................... 66 
4.3.6 Immunoswitch biodistribution ..................................................................................................... 68 
4.3.7 Efficacy in multiple cancer models ............................................................................................. 70 
4.3.8 Efficacy by intravenous immunoswitch injection ........................................................................ 72 
4.3.9 Intratumoral treatment results in a systemic memory response ................................................... 73 
4.4 Discussion and conclusions ................................................................................................................ 74 
Chapter 5. Separating T cell Targeting Components onto Magnetically-Clustered Nanoparticles 
Boosts Activation ......................................................................................................................................... 79 
5.1 Introduction ......................................................................................................................................... 79 
5.2 Methods .............................................................................................................................................. 82 
5.2.1 Mice ............................................................................................................................................. 82 
ix 
 
5.2.2 Reagents and Cell Lines .............................................................................................................. 82 
5.2.3 Particle synthesis and characterization ........................................................................................ 83 
5.2.4 CD8+ T cell aAPC stimulation .................................................................................................... 86 
5.2.5 Specific lysis assay ...................................................................................................................... 87 
5.2.6 Particle clustering analysis .......................................................................................................... 87 
5.2.7  Matlab clustering analysis .......................................................................................................... 88 
5.2.8 Fold-enrichment studies ............................................................................................................... 89 
5.2.9 Endogenous CD8+ T cell cytokine functionality ......................................................................... 89 
5.2.10 In vivo adoptive transfer studies ................................................................................................ 89 
5.3 Results ................................................................................................................................................. 90 
5.3.1 Separate particle platform activates CD8 cells ............................................................................ 90 
5.3.2 Dependence of particle size ......................................................................................................... 93 
5.3.3 Dependence of signal co-clustering ............................................................................................. 96 
5.3.4 Increased expansion of antigen-specific endogenous CD8 cells ................................................. 99 
5.3.5 High throughput co-stimulatory molecule customization .......................................................... 103 
5.3.6 Co-stimulatory molecule selection impacts memory formation in vivo .................................... 106 
5.4 Discussion and conclusions .............................................................................................................. 107 
Chapter 6. Improving the Efficacy of Biodegradable Artificial Antigen Presenting Cell Platforms . 112 
6.1 Introduction ....................................................................................................................................... 112 
6.2 Methods ............................................................................................................................................ 115 
6.2.1 Artificial antigen presenting cell synthesis and characterization ............................................... 115 
6.2.2 Anti-PD1 monoclonal antibody synthesis ................................................................................. 117 
6.2.3 In vitro artificial antigen presenting cell T cell stimulation ....................................................... 117 
6.2.4 In vitro anti-PD-1 mAb functionality assay ............................................................................... 118 
6.2.5 In vitro anti-PD-1 mAb and aAPC assay ................................................................................... 120 
6.2.6 In vivo particle and cell biodistribution study ............................................................................ 120 
6.2.7 In vivo tumor treatment study .................................................................................................... 121 
6.2.8 In vivo CD8+ T cell harvest and analysis .................................................................................. 123 
x 
 
6.3 Results ............................................................................................................................................... 124 
6.3.1 PLGA-based aAPC synthesis and characterization ................................................................... 124 
6.3.2 aAPC stimulate peptide-specific CD8+ T cells ......................................................................... 127 
6.3.3 Anti-PD-1 mAb and aAPC activate cognate CD8 cells in vitro ................................................ 128 
6.3.4 PLGA aAPC biodistribution ...................................................................................................... 131 
6.3.5 Combination therapy delays tumor growth and extend survival ............................................... 132 
6.3.6 Combination therapy increases T cell functionality .................................................................. 135 
6.3.7 PLGA/PBAE hybrid aAPC outperforms traditional PLGA....................................................... 138 
6.4 Discussion and conclusions .............................................................................................................. 143 
Chapter 7. Conclusions ............................................................................................................................. 148 
7.1 Summary of work ............................................................................................................................. 148 
7.2 Future directions ............................................................................................................................... 150 
Bibliography .............................................................................................................................................. 153 















List of Figures 
Figure 4-1. Immunoswitch particles combine anti-4-1BB and anti-PD-L1 antibodies on a nanoparticle 
platform. ........................................................................................................................................................ 52 
Figure 4-2. Immunoswitch particles link PD-L1 checkpoint blockade with 4-1BB co-stimulation .............. 53 
Figure 4-3. In vitro model results in upregulated inhibitory molecules on CD8 and B16 cells. ................... 55 
Figure 4-4. Soluble anti-4-1BB and anti-PD-L1 mAb increase T cell activation when co-incubated with 
target cells. .................................................................................................................................................... 55 
Figure 4-5. Immunoswitch particles increase effector-target cell conjugation .............................................. 58 
Figure 4-6. Immunoswitch particles inhibits tumor growth in vivo .............................................................. 60 
Figure 4-7. Immunoswitch particles delay tumor growth in the absence of adoptively transferred cells ...... 61 
Figure 4-8. Tumor specific CD8+ T cells are present in the periphery at the same levels in treated and non-
treated mice ................................................................................................................................................... 63 
Figure 4-9. A significant portion of the anti-tumor response in the presence and absence of immunoswitch 
treatment is Kb-SIY specific. ........................................................................................................................ 64 
Figure 4-10. Tumor-specific CD8+ tumor-infiltrating lymphocytes of immunoswitch treated mice have 
increased functionality. ................................................................................................................................. 65 
Figure 4-11. Immunoswitch treatment alters the CD8+ T cell repertoire ...................................................... 67 
Figure 4-12. Immunoswitch particles remain at injection site longer than soluble antibody ........................ 69 
Figure 4-13. Immunoswitch particles reverse tumor growth and extend survival in multiple tumor models 
and injection routes ....................................................................................................................................... 71 
Figure 4-14. Intratumoral immunoswitch treatment results in a systemic memory immune response .......... 74 
Figure 5-1. Standard curves relate absorbance to particle concentration of nanoparticles ............................ 85 
Figure 5-2. CD8+ T cells are activated by nanoparticles separately expressing signal 1 and signal 2 when 
particles are clustered within a magnetic field .............................................................................................. 91 
Figure 5-3. Traditional aAPC activate a more robust T cell response at larger particle sizes ....................... 94 
Figure 5-4. Separate particle platform requires particles on the nanometer size scale for efficient CD8+ T 
cell stimulation .............................................................................................................................................. 95 
xii 
 
Figure 5-5. Number of nanoparticle clusters per cell is affected by particle size .......................................... 95 
Figure 5-6. Polystyrene and iron-dextran nanoparticles have similar protein densities ................................ 96 
Figure 5-7. Signal 1 and signal 2 only nanoparticles must be co-clustered on the cell surface for efficient 
CD8+ T cell activation .................................................................................................................................. 97 
Figure 5-8. Separate particle platform results in greater expansion of functional cognate CD8+ T cells ... 100 
Figure 5-9. Percent recovery of cognate T cells is equivalent with aAPC and separate particle platform .. 101 
Figure 5-10. Separate particle platform improves T cell expansion against various antigens ..................... 102 
Figure 5-11. Separate particle platform results in greater or equal T cell cytokine secretion ..................... 103 
Figure 5-12. Separate particle platform allows for manipulation of co-stimulatory signal 2 composition . 104 
Figure 5-13. Separate particle platform enables customization of co-stimulation....................................... 105 
Figure 5-14. Separate particle platform activates optimal CD8+ T cells for adoptive cell transfer ............ 107 
Figure 6-1.  aAPC characterization and functional assessment ................................................................... 126 
Figure 6-2. aAPC and anti-PD-1 mAb show greater CD8+ T cell activation in combination .................... 129 
Figure 6-3. Co-administration of aAPC with CD8+ T cells impacts aAPC biodistribution ........................ 131 
Figure 6-4. Anti-PD1 mAb and aAPC synergize to mediate anti-tumor activity in vivo ............................ 134 
Figure 6-5. Anti-PD1 mAb and aAPC combination therapy decreases PD-1 expression and increases 
expansion of tumor-specific CD8+ T cells .................................................................................................. 137 
Figure 6-6. PLGA/PBAE and PLGA particle characterization ................................................................... 140 
Figure 6-7. PLGA/PBAE hybrid particles activate cognate CD8+ T cells. ................................................. 141 
Figure 6-8. PLGA/PBAE bind cognate cells at a higher level than PLGA aAPC ....................................... 142 





Chapter 1. Summary of the Dissertation 
The organization of the dissertation is as follows: 
 Chapter 2 includes background information on the interaction between cancer and 
the immune system, especially in regards to T cells. It explains how the immune system 
may be targeted to induce cancer recognition.  
 Chapter 3 is a literature review on current immunoengineering approaches to 
modulate the anti-tumor T cell response. It focuses on cell-based and synthetic particles, 
protein engineering, and combination immunotherapies. Chapters 2 and 3 are largely 
based on an invited book chapter I am co-authoring with fellow graduate student John 
Hickey, Engineered platforms for T cell modulation, to be published in the International 
Review of Cell and Molecular Biology, book 342.  
 Chapter 4 describes a new genus of dual-targeting nanoparticles, termed 
immunoswitch particles, that delay and reverse melanoma and colon cancer growth in 
murine models. It includes in vitro and in vivo data that demonstrate the efficacy and 
mechanism of action of these tumor- and T cell-targeting nanoparticles. This study was 
published in ACS Nano1 and is reprinted here with additional data and minor 
modifications.  
 Chapter 5 describes a new CD8+ T cell stimulation platform that enhances in 
vitro T cell activation. This platform builds on previous work from the lab and 
demonstrates how separating signaling components onto separate nanoparticles and 
subsequently clustering them within a magnetic field enhances activation. This platform 
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also presents a more streamlined and high throughput approach to customize co-
stimulatory signals for activation. This study is not yet published.  
 Chapter 6 describes ways that biodegradable artificial antigen presenting cells 
(aAPC) can be improved by altering the aAPC material and by combination 
immunotherapy. I first show that anti-PD-1 monoclonal antibody checkpoint blockade 
and poly(lactic-co-glycolic acid) (PLGA)-based aAPC synergize to delay melanoma 
growth in murine models. This study was published in Biomaterials2 and is reprinted here 
with minor modifications. Second, I describe preliminary work on a hybrid-polymer 
aAPC that increases T cell activation up to 100-fold. This data is not yet published.  
 Chapter 7 is a summary of the other chapters and outlines potential future work in 













Chapter 2. The Cancer-Immunity Cycle 
 The immune system is a complex organization of many different cell types that 
protect the human body from infection, disease, and foreign material. A breach of the 
body’s physical barriers provokes an influx of innate and adaptive immune cells that can 
detect and eliminate infection, along with a surge of small molecule cytokines and 
chemokines that shape the local inflammatory response. The precision, effectiveness, and 
speed of the immune system is remarkable.  
 In addition to recognizing bacteria and viruses, the immune system can also 
recognize less obvious “non-self” material. Cancer develops from progressing mutations 
that give cells an increased capacity for proliferation, survival, and metastasis. These 
mutations may be expressed by cancerous cells and recognized as foreign and 
subsequently attacked by the immune system. However, cancer grows when it has 
developed mechanisms to evade immune recognition and attack. Cancer 
immunotherapeutics are a class of clinical therapies that aim to eliminate these defenses 
and stimulate an anti-cancer immune response, notably a T cell based cellular immune 
response. Here, I review the basic requirements for T cell activation and how cancer can 
be recognized or evade recognition by the immune system. 
2.1 T cell activation 
Minimally, T cells require two signals for activation—signal 1, specific peptide 
presented in the context of the major histocompatibility complex (MHC), and signal 2, a 
co-stimulatory signal such as B7.3 The peptide-MHC complex presented by an antigen 
presenting cell interacts with the T cell via its T cell receptor (TCR) and is what confers 
4 
 
the specificity of T cell activation. Signal two provides co-stimulation and is required for 
the activation of naïve T cells. The interaction of B7 on an antigen presenting cell with 
CD28 on the T cell is thought of as the prototypical co-stimulation, although many 
different co-stimulatory molecules exist that modulate the T cell expansion, phenotype, 
and functionality.4–13  
Before activation, TCR are pre-clustered in small 35-70 nm islands with 7-30 
TCRs per island.14 Upon recognition of cognate antigen, these nanoclusters begin to 
merge and form what is known as the immune synapse.15 The lateral organization of the 
microscale immune synapse is defined by supramolecular activation clusters, or SMACs. 
TCR and CD28 co-localize within the central SMAC (cSMAC), with a TCR-rich core 
surrounded by a CD28-rich periphery.16 Larger adhesion molecules, such as LFA-1, 
localize within the peripheral SMAC (pSMAC).17  This nanoscale co-localization of TCR 
and CD28 is necessary for activation, as separating signal 1 and signal 2 activation by 
several microns inhibits T cell activation.18 
There are two major subsets of T cells—CD4+ and CD8+ T cells, otherwise 
known as T helper cells and cytotoxic T cells, respectively. Upon activation, CD4+ T 
cells differentiate into different subtypes and can carry out multiple functions, from 
activating B lymphocytes to suppressing the immune reaction.19,20 The major subtypes 
include Th1 and Th2, type 1 and 2 T helper cells,19 Th17 cells which play roles in allergy 
and autoimmunity,21 and Treg cells22 which play important roles in immune response 
homeostasis. Cytotoxic CD8+ T cells secrete cytokines and kill target cells upon 
activation.23 This subtype is responsible for selectively eliminating virally infected cells. 
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Upon activation, T cells clonally divide, secrete cytokines, and most importantly, 
maintain a memory response that provides long-term protection.  
In most cases, the immune system is a powerful defense against infection and 
disease. However, dysfunctions or deficiencies in any part of the system can reduce its 
effectiveness or even create disease itself. Cancer’s ability to evade immune recognition, 
chronic infection, and autoimmune diseases are all examples of pathologies that defy 
standard immune responses. 
2.2 Blockades allow cancer progression 
Cancer arises from the culmination of a series of mutations that lead to a break in 
normal cell-regulating functions, including enhanced proliferation or a lack of normal 
apoptotic processes. This can lead to the expression of mutated neo-antigens,24,25 
differentiation antigens, or viral antigens that can be recognized as foreign by the immune 
system.26 These antigens are presented on major histocompatibility class I molecules 
(MHC-I) by resident dendritic cells (DCs) and subsequently activate tumor-antigen 
specific CD8+ T cells. While a T cell response can sometimes be mounted against these 
tumor-antigens, mechanisms of central and peripheral tolerance and immunosuppressive 
actions of the tumor micro-environment often hinder an effective immune response.27 
The interplay between cancer and the immune system can be viewed as a 
potentially self-propagating cycle, termed the Cancer-Immunity Cycle, which has been 
elegantly reviewed by Chen and colleagues.28  To achieve effective anti-tumor immunity, 
antigens released upon cancer cell death are processed and presented by antigen 
presenting cells to activate cognate T cells. These T cells may then recognize and kill the 
tumor cells, leading to a positive feedback loop for immune activation. Cancer expands 
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when there is a blockade in a step of this cycle that shields the tumor from immune 
recognition or attack.  
In many cases, tumor antigens do not differ sufficiently from self-antigens to be 
recognized as foreign by the immune system. This is evidenced by the fact that tumors 
with higher frequencies of neo-antigens, tumor-specific antigens derived from tumor 
mutations, correlate with better prognosis following immunotherapy.24,29–31 Even the 
response to tumors with many tumor antigens may be limited by an immunosuppressive 
tumor microenvironment. There are three major pathways by which tumor cells evade 
immune attack—reduced MHC expression of tumor antigens, secretion of 
immunosuppressive factors, and the upregulation of negative costimulatory pathways 
within the tumor microenvironment.32 Downregulation of MHC expression can protect 
tumor cell recognition by T cells and is sometimes a method of tumor immune escape.33 
Tumor or stromal cells also can secrete soluble factors, including TGF-β, IL-10, and 
PGE2, or express inhibitory checkpoint molecules that suppress immune function. Tumor 
cells that upregulate immunosuppressive TIM family proteins or the checkpoint molecule 
programmed death ligand 1 (PD-L1) are correlated with poor prognosis.34,35  
Immunoengineering therapies target these various pathways to establish a more 
robust anti-tumor immune response. Many of these therapies target CD8+ T cell 
activation since CD8+ T cells can directly lyse tumor cells. Therapies may involve 
stimulating a T cell response that was previously inhibited due to tolerance or 
immunosuppression, blocking immunosuppressive checkpoint molecules upregulated by 
cancerous cells, or a combination approach to activate stimulatory pathways while 
simultaneously blocking inhibitory pathways. Incorporating engineering concepts into the 
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development of immunotherapies can enhance biomimicry or fine-tune biodistribution 
and targeted delivery. The next chapter reviews important concepts in engineering 





















Chapter 3. Immunoengineering Approaches for T 
Cell Modulation 
The dynamics of the immune synapse make T cell activation sensitive to many 
micro- and nano-scale properties of aAPC activators. The organization and composition 
of signaling molecules, as well as substrate size, shape, and stiffness of activating 
particles, interact to affect T cell activation and further to shape the phenotype of the 
activated cells. Immunoengineering seeks to systematically vary these factors to achieve 
optimal T cell activation and cancer suppression. 
3.1 Properties to consider when designing a platform 
3.1.1 Ligand choice and arrangement 
T cell activation is modulated through different co-stimulatory and co-inhibitory 
pathways. When engineering a therapeutic, one first has to determine which specific 
signaling pathways to activate or inhibit. In addition to pathway choice, ligand nano- and 
micro-scale arrangement, density, strength, and duration can play a significant role.   
T cells require a signal 1 for activation. This can be provided through stimulating 
the cognate TCR for a particular antigen or through CD3, an invariant molecule which is 
constitutively associated with the TCR and is responsible for its intracellular signaling.36 
pMHC stimulation of TCR is  antigen-specific, while activation through CD3, with an 




While signal 1 is minimally required for activation to occur, the T cell response to 
that signal alone results in an anergic, under-responsive state. Full activation after 
receiving signal 1 is modulated by dozens of co-stimulatory and co-inhibitory 
molecules.37 CD28 is the pro-typical co-stimulatory molecule, although several other co-
stimulatory molecules exist that modify T cell proliferation and phenotype. For example, 
4-1BB co-stimulation has been shown to preferentially activate CD8+ T cells over CD4+ 
T cells,38 preferentially activate memory CD8+ T cell populations,8 increase T cell 
maintenance of CD28 expression,7 and increase CD8+ T cell secretion of IL-2.9 
Stimulation through the co-stimulatory molecules OX40 and CD27 expressed by T cells 
has also been shown to enhance activation.5,6 Altering the combinations and ratios of 
different co-stimulatory molecules without varying the total number of co-stimulatory 
molecules can also have tremendous impacts on activation.6,10 
Besides co-stimulators, T-cell activity is inhibited through several different 
pathways. These pathways are involved with maintaining homeostasis and establishing a 
self-regulated immune response following pathogen removal.39 However, these inhibitory 
pathways can be utilized by cancer cells to evade and inhibit an anti-tumor response. 
Programmed death 1 (PD-1) and CTLA-4 expressed by T cells are two checkpoint 
molecules commonly targeted by immunotherapies.40,41 Monoclonal antibodies blocking 
these checkpoint pathways as well as other immuno-inhibitory molecules such as IDO 
can rescue exhausted T cells.42 Blocking inhibitory pathways along with activating co-




The nano- and micro-scale arrangement of signaling ligands plays an important 
role in modulating the T cell response to engineered platforms. At the microscale, a focal 
co-clustering of signal 1 and signal 2 molecules is necessary to initiate activation. When 
anti-CD3 mAb is patterned on a planar substrate in focal spots, T cells proliferate and 
secrete cytokines.46 However, T cell activation is reduced when the same anti-CD3 mAb 
is tethered in an annular pattern that precludes centralized TCR clustering.46 Signal 2 
must also be co-clustered with signal 1 during stimulation. Separating anti-CD3 and anti-
CD28 by a distance of several microns inhibits IL-2 cytokine production.18  
TCR intermolecular distance must be sufficiently small, on the nano-scale, to 
induce activation. When anti-CD3 is patterned on planar substrates at defined densities, 
only surfaces displaying anti-CD3 with intermolecular distances smaller than 
approximately 60 nm induce optimal activation.47,48 Interestingly, the minimum 
intermolecular distance for CD4+ T cell-specific activation with MHC II is close to 115 
nm,49 indicating that ligand organization on aAPC may need to be optimized based on the 
T cell subset that is targeted.  
While TCR and CD28 organization have been most extensively studied, some 
data indicates that signaling through other co-stimulatory and co-inhibitory pathways 
may also be sensitive to nanoscale arrangement. T cell inhibition through PD-1 signaling 
has been shown to depend on the formation of microclusters within the immune 
synapse.50,51 When the extracellular domain of PD-1 was extended to preclude its co-
localization within the immune synapse, the molecule was not inhibitory. 4-1BB has also 
been shown to localize within the immune synapse along with CD28 during co-
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stimulation.52 Thus, it is evident that in addition to ligand selection, the micro- and nano-
scale arrangement of these various signaling molecules can have tremendous impacts. 
3.1.2 Particle size 
Engineered particle size is important to many aspects of T cell modulation at both 
the cellular and systemic level. At the cellular level, the size of the particle affects how it 
will interact with a T cell by changing the curvature and avidity. For particle therapeutics 
that will be used in vivo, the role of size on biodistribution and circulation time also 
comes into play, as larger particles are less biocompatible and have reduced drainage to 
lymphatics and tumor sites. When developing a new platform, it is important to 
understand how size may affect efficacy and whether it is important to be optimized for 
in vivo applications.  
At the cellular level, it is generally thought that particles that most closely mimic 
endogenous interactions are most effective. Micro-scale particles that most closely mimic 
the size of endogenous antigen presenting cells are thus most effective in stimulating a 
response.53 A majority of T cell activation particles that have been developed so far are 
about 4-5 μm, comparable to the size of a T cell.10,54,55 
While microscale particles are most effective at stimulating a T cell response at 
the cellular level, they become less feasible for in vivo applications when systemic 
biodistribution plays a role. As particle size increases, lymphatic drainage is limited from 
an injection site and clearance by certain phagocytic cells increases.56–58 At the systemic 
level, nanoparticles display improved trafficking properties, slower clearance and 
enhanced localization to T cells, compared to microparticles .   
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More recent technologies have demonstrated how sub-micron scale particles can 
be used to elicit a T cell response. These approaches generally aim to increase the contact 
area between the T cell and nanoparticle by altering the distribution of particles on the 
cell surface or local curvature of the nanoparticle. Sub-100 nm particles have been shown 
to activate T cells at sufficiently high surface densities of stimulatory ligands.59 In 
contrast to altering the distribution of ligands on the surface of the nanoparticle, external 
forces can be used to affect particle distribution on the T cell surface. Superparamagnetic 
iron-dextran nanoparticles have increased stimulatory capability when clustered on the 
surface of a T cell to enable micro-scale clustering of signaling molecules.60 
3.1.3 Particle shape 
When synthesizing synthetic platforms for T cell modulation, particle shape can 
have surprising impacts on their interaction with T cells and macrophages as well as their 
biodistribution. Spherical and ellipsoidal particles have differing interfacial geometries 
despite similar length scales and can thus be optimized for T cell interactions. By using 
shape to vary biodistribution, the half-life and cell and organ targets can be modified. 
Particle shape affects biodistribution in part by modifying phagocytosis by the 
reticuloendothelial system (RES). In contrast to spherical particles, ellipsoidal particles 
reduce nonspecific RES phagocytosis, an important consideration for extending the half-
life of therapeutics to be injected in vivo.56,61–63 In fact, phagocytosis is more dominantly 
affected by shape rather than size in the range of approximately 1-10 μm.61  However 
interestingly, receptor-mediated endocytosis of non-spherical particles is enhanced.64 
Thus, elongating particles for applications where targeted internalization is preferred, 
such as drug delivery, may also take advantage of longer circulation times. 
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In addition to affecting biodistribution and half-life, particle geometry plays an 
important role at the T cell-particle interface. While most T cell-interacting particles, 
such as artificial antigen presenting cells (aAPC), are spherical in nature, this shape does 
not recapitulate biological T cell-APC interactions. Spherical particles maximize the 
curvature and thus minimize the surface area of contact between the T cell and particle. 
This is especially detrimental as ligand avidity decreases as particle size also decreases to 
the nanoscale, despite biocompatibility incentives to move to smaller size scales. 
Ellipsoidal microparticle aAPC were shown to preferentially interact with T cells along 
their long axis and significantly increase T cell activation in vitro and in vivo.65 Nano-
aAPC also result in a similar increase in T cell activation with ellipsoidal versus spherical 
particles while also taking advantage of the increased biocompatibility and superior 
biodistribution based on particle size.66  
3.2  Particle-based approaches  
One approach to initiating or re-activating an anti-tumor T cell response is to 
mimic portions of endogenous T cell activation using an engineered platform. Scientists 
and engineers have developed biocompatible platforms that mimic antigen presentation, 
orchestrate the delivery of immune-stimulatory drugs, or prompt a new type of immune 
interaction. These platforms have been built upon a wide variety of biocompatible 
platforms, from cultured cell lines to biodegradable polymers. Here, I review these 
particle-based approaches for activating T cells by dividing them into three main 
categories—artificial antigen presenting cells, drug-delivery platforms, and particles that 
interact with other immune subtypes with the goal of T cell activation.  
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3.2.1  Artificial antigen presenting cells 
Artificial antigen presenting cells are micro or nano sized platforms designed to 
mimic endogenous antigen presenting cells for T cell activation. Their major role lies in 
adoptive cell therapy (ACT)–ex vivo activation of autologous lymphocytes with aAPCs 
expressing tumor-specific peptide-MHC (pMHC), followed by re-infusion of the 
expanded cells into the patient.67 Large numbers of expanded lymphocytes, up to 1011, 
are needed to treat a single patient with ACT.68 Such robust activation requires the 
development of optimized aAPC that are both effective and economical. Additionally, 
research has shown the importance of not just quantity, but more importantly, quality of 
the resultant cells for a long-lived effector population post-transfer.69 Thus, extensive 
work has been done to develop optimal aAPC for this purpose.  
aAPC are three dimensional cellular or synthetic platforms that minimally present 
the two necessary signals for T cell activation—peptide MHC, signal 1, and B7-1/B7-2 or 
anti-CD28 monoclonal antibody (mAb), signal 2.70 Many of the earliest aAPC were built 
upon APC-like cultured cell lines engineered to express signal 1 and signal 2, most 
notably K5626,71–73 and the murine NIH/3T3 fibroblast line.74–76 Despite their early 
successes, acellular aAPC have become the favored platform due to several benefits over 
their cellular counterparts. Acellular platforms allow for the ability to control molecule 
expression, geometry, rigidity, and shape, as well as eliminate unwanted cytokine and 
cell surface molecule expression. Synthetic platforms can also decrease costs by creating 
a more easily manufactured all-in-one off-the-shelf therapy. 
 When engineered on a synthetic platform, aAPC can be created with defined 
sizes. Most commonly, they are spheres several microns in diameter, meant to closely 
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mimic the general scale of an endogenous antigen presenting cell.10,77–80 Large, micron-
scale particles reduce the curvature at the T cell-aAPC interface compared to smaller 
particles and allow for a higher avidity interaction. The aAPC can thus interact with 
multiple TCR and induce robust activation. The importance of this multivalent interaction 
has been demonstrated experimentally by stimulating T cells with planar and three-
dimensional platforms with differing signal densities. Spherical microparticles with 
reduced densities of MHC signal 1 cannot activate T cells to the same extent as particles 
with a high density despite increasing particle dose79,81, and higher densities of 
stimulatory molecules correlate with lower effective concentration and prolonged 
activation.82 
Despite their success in activating T cells at the cell-particle level, microscale 
particles have poor biodistribution properties and are thus less than optimal for in vivo 
applications. Microparticles cannot take advantage of the enhanced permeability and 
retention effect to localize aAPC at the tumor site83 and do not effectively drain to lymph 
nodes where effective immune stimulation takes place.84,85 Thus, more recent work has 
explored ways to optimize aAPC on more biocompatible nano-scale platforms. 
The spherical shape of aAPC is popular largely because of the ease of synthesis 
using standard chemical synthesis procedures, such as emulsion techniques for 
PLGA.86,87 However, spheres minimize the contact area at the T cell-aAPC interface 
despite the importance of multivalent pMHC-TCR interactions. Recent work has 
demonstrated how altering aAPC geometry can improve the stimulatory capabilities of 
both micro- and nano- aAPC. Importantly, modifications to aAPC shape have also helped 
to bring nano-aAPC into the playing field.  
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Ellipsoidal synthetic aAPC can be developed by physically stretching spherical-
shaped PLGA particles following single emulsion techniques.65 These oblong particles 
can be synthesized with aspect ratios over six and be conjugated with equivalent protein 
densities to spherical particles, allowing for controlled comparison to their spherical 
counterparts. It was shown that increasing micro-aAPC aspect ratio (i.e. degree of 
stretching) positively correlates with CD8+ T cell proliferation and maximally induces a 
20-fold stronger T cell response. Interestingly, proliferation did not increase linearly with 
increased particle stretching but rather resulted in more significant gains at specific aspect 
ratio intervals. This geometry-driven change in T cell proliferation was shown to be 
correlated with changes to the T cell-aAPC interface. Ellipsoidal aAPC conjugated to 
more T cells and individual contact areas were larger than spherical interactions, 
indicating that increased avidity and interactions with multiple TCR may drive their 
improved efficacy.  
This geometry effect has also been shown to be maintained on the nanoscale.66 
Nano-aAPC with spherical diameters on the order of approximately 200 nm induce a 
five-fold stronger T cell response when they are ellipsoidal in shape. As shown with other 
systems,56,61,62 ellipsoidal aAPC resisted uptake by RES cells and had longer circulation 
times in vivo. Nearly 80% of spherical nano-aAPC were uptaken by macrophages, in 
contrast to less than 15% of ellipsoidal aAPC, demonstrating improved biodistribution of 
ellipsoidal particles. This increased ability to stimulate T cells and longer circulation 
times led to significantly increased T cell proliferation in vivo.  
In contrast to manipulating the geometry of the base particle, magnetic fields have 
also been utilized to alter how nano-aAPC are perceived by and interact with T cells. 
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Superparamagnetic spherical iron-dextran aAPC with a diameter of 100 nm do not 
normally activate a robust T cell response. However, when an external magnetic field is 
applied, the nano-aAPC cluster on the T cell surface, changing the perceived shape and 
size of the aAPC by the T cell, and likewise increase proliferation.59,60 This method 
enables nano-aAPC to activate rare endogenous T cell populations, such as would be 
necessary for adoptive cell transfer.  
In parallel to studies on how physical properties of the aAPC, such as geometry 
and size, affect T cell activation, others have demonstrated the significant impacts of 
ligand choice. Traditionally, aAPC are conjugated with the two necessary signals for T 
cell activation—anti-CD3 mAb or a specific pMHC, signal 1, and B7 or anti-CD28 mAb, 
signal 2. Often, a pMHC will be chosen so that T cell activation is limited to be against a 
specific target antigen, although interesting work has demonstrated how phenotypic 
markers can be used post-nonspecific activation to select a specific T cell subset.88 A 
great deal of work in antigen discovery and immunogenicity has been conducted for the 
selection of a specific pMHC targets for different applications, but these details are 
outside of the scope of this chapter.   
Despite the fact that signaling through CD28 is the main co-stimulatory signal 
provided by synthetic aAPCs, the composition of co-stimulatory signals greatly impacts 
T cell activation. There are dozens of different types of co-stimulatory signal 2 
molecules, and altering the combinations and ratios of these signals can impact 
proliferation, phenotype, and survival in vivo. These T cell co-stimulatory molecules 
include pathways such as CD70-CD27, CD40-CD40L, 4-1BB-4-1BBL, OX40L-OX40, 
and others expressed on the antigen presenting cell and T cell, respectively.37  
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Studies have shown that co-stimulation through 4-1BB during the rapid expansion 
protocol for adoptive cell transfer improves the expansion and effector function of tumor-
specific T cells.89 4-1BB co-stimulation has also been associated with the preferential 
expansion of memory T cells which are often desired for in vivo transfer applications.90 
Combining multiple co-stimulatory signals on the same aAPC also can have significant 
impacts on T cell functionality. A study combining CD28, 4-1BB, and CD27 signaling on 
K562 aAPC demonstrated that certain combinations of the co-stimulatory molecules can 
increase proliferation over 10-fold.6 Even when the total amount of co-stimulation is 
equivalent, simply changing the ratio of signal 2 ligands can impact the resultant T cells. 
In one study, micron sized polystyrene aAPC conjugated with different ratios of anti-
CD28 and anti-4-1BB mAb impacted antigen-specific proliferation as much as five-
fold.10 Other co-stimulatory molecules, such as activation through OX4091 and 
CD40L92,93 which been shown to have stimulatory effects on T cells, could also be 
incorporated in next generation aAPC.  
In addition to the choice of signal 1 and signal 2, aAPC can be conjugated with 
other molecules to enhance their efficacy. CD47 is a molecule ubiquitously expressed by 
normal cells that protects self-cells against phagocytosis.94 aAPC that also express CD47 
have been shown to also be protected from phagocytosis and induce greater stimulation 
of T cells in vivo.95 
3.2.2  Drug-carrier particles 
T cells receive many different signals that shape their activation. These signals 
include interaction of T cell surface molecules with stimulatory or inhibitory ligands 
presented on the surface of antigen presenting cells and tumor cells, as well as signaling 
19 
 
by soluble cytokines and chemokines through cell surface receptors. Synthetic particles 
that allow for the engineering of shape, biodegradation properties, and conjugation or 
encapsulation with drugs that affect these various pathways provide a mechanism to 
dictate drug release distribution and kinetics.  
 During endogenous T cell stimulation, T cells receive soluble “signal 3” 
molecules that drive proliferation and cytotoxicity.96 These soluble mediators are secreted 
in a localized paracrine or autocrine fashion that increases their local concentration and 
limits exposure to the desired cells. Because these signals are often broadly immune 
activating, local delivery ensures that only the target cells are affected. This important 
aspect of local immune stimulation is lost when immune-activating drugs are 
administered in a systemic fashion. To more closely mimic the endogenous process and 
enable maximum T cell expansion, nanoparticles have been used to selectively deliver 
stimulatory signals in a paracrine manner to T cells of interest. Biodegradable polymers 
are often the material of choice due to the ability to manipulate their degradation and 
intracellular delivery properties.  
Various methods have been used to target these drug-delivery particles to specific 
immune subsets. One approach is to combine drug delivery with an aAPC to take 
advantage of both aAPC-based extracellular stimulation as well as localized drug 
delivery. In one study, biodegradable aAPC were engineered to encapsulate soluble IL-2, 
a T cell growth factor, and released IL-2 locally while stimulating T cells via signal 1 and 
signal 2 expressed on its surface.54,97 These particles increased T cell proliferation 10-fold 
compared to non-encapsulating aAPC with bulk IL-2.  
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Similarly, nanoparticles conjugated with T cell signaling molecules have been 
used to simply target the nanoparticles to T cells with the goal of intracellular drug 
delivery. Gelatin nanoparticles approximately 200 nm in diameter conjugated with anti-
CD3 mAb have been shown to be selectively internalized by T cells.98 Over 80% of T 
cell leukemia cells were observed to uptake the particles, demonstrating the potential for 
nanoparticles to be used to target the delivery of intracellular signals. More recently, this 
approach has demonstrated success in transfecting T cells with genetic material. Anti-
CD3 mAb-coated biodegradable nanoparticles approximately 150 nm in diameter were 
engineered to encapsulate a DNA plasmid encoding for a specific chimeric antigen 
receptor (CAR).99 The particles showed specific transfection of T cells with 
approximately 5% of non-T cells showing uptake following intravenous administration. 
Remarkably, systemic administration of these nanoparticles resulted in the same degree 
of anti-leukemia activity as compared to adoptive cell transfer of ex vivo transfected CAR 
T cells. Thus, the nanoparticle approach was able to significantly reduce the cost and time 
requirements of lymphodepletion and ex vivo T cell manipulation. More specific targeting 
of T cell subsets is also possible, as anti-CD4 mAb conjugated lipid nanoparticles have 
been shown to selectively target CD4+ T cells in vitro and in vivo.100 These nanoparticles 
selectively delivered a CD45 siRNA and induced gene silencing up to 20% in CD4+ T 
cells five days post intravenous administration.  
Localized drug delivery to T cells can also be achieved through combination with 
adoptive cell therapy. For example, nanoparticles can be covalently linked to T cells 
expanded in vitro prior to re-infusion. In one study, drug-releasing nanoparticles were 
covalently linked to the surface of tumor-targeting T cells prior to adoptive cell 
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transfer.101 When synthesized to release an inhibitor of immune-inhibitory signals, 
nanoparticle-functionalized T cells achieved greater expansion at the tumor site compared 
to systemic administration of the drug, achieving a 14 day survival advantage. 
Importantly, this study also demonstrated that the nanoparticles were translocated into the 
immune synapse during T cell activation. To further modulate not just the cell-proximity 
of drug release but also its temporal profile, T cell-bound nanoparticles have been 
developed that release drug only upon T cell stimulation.102 When CD8+ T cells become 
activated they release lytic granules, and this property has recently been used to trigger 
nanoparticle degradation. These nanoparticles, when bound to HIV-specific CD8+ T 
cells, were shown to enable the delivery of an immunotherapeutic to a site of high viral 
replication. 
A majority of T cell targeting nanoparticles for local drug delivery to date have 
targeted CD4, CD3, or TCR expression. However, it is important to appropriately select 
the targeting molecule for the most effective response. Whether or not a targeting 
molecule is internalized can significantly affect the T cell response to nanoparticle-
mediated drug delivery. A study that investigated targeting nanoparticles that released a 
TGF-β inhibitor to T cell internalizing versus non-internalizing receptors showed 
differing responses, and this effect changed if T cells were conjugated with nanoparticles 
prior to adoptive cell transfer or targeted directly by intravenous particle 
administration.103 
When widespread circulation of a drug is important, smaller particles or 
molecules are often preferred due to their superior biodistribution. However, in some 
cases, limiting the circulation of a drug may be desired such as with non-specific immune 
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activators meant to target T cells infiltrating a tumor. Systemic administration of 
stimulatory molecules such as IL-2 and anti-4-1BB mAb are associated with various off-
target toxicities due to widespread immune activation.104,105 Thus, a different approach to 
drug delivery is to anchor drugs to particles and inject them locally to the site of interest 
for the purpose of prolonging drug retention. Studies have shown that anchoring IL-2 and 
anti-4-1BB mAb to the surface of liposomes approximately 160 nm in diameter 
significantly reduces off-target toxicities when injected intratumorally.106,107 Even when 
injected intratumorally, the soluble antibody and cytokine were detectable at high levels 
18 hours post injection and resulted in significant weight loss in treated mice. In contrast, 
the nanoparticle-anchored drugs limited drug exposure to the tumor site and were shown 
to treat murine melanoma. 
3.2.3  Non-T cell interacting particles 
Activating a T cell response through the conjugation of stimulatory molecules on 
the surface of synthetic particles is a straightforward and direct way to modulate T cells 
by mimicking endogenous antigen presenting cells. However, T cell signaling involves 
many complex interactions with membrane-bound and soluble factors. Synthetic particles 
can be engineered to affect which cell types T cells interact with, alter a cell interaction 
that is already present, or alter the phenotype and activity of other immune cells that 
modulate T cell activity.  
Dendritic cells (DCs) play a central role in orchestrating both the innate and 
adaptive immune response.108 In an optimal response, dendritic cells express peptide 
fragments of invading pathogens to T cells and express co-stimulatory molecules that 
enable their efficient activation. However, in the instance of cancer or chronic infection, 
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this process does not always occur appropriately. One method to initiate a more robust T 
cell response is thus to enhance antigen or co-stimulus presentation by DCs which can 
then mediate the T cell response.  
Activation of DCs and other antigen presenting cells, like T cell activation, is 
sensitive to the environment. A stimulatory environment with appropriate kinetics is 
crucial to induce activation rather than tolerance. In order to control the stimulatory 
conditions, DCs can be extracted from a patient and the signals for activation can be fully 
controlled ex vivo. Cell-based DC vaccines, such Sipuleucel-T,109,110 involve this ex vivo 
activation of DCs against a tumor antigen followed by their re-infusion into the patient 
where they can circulate throughout the body and activate an anti-tumor immune 
response. However, this approach is time-consuming and expensive as it involves 
manipulating cells outside of the human body and often has to be completed at non-local 
sites. Nanoparticles have gained interest in the field of vaccine delivery due to their 
ability to be engineered to manipulate the biodistribution and kinetics of vaccine delivery 
in vivo.111 Biomaterials can also potentially be used to target vaccination to specific DC 
subsets which has an effect on vaccine efficacy.112 
Various studies have explored using nanoparticles to effectively delivery antigen 
to DCs directly in vivo. In the design of nanoparticle-based vaccination, particle size 
plays an important role in lymph node trafficking. 25 nm pluronic copolymer-coated 
nanoparticles injected intradermally were shown to travel to draining lymph nodes 
through interstitial flow and remain there for at least 120 hours where they could activate 
a humoral and cellular immune response against a model antigen.113 In contrast, particles 
just four times as large—100 nm—were approximately 10% as efficient and were 
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undetectable in draining lymph nodes within 24 hours. In another study using polystyrene 
particles ranging in size from 20 nm to 2 μm, 40 nm particles most efficiently trafficked 
to lymph nodes and activated resident DCs.114 Similar to spherical nanoparticles, 
nanodiscs have been used for vaccine delivery. Small vaccine-carrying lipoprotein 
nanodiscs approximately 10 nm in diameter were shown to be more effective than soluble 
vaccines.115 These nanodiscs were coupled with antigen peptides and adjuvant and were 
shown to elicit up to a 47-fold greater frequency of tumor-specific T cells than soluble 
vaccines. By utilizing a nanodisc carrier, antigen and adjuvant accumulated more in 
lymph nodes than soluble injected vaccines where there is a high density of dendritic 
cells. Most successful particle-based vaccines are engineered with sub-100 nm particles. 
Particles larger than approximately 200 nm require cellular transport by DCs in the skin 
to travel to the lymph node.58  
Various other similar techniques have been utilized that take advantage of 
nanoparticle trafficking to secondary lymphoid organs by altering size, biomaterial, or 
incorporating specific receptors. Nanoparticle “backpacks” have been developed that 
deliver vaccines to lymph node DCs by binding DC receptors, such as CD40 or DEC-
205, or by binding endogenous albumin.116–120  In addition to modulating the 
biodistribution of the vaccine, approaches have been developed to alter how the delivered 
peptide is presented by the DC. During normal activation, intracellular antigens are 
presented on MHC-I and activate a cell-mediated CD8+ T cell response, whereas 
endocytosed antigens are presented on MHC-II and activate a humoral CD4+ T cell 
mediated response.  To induce presentation by DC on MHC-I, nanoparticle-based 
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vaccines have been developed that are capable of escaping the endosome upon 
internalization.121 
In addition to particles that interact only with T cells (i.e. aAPCs) and particles 
that interact only with antigen presenting cells (i.e. particle-based vaccines), particles can 
bind multiple cell types simultaneously to induce new interactions or change existing 
ones. In these instances, a nanoparticle platform is used to increase avidity for the 
targeted antigens or alter biodistribution. For example, 50 nm particles have been used to 
redirect a T cell response against a specific tumor antigen, similar in approach to 
bispecific T cell engagers.122 These nanoparticles, termed antigen-specific T cell 
redirectors (ATR), were conjugated with an antibody against the CD19 tumor antigen and 
non-tumor peptide-MHC. When MHC-bound ATR were loaded with a human flu 
peptide, human flu-specific T cells were able to be redirected to kill CD19+ tumor cells.  
3.2 Protein engineering 
At the smallest scale, proteins and small molecules can be engineered to target 
specific signals involved with T cell activation. This may involve developing a high 
affinity antibody to activate or block one or more immune stimulatory or inhibitory 
pathways, synthesizing modified cytokines that can more effectively bind their targets, or 
utilizing antibodies to target the delivery of a drug or cytokine to a specific anatomical 
site. In this section, I review these many different approaches and how engineering 
principles have been applied to their design. I will focus on how these engineered 
molecules have been used as monotherapies, although many are combined with synthetic 
particles or scaffolds for further modulation of their delivery.  
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3.2.1  Engineered cytokines 
During T cell activation, T cells receive soluble pro-inflammatory or anti-
inflammatory “signal 3” signals. These signals help to drive cell proliferation, 
differentiation, and chemotaxis among other functions. Administration of pro-
inflammatory cytokines important for immune activation, most commonly the T cell 
growth factor IL-2, can activate a robust anti-tumor immune response, but systemic 
injection is complicated by life-threatening toxicities.123,124 The clinical use of cytokines 
is also hindered by their rapid clearance from the bloodstream, leading to a typical serum 
half-life on the order of minutes. Longer-acting engineered cytokines that can selectively 
activate immune subsets and antibodies that can direct their localization have thus 
infiltrated the field of immunoengineering.  
In the field of cytokine engineering, scientists and engineers have developed 
cytokines with altered binding to immune cell subsets to create a more clinically-
favorable therapeutic. IL-2 signaling occurs through a dimeric or trimeric receptor 
complex, consisting of IL-2Rα, IL-2Rβ, and IL-2Rγ. Different immune subsets modulate 
their sensitivity to IL-2 signaling by modulating their expression of these three subunits. 
Naïve T cells only express the moderate affinity IL-2Rβ and IL-2Rγ subunits, whereas 
memory T cells and regulatory T cells also express the high affinity IL-2Rα and are thus 
more sensitive to IL-2 signaling.125 Importantly, pulmonary edema, a major toxicity upon 
systemic IL-2 administration, has been shown to be mainly IL-2Rα-dependent.126 An 
engineered IL-2Rα-independent “superkine” was shown to shift the cellular response 
upon in vivo treatment compared to wild-type IL-2.127 This IL-2 superkine was 
engineered to have increased binding for the IL-2Rβ subunit and thus activated cells in an 
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IL-2Rα-independent fashion. The IL-2 superkine significantly increased the expansion of 
CD8+ T cells in vivo while having no changed effect on regulatory T cell expansion. By 
shifting the cellular response, it was also shown to significantly reduce pulmonary edema 
and increase the anti-tumor effect in several murine models. Further modifications of this 
engineered IL-2 cytokine have demonstrated how modulating binding activity to the 
other sub-units can further control the cellular response. 
Superagonists against other immunomodulatory cytokines have also been 
developed. For example, IL-15 is a cytokine that contributes to T cell and NK cell 
development, proliferation, and activation.128 Endogenously, IL-15 is bound to IL-15Rα 
and expressed on the cell surface of antigen presenting cells to T cells and NK cells 
displaying IL-2Rβγc. This cell surface expression by IL-2Rβγc induces a necessary 
conformational change that enhances binding to IL-2Rβγc. Thus, the administration of 
soluble IL-15 has only a moderate effect on T cell expansion. Early IL-15 superagonists 
were engineered by binding IL-15 to a recombinant IL-15Rα prior to transfer, and was 
shown to selectively induce robust expansion of memory CD8+ T cells and natural killer 
cells.129 More recently, IL-15 superagonists have been engineered that have four- to five-
fold higher binding to IL-2Rβγc than endogenous IL-15,130 and superagonists linked to Fc 
binding domains to enhance serum half-life.131 
High-affinity superagonist cytokines can modulate the cells that respond to 
treatment and increase the efficacy compared to endogenous cytokines but often do not 
solve the problem of systemic toxicities. In this regard, cytokines have been bound to 
tumor-targeting antibodies to increase their localization to the tumor microenvironment. 
Cytokine-antibody fusion proteins have been developed in over a dozen types of variants. 
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In the simplest terms, cytokines can be linked via the N- or C- terminus of an antibody to 
affect the spatial relationship between cytokine delivery and antibody binding.132 
Additional modifications of the constant region can also modulate how the fusion protein 
interacts with Fcγ receptors, initiates the complement cascade, or alters molecular weight 
and biodistribution.133 In addition to targeting cytokines to the tumor microenvironment, 
the physical constraint of a tumor-targeting antibody with a T or other immune cell 
targeting cytokine can present synergies by additional mechanisms. For example, 
immunocytokines that target tumor-expressed antigens have been shown to increase 
effector-target cell conjugation between tumor cells and T cells or natural killer cells 
much like a bispecific antibody.132 Other families of immunocytokines that link cytokines 
with tumor-associated extracellular matrix components are thought to mediate an anti-
tumor effect primarily through localizing the cytokine delivery.134 
Immunocytokines have been developed that incorporate various different tumor-
associated antigens, from PD-L1 or CD20. However, a majority of those previously 
developed have utilized IL-2, IL-12, IL-15, or TNF.132 For example, authors have shown 
superior anti-tumor activity of an IL-15 superagonist-rituximab fusion protein compared 
to rituximab alone.135,136 By linking the cytokine with a tumor-targeting antibody, the 
fusion proteins were capable of taking advantages of both—specific binding to CD20 on 
tumor cells, stimulation through the IL-2Rβγc on immune cells, and binding to Fcγ 
receptors on macrophages and natural killer cells. Other immunocytokines that deliver 
anti-inflammatory cytokines for organ-specific autoimmune disease,137 target cytokine 
delivery to necrotic areas of tumors through incorporation of anti-DNA antibodies,138 or 
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combine the blockade of tumor-expressed immune-inhibitory molecules139 have also 
been developed. 
3.2.2  Antibody Engineering 
In addition to cytokine engineering, antibodies are constantly being developed to 
block or stimulate cell targets, alter cell-mediated cytotoxicity and biodistribution, or 
selectively deliver drugs to a site of disease. Monoclonal antibodies are able to selectively 
bind an antigen that may be uniquely expressed or upregulated on tumor cells and possess 
longer half-lives than small molecules.140 Their precision thus makes them a common 
method to target individual pathways with fewer off-target toxicities. However, beyond 
selecting a molecular target, applying engineering principles to their design can improve 
their biodistribution, alter their interaction with immune cells, turn them into a 
“backpack” to deliver a drug or nanoparticle to a disease site, or manipulate an antibody 
to target multiple cell types simultaneously. Here, I will not review the process of 
monoclonal antibody production or selection of target antigen, but rather will explore 
how these antibodies have been further manipulated to customize their in vivo effects.  
Antibodies can be separated into three major categories—those whose major 
mechanism of action is through the blockade or stimulation of the targeted pathway, 
those used to deliver a drug payload, and those whose structure has been engineered to 
bind multiple different cell types simultaneously to redirect functionality. Endogenously, 
antibodies often bind infected cells or foreign pathogens. The exposed constant region of 
these antibodies can then mediate antibody-dependent cellular cytotoxicity or 
complement-dependent cytotoxicity. Thus most fundamentally, antibody engineering 
often involves the modification of the Fc region to modulate how the bound antibodies 
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will interact with the immune system.141 When antibody-mediated cell death is desired, 
such as when antibodies target molecules on infected or tumor cells, isotypes such as 
human IgG1 are often incorporated that initiate these processes.142,143 In other cases, an 
antibody may be developed to block or stimulate a certain pathway on a healthy cell-type, 
such as the programmed death 1 (PD-1) inhibitory molecule on T cells. When cell death 
would be detrimental, the antibody is engineered to have an IgG2 or IgG4 isotype that 
has limited interaction with Fc receptors.144 In all cases, antibodies are humanized by 
replacing the constant region and sometimes parts of the variable region with the human 
sequence.145 
T cells have a complex interaction with cancerous cells. While cancerous cells 
may express mutated neo-antigens that are recognized by the immune system, they also 
often upregulate immunosuppressant molecules that inhibit efficient T cell stimulation 
and lack expression of co-stimulatory molecules.37 Many monoclonal antibodies have 
been developed that block these inhibitory pathways on T cells or tumor cells or stimulate 
signaling pathways on T cells directly to jumpstart the cancer immunity cycle. Clinical 
administration of soluble antagonist antibodies against the inhibitory checkpoint 
molecules PD-141,146 and its ligand, PD-L1,147 and CTLA-440,148,149 have shown 
tremendous success in recent years. The success of these checkpoint blockades have been 
correlated with tumor mutation load—tumors with more mutations and more neoantigens 
are associated with improved clinical benefit.150,151 Agonistic antibodies have also been 
developed that stimulate T cell signaling through co-stimulation, such as anti-CD28, anti-
4-1BB, and anti-OX40.5,9,91,152 However, because of the structured arrangement of the 
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signaling molecules during T cell activation, co-stimulatory molecules are often delivered 
on particle platforms6,10 that enable the formation of the immune synapse.  
The direct function of an antibody is often to affect a certain pathway. However, 
antibodies have also been conjugated with various drugs and utilized to deliver payloads 
to specific T cells or tumor cells. In cancer immunotherapy, many of these antibody-drug 
conjugates target tumor-expressed antigens, such as Her2, CD19, or CD22, and 
interesting strategies have been engineered to increase tumor-specificity. For example, a 
protein was developed that has a peptide sequence that shields the antibody’s antigen 
binding site from binding until it is cleaved within the tumor microenvironment.153 This 
method can thus enhance tumor-specificity when the antigen target is not uniquely 
expressed by cancerous cells. This type of approach could also potentially be used to 
decrease off-target toxicities of checkpoint inhibitors and co-stimulatory antibodies as 
these are not limited to the cancerous tissue. Fusion proteins have also been made that 
deliver multiple payloads simultaneously. For example, a trifunctional fusion protein 
linked an antibody against a tumor-associated antigen with both 4-1BBL and IL-15.154 
The fusion protein was more efficient than corresponding bifunctional proteins in 
activating T cells and inducing an anti-tumor response in vivo. The approach to lymphoid 
malignancies is slightly different, where antibodies have been developed to delivery 
cytotoxic drugs to T cells themselves. An antibody drug conjugate targeting IL-7R 
expressed on lymphatic cells demonstrated how this method could be used to treat 
lymphoid malignancies or autoimmune disorders.155 
One of the most unique antibody based approaches in cancer immunotherapy has 
been the development of bispecific antibodies. Bispecific antibodies are antibodies that 
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have been engineered to have two different variable portions, each specific for a different 
antigen. Their specific structure can come in many forms and each varies in terms of size, 
spatial relationship between antigen-binding sites, and synthesis protocol and thus may 
affect half-life and interactions with the corresponding ligands.156 The physical constraint 
of the two antibody fragments is often central to their function. Bispecific antibodies are 
used to physically link two different cell types or dimerize two different molecules on the 
surface of the same cell. On the larger scale are individual antibodies linked by a 
chemical linker and a family of bispecific antibodies called Triomab which maintain the 
full IgG shape by linking two half antibodies, each with one heavy and one light chain.157 
These types of approaches can be easily synthesized by standard protocols to allow for 
high-throughput manufacturing and have extended half-lives compared to smaller 
proteins, but maintain expression of the Fc region which may be recognized by Fc 
receptors and lead to unwanted off-target effects. At the opposite end of the spectrum are 
bispecific T cell engagers (BiTEs) where the heavy and light chain of two different 
variable domains are linked by a short serine-glycine linker.158 These bispecific 
antibodies reduce Fc receptor recognition, but their small size, approximately 55 kDa, 
reduces half-life and necessitates constant intravenous infusion.159  
Likely the most well-known type of bispecific antibodies in the field of cancer 
immunotherapy are bispecific T cell engagers (BiTEs). BiTEs link an anti-CD3 antibody 
fragment with an antibody fragment against a tumor-associated antigen.160 The BiTE can 
thus physically link tumor cells with T cells while activing T cells to induce tumor cell 
lysis. Because BiTEs incorporate anti-CD3 rather than a pMHC, they can activate all T 
cells and thus are associated with dose-limiting toxicities including cytokine storms.161 
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BiTEs have been developed linking T cell stimulation with various tumor-associated 
antigens such as CD19,162,163 BCMA,164 and EphA2.165 However, like many targeted 
immunotherapies, they require the selection of a tumor-associated antigen to target and 
thus antigen escape is a concern. Interestingly, it was recently shown that BiTEs can 
mediate lysis of bystander tumor cells not expressing the targeted antigen.166 
T cell-targeting bispecific antibodies have also been developed that link molecules on 
the same cell. A recent bispecific antibody, synthesized by chemically linking agonistic 
antibodies against the co-stimulatory receptors CD137 and CD134 on T cells, was more 
effective at activating an anti-tumor T cell response than either antibody individually.167 
In contrast to monotherapy, the platform uniquely induced preferential expansion of 
effector T cells. Thus, in addition to redirecting cells, bispecific antibodies can potentially 
impact T cell activation by physically co-clustering molecules on the surface of the same 
cell. This approach may be interesting in the targeting other T cell signaling molecules 
since the activation process is highly sensitive to receptor clustering and spatial 
localization.  
3.3 Combination immunotherapies 
Methods of both direct T cell activation and blockade of inhibitory checkpoint 
pathways have resulted in exciting results in preclinical studies and clinical trials. 
However, there remains a large population of patients who do not respond to 
monotherapies. Thus, it has become evident that targeting a single stage of the Cancer-
Immunity Cycle is not sufficient and that combination therapies that target multiple 
complementary pathways will have a greater chance of capturing a large response pool. 
Because there is a diverse array of inhibitory and stimulatory pathways that affect T cell 
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activation, monotherapies allow for tumor escape through the upregulation of alternative 
pathways.  
Combination therapies against multiple checkpoint molecules can de-activate 
multiple different T cell inhibitory pathways. Notably, anti-PD-1 mAbs have been co-
administered with anti-CTLA-4 mAb in several clinical trials. Because these two 
pathways are non-redundant, blocking both can synergize T cell activation. The 
combination therapy significantly enhances the objective response rate to as high as 60%, 
but also increases the amount of adverse toxicities associated with widespread immune 
activation.40 Importantly, the efficacy of combination checkpoint blockade in comparison 
to monotherapy is dependent on biomarker expression, such as PD-L1, in a patient’s 
tumor and indicates the importance of using biomarkers to guide therapeutic 
interventions to reduce costs due to unnecessary combinations.148 Additional 
combinations of inhibitory molecule blockades have also demonstrated improved 
efficacy. Doublets of anti-CTLA-4, anti-PD-L1, and an IDO inhibitor all enhanced the re-
activation of tumor infiltrating lymphocytes in a murine melanoma model. These studies 
demonstrated that the combination therapies were effective by re-activating tumor 
infiltrating lymphocytes rather than inducing new T cell migration.42 Thus, in tumors 
lacking T cell infiltration, combination therapies that also induce migration into the tumor 
may be more effective. 
Combination therapies that link T cell stimulation with checkpoint blockade aim 
to intervene at the two major ways by which T cell activation is modulated. T cell 
stimulation can be mediated directly through the administration of co-stimulatory 
antibodies, or indirectly through a DC-based vaccine. Even when an anti-tumor T cell 
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population is present, however, activated T cells upregulate inhibitory molecules such as 
PD-1 and CTLA-4 in a homeostatic fashion. Tumor cells can also upregulate inhibitory 
ligands such as PD-L1, especially in response to T cell secretion of IFN-γ, which 
diminish the activity of these cells.  
Checkpoint blockade has now been combined with almost every approach to T 
cell stimulation to maintain activation. In chronic viral infection, co-administration of 
antagonistic antibodies against PD-L1 and agonistic antibodies against 4-1BB were 
shown to enhance the expansion of viral-specific CD8+ T cells compared to 
monotherapy.45 The combination therapy also impacted the kinetics of the T cell 
response, indicating that combination therapies may be used to modulate how quickly T 
cells are expanded against a certain antigen. In cancer immunotherapy, co-administration 
of anti-PD-1 and anti-4-1BB can enhance an anti-tumor response by modulating T cell 
phenotype and density of tumor infiltrating lymphocytes.43,44 Checkpoint blockade has 
also been shown to increase the efficacy of peptide-pulsed DC vaccination, in this case 
blocking inhibitory molecules on DCs.168 Various other approaches have shown synergy 
between the combination of anti-PD-1 checkpoint blockade and granulocyte macrophage 
colony-stimulating factor,169 OX40 and CD27 co-stimulation with anti-PD-L1 checkpoint 
blockade,5 and anti-OX40 co-stimulation and vaccination.91 
Checkpoint blockade has also been combined with therapeutics that enhance 
tumor immunogenicity. Treatments that induce tumor cell death or increase mutational 
load, including oncolytic viruses, radiation, or chemotherapy, can enhance antigen 
presentation and activation to tumor-specific T cells.170 However, the anti-tumor T cell 
response is often still limited by the expression of inhibitory molecules by both tumor and 
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immune cells. Radiation has been shown to synergize with anti-CTLA-4 checkpoint 
blockade, with local radiation leading to the regression of even distant metastases.171 
However, resistance to this dual treatment was shown to be mediated at least partially by 
tumor upregulation of PD-L1. In response to this observation, combination therapy 
comprised of radiation, anti-CTLA-4, and anti-PD-L1 was shown to increase the 
response rate and minimize tumor immune escape.172 Checkpoint blockade also can 
increase the efficacy of oncolytic viruses that preferentially infect and lyses cancerous 
cells. A study with the oncolytic Newcastle Disease Virus demonstrated that its 
combination with anti-CTLA-4 could completely eliminate established murine melanoma 
and even lead to an improved abscopal effect.173 
While combination therapies often involve the co-administration of multiple 
therapeutics, another approach to combination therapy is to develop a single therapeutic 
with multiple mechanisms of action. CD80, the ligand expressed by antigen presenting 
cells that induces T cell proliferation upon ligation with T cell expressed CD28, has 
additional binding partners. CD80 has also been shown to bind PD-L1 and plays a role in 
inducing apoptosis of activated CD8+ T cells.174,175 This dual interaction has been taken 
advantage of in a soluble form of CD80 as a therapeutic.176 This CD80-Fc fusion protein 
was shown to both neutralize the inhibitory PD-1/PD-L1 interaction while simultaneously 
stimulating T cells through CD28.  
While combining stimulatory and inhibitory molecules in a single all-in-one 
therapeutic may be desirable from an engineering perspective, the immunological 
mechanisms behind their success may indicate that sequential delivery may be more 
effective. In one study, anti-PD-1 administration following anti-OX40 co-stimulation was 
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effective at delaying tumor growth, but not vise-versa or co-injection—it was necessary 
for the co-stimulation to first boost the T cell response to a state where checkpoint 
molecules played a role in inhibiting the response.177 Thus, sequential delivery or 

















Chapter 4. Dual Targeting Nanoparticle Stimulates 
the Immune System to Inhibit Tumor Growth1 
4.1. Introduction 
Cancer provokes an immune response to tumor-associated antigens. This can 
initiate the activation of tumor-specific T cells and result in tumor cell death in a process 
known as the cancer-immunity cycle.28 Cancer thrives when there is a blockade in this 
cycle that allows cancer escape, and current immunotherapeutics aim to take down these 
barriers.178 
Many emerging immunotherapies target activation of a tumor-specific T cell 
response.68,70,179–181 T cell activation can be initiated by ligating two necessary signals—
the T cell receptor with its cognate peptide-MHC, termed signal 1, and a costimulatory 
molecule, termed signal 2—using cellular or nanoparticle-based platforms. Different 
molecules can serve as co-stimulatory signals to T cells37 such as B7-1/B7-2 or 4-1BBL 
which bind to CD28 and 4-1BB on the T cell, respectively. Signaling through 4-1BB in 
particular has gained interest in recent years for its ability to induce a more effective anti-
tumor immune response than CD28 alone. Ligation of 4-1BB on T cells has been 
demonstrated to enhance cytotoxicity, prevent activation-induced cell death, and increase 
expansion and cytokine secretion preferentially in cytotoxic CD8+ T cells.8,9,38 Despite 
the ability of 4-1BB activation to initiate and maintain more effective tumor-targeting 
CD8+ T cells, the tumor microenvironment often upregulates immunosuppressive surface 
                                                          
1 Sections of this chapter are reprinted (adapted) with permission from “Kosmides, A., Sidhom, J.-W., 
Fraser, A., Bessell, C.A., and Schneck, J.P. Dual Targeting Nanoparticle Stimulates the Immune System to 
Inhibit Tumor Growth. ACS Nano 2017, 11, 5417-5429.” Copyright 2017 American Chemical Society.  
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antigens and cytokines that diminish their cytotoxic effects.27,32,182–185 Programmed death 
ligand 1 (PD-L1) is one such cell surface antigen, a checkpoint molecule upregulated on 
many cancers including melanoma, ovarian cancer, renal cell cancer, and non-small cell 
lung cancer.186 Since a large proportion of tumor-infiltrating lymphocytes express PD-
L1’s receptor, programmed death 1 (PD-1),180 expression of PD-L1 suppresses tumor-
infiltrating lymphocyte effector functions.187,188  
Monoclonal antibodies (mAb) that block checkpoint molecules such as PD-1, PD-
L1, and CTLA-4 delay tumor growth in murine melanoma models,168,187 and anti-PD-1 
and anti-CTLA-4 mAb have been approved by the FDA with overall patient response 
rates of up to approximately 30%.41,189–191  While expression of PD-L1 within the tumor 
microenvironment correlates with outcome, its overall expression cannot predict response 
indicating that there are other mechanisms at play.192 Complete response rates in these 
patients have been as low as 5%193 and demonstrates the need for additional 
development.  
Recent studies have shown that checkpoint blockade efficacy can be further 
improved through combination with immunotherapies targeting diverse pathways. For 
example, a clinical trial combining PD-1 and CTLA-4 blockade nearly doubled survival 
time compared to anti-PD-1 mAb alone.148 Additional studies in mice have shown similar 
results, with superior tumor control in mice treated with PD-1 antagonists in combination 
with CTLA-4 checkpoint blockade and 4-1BB co-stimulation.42,43 However, these non-
specific approaches require high concentrations of antibody, as high as 100-200 μg/dose 
in murine models, and a majority of patients experience significant off-target side effects, 
especially when treated with a combination of antibodies.148 Improvements in 
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combinatorial immunotherapeutics are thus imperative to enable their use at safe and 
effective levels. 
Here, we describe our development of a nanoparticle platform for combinatorial 
immunotherapeutics. These nanoparticles, termed immunoswitch particles, switch off the 
immunosuppressive PD-L1 pathway on tumor cells while simultaneously switching on 
the costimulatory 4-1BB pathway on CD8+ T cells. By physically constraining the 
antibodies on a nanoparticle platform, immunoswitch particles result in synergy between 
the two immunotherapies and are thus effective at low doses. In vivo we found that 
immunoswitch treatment had significant anti-tumor activity in both murine melanoma 
and colon cancer models and that the anti-tumor activity was seen with or without a 
model foreign antigen. The particles increase tumor-specific CD8+ T cell activation as 
compared to soluble antibody and do not require a priori selection of a cognate signal 1, 
allowing for activation of a robust polyclonal response. We show that immunoswitch 
particles mediate not only an increase in the number and specificity of tumor-specific 
CD8+ T cells, but also a change in the endogenous T cell receptor repertoire. This 
conserved change demonstrates that therapy recruits an altered set of T cell receptors for 
more effective recognition even when recognizing a defined tumor antigen. 
Immunoswitch particles represent a signal-switching approach to T cell-mediated cancer 
immunotherapy that simultaneously targets two stages of the cancer immunity cycle.  
4.2. Methods 
4.2.1 Mice 
2C T cell receptor transgenic mice were maintained as heterozygotes by breeding 
on a C57/BL6 background. C57BL/6 and Nu/J mice were purchased from Jackson 
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Laboratories (Bar Harbor, ME, USA). All mice used were 6-8 weeks of age and were 
maintained according to Johns Hopkins University's Institutional Review Board. 
4.2.2 Reagents and cell lines 
B16-SIY was a gift from Tom Gajewski (The University of Chicago, IL, USA). 
B16-F10 and MC38-OVA were a gift from Charles Drake (Johns Hopkins University, 
MD, USA). RMA-S cells were a gift from Michael Edidin (Johns Hopkins University, 
MD, USA). Tumor cell lines have been authenticated by cognate T cell cytotoxicity.  
Anti-PD-L1 monoclonal antibody clone 10F.9G2, anti-4-1BB clone 3H3, anti-
CD3 clone 145.2C11, anti-CD28 clone 37.51, and their respective isotype controls were 
purchased from BioXCell (West Lebanon, NH). Fluorescently labeled monoclonal 
antibodies were purchased from BioLegend (San Diego, CA, USA). SIY peptide was 
purchased from GenScript (Piscataway, NJ).  
4.2.3 Immunoswitch particle synthesis and characterization 
Anti-biotin coated iron-dextran 50-100 nm particles were purchased from 
Miltenyi (Miltenyi Biotec; Auburn, CA). Anti-PD-L1 antibody clone 10F.9G2, anti-4-
1BB clone 3H3, and their respective isotype controls were biotinylated using EZ-Link 
sulfo-NHS-biotin (Thermo Fisher Scientific; Waltham, MA) according to the 
manufacturer’s protocol. Particles and a 2-fold molar excess of the biotinylated 
antibodies of interest were combined and allowed to conjugate for 24 hours at 4˚C. 
Unbound antibody was removed by running the particles over an MS column (Miltenyi 
Biotec, Auburn, CA) and washing according to the manufacturer’s protocol.  
Particle size was determined by nanoparticle tracking analysis using a Nanosight 
LM10. To characterize particle conjugation, a standard curve relating absorbance to 
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particle concentration was made using a Beckman Coulter AD340 plate reader and 
Nanosight LM10. Particles were then subsequently measured for absorbance to determine 
concentration, and all particles were brought to a concentration of 1.4 x 1012 particles/ml. 
The amount of specific antibody per particle was determined by staining the particles 
with fluorescently-labeled secondary antibodies against the antibody of interest. Excess 
antibody was removed by running the particles over an MS column (Miltenyi Biotec; 
Auburn, CA), and antibody concentration was measured by comparing particle 
fluorescence to a standard curve and correlating with the total bead concentration.  
4.2.4 In vitro CD8+ T cell activation model 
On day -8, primary splenocytes were isolated from naïve 2C transgenic mouse 
spleens through cell straining. Cells were treated with 4 mL of ACK lysis buffer for 1 
minute to lyse red blood cells. CD8+ T cells were isolated by negative selection with the 
Miltenyi CD8a+ isolation kit IIa following the manufacturer’s protocol (Miltenyi, 
Auburn, CA). Micro anti-CD3/anti-CD28 expander beads were synthesized on 4.5μm M-
450 Epoxy Dynabeads (Life Technologies; Grand Island, NY) at a 1:1 molar protein 
ratio, following manufacturer’s protocol. 2C CD8+ T cells were mixed with micro 
expander beads at a 1:1 ratio and cultured in RPMI supplemented with L-glutamine, non 
essential amino acids, vitamin solution, sodium pyruvate, β-mercaptoethanol, 10% FBS, 
ciproflaxin, and a cocktail of T cell growth factors. On day -4, additional T cell growth 
factors and expander beads were added at a 2:1 bead:cell ratio. On day -2, B16-SIY and 
B16-F10 cells were cultured in RPMI supplemented with L-glutamine, non essential 
amino acids, vitamin solution, sodium pyruvate, β-mercaptoethanol, 10% FBS, 
ciproflaxin, and 20 ng/ml recombinant murine IFN-γ (R&D Systems, Minneapolis, MN). 
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On day 0, B16-F10 and B16-SIY were harvested and washed three times to remove all 
IFN-γ, as confirmed by ELISA. 2C cells were also harvested, washed three times, and 
beads were removed with a magnet. Live CD8+ cells were isolated by density 
centrifugation using Ficoll-Paque PLUS (GE Healthcare Life Sciences; Pittsburgh, PA). 
Surface marker expression on both cell types was measured using a BD FacsCalibur flow 
cytometer and analyzed in FlowJo (TreeStar). For IFN-γ release studies, 2C cells and 
B16-SIY or B16-F10 cells were mixed at a 1:1 effector target ratio in the presence of 
particles or soluble antibody. The cells were incubated for 18 hours at 37˚, then 
supernatants were collected. IFN-γ was measured by ELISA using the ebioscience 
murine IFN-γ Ready-SET-Go! Kit (San Diego, CA). For cytotoxicity assay, 2C cells and 
B16-SIY cells were mixed at a 1:1 effector target ratio in the presence of immunoswitch 
particles and 100 µg/ml anti-Kb (clone 20.8.4) or respective isotype mAb. After four 
hours, supernatant was harvested and cytotoxicity was measured using a CytoTox-Glo 
Cytotoxicity Assay (Promega; Madison, WI) according to the manufacturer’s protocol. 
Luminescence was read on a Tropix TR717 Microplate Luminometer.  
4.2.5 B16 in vivo tumor growth experiments 
Immunoswitch and isotype particles were synthesized and characterized as 
described above. Amount of antibody on the particles was quantified and a solution of 
equal concentration non-biotinylated antibody was diluted in PBS. Particles and soluble 
antibody were put to a concentration of 13μg/mL total antibody (6.3μg/mL anti-PD-L1 
and 6.3μg/mL anti-4-1BB) and treated mice received 100 μl each. 
C57BL/6 mice were injected with 1x106 B16-SIY or 3x105 B16-F10 cells 
subcutaneously on the right flank on day 0. For adoptive transfer experiments, CD8+ 
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cells were harvested from naïve 2C splenocytes and stimulated with anti-CD3/anti-CD28 
expander beads on days 0 and 4 as described above. On day 8, when all mice had 
palpable tumor, beads were isolated from CD8+ cells and live cells were isolated by 
density centrifugation using Ficoll-Paque PLUS (GE Healthcare Life Sciences; 
Pittsburgh, PA). 5x105 2C CD8+ cells were intravenously injected into all groups (except 
no treatment group). For all experiments, isotype particles, immunoswitch particles, or 
soluble antibody were injected intratumorally on days 8, 11, and 15. For intravenous 
studies, immunoswitch particles or soluble antibody were injected retro-orbitally on days 
4, 8, 11, and 15. Beginning on day 4-8, tumors were measured every 2-3 days using 
digital calipers, and tumor size was computed by multiplying the longest dimension by 
the length of the perpendicular dimension. Mice were sacrificed when tumor area 
surpassed 200 mm2. 
4.2.6 B16-SIY tumor infiltrating lymphocyte analysis 
Immunoswitch particles were synthesized and characterized as above. C57BL/6 
(Jackson Labs; Bar Harbor, ME) mice were injected with 1x106 B16-SIY cells 
subcutaneously on day 0. Immunoswitch particle treatment was administered 
intratumorally on days 8 and 11 (n=5/group).  
On day 14, tumors were measured and peripheral blood, tumors, spleens, and 
tumor draining lymph nodes were isolated. Spleens and tumor draining lymph nodes 
were brought to a single cell suspension using a cell strainer, washed, then re-suspended 
in PBS. Tumors were coarsely sectioned using scissors then brought to a single cell 
suspension using a cell strainer. Tumor-infiltrating lymphocytes were isolated by density 
centrifugation using Ficoll-Paque PLUS (GE Healthcare Life Sciences; Pittsburgh, PA) 
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then washed three times and resuspended in PBS. Cell counts were taken using a 
hemocytometer.  
For phenotypic analysis, isolated cells were stained with a fluorescently labeled 
with a live/dead stain (Thermo Fish Scientific; Waltham, MA), CD8 antibody 
(BioLegend; San Diego, CA), and biotinylated Kb-SIY dimer followed by fluorescently 
labeled streptavidin. Cells were run on a BD LSR II flow cytometer and analyzed using 
FlowJo (TreeStar). CD8 cell density was measured by multiplying the CD8 purity 
measured by flow cytometry by the total cell count, and dividing by the tumor volume 
(longest dimension squared and multiplied by the perpendicular dimension).  
For functional analysis, an equivalent number of tumor-infiltrating lymphocytes from 
individual mice (n=3/group) were co-incubated with SIY pulsed RMA-S cells and anti-
CD107 FITC. After 12 hours, GolgiStop/GolgiPlug (BD Biosciences, San Jose, CA) 
were added to solution. Six hours later, cells were stained for surface markers, then fixed 
and permeabilized with BD Cytofix/Cytoperm and stained with fluorescently labeled 
antibodies against intracellular cytokines according to the manufacturer’s protocol.  
Labeled cells were read on an LSR II and analyzed with FlowJo. 
4.2.7 T cell receptor sequencing analysis 
In vivo tumor administration and treatment was identical to that in 4.2.6 B16-SIY 
tumor infiltrating lymphocyte analysis (n=3/group). On day 14, tumor-infiltrating 
lymphocytes were isolated as above. Isolated cells were stained with a fluorescently 
labeled anti-CD8 mAb and live/dead stain (Thermo Fish Scientific; Waltham, MA) and 
CD8 antibody (BioLegend; San Diego, CA), and each sample was sorted based on 
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live/CD8+ cells. CD8+ cell samples were sent to Adaptive Biotechnologies for deep 
sequencing of the T cell receptor beta chain.  
To assess V-beta usage analysis compared to a Kb-SIY response, spleens were 
isolated and pooled from 3 non-tumor bearing C57BL/6 mice. CD8+ T cells were 
isolated by negative selection as described above, and stimulated for 7 days with Kb-
SIY/anti-CD28 nano-aAPC according to our previously published Enrichment + 
Expansion protocol.194 On day 7, cells were fluorescently labeled with a live/dead stain, 
CD8 antibody, and Kb-SIY dimer as described above. Cells were sorted for 
live/CD8+/Kb-SIY+ and sent to Adaptive Biotechnologies for sequencing.  
To assess characteristics of T cell receptor sequence repertoire, tsv files from 
adaptive were downloaded from their online portal, converted to excel files, and 
unproductive sequences were removed (only clones with amino acid CDR3 sequences 
were examined). All clones with the same amino acid sequence were combined and their 
net frequency was calculated. In order to examine the presence of clones in either 
immunoswitch or non-treated cohorts, only sequences with a contribution above 0.5% 
were examined. To examine the conservation of the response between animals in both 
cohorts, the top 85% of the CD8+ T cells response was examined and conservation of 
response was determined as the weighted average (by reads) an identical sequence makes 
up in the two samples being compared.  
4.2.8 MC38-OVA in vivo tumor models 
Immunoswitch particles and isotype particles were synthesized as described 
above. Amount of antibody on all particles was quantified by the methods described 
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above, and particles were put at a concentration of 13μg/mL total antibody. Treated mice 
received 100 μl particles/mouse. 
C57BL/6 (Jackson Labs; Bar Harbor, ME) mice were injected with 1x106 MC38-
OVA cells subcutaneously on the right flank on day 0 and cages were randomly assigned 
to one of three groups: 1) no treatment, 2) isotype particles, or 3) immunoswitch particles 
(n=6 in isotype, n=10/other groups). On days 8, 11, 15, and 18 treated mice received 
intratumoral injections of immunoswitch or isotype particles and tumors were measured 
every 2-3 days. For re-inoculation studies, cured or age-matched C57BL/6 mice were 
injected with 1x106 MC38-OVA cells subcutaneously on the opposite (left) flank on day 
28. Beginning on day 8, tumors were measured every 2-3 days using digital calipers, and 
tumor size was computed by multiplying the longest dimension by the length of the 
perpendicular dimension. Mice were sacrificed when tumor area surpassed 200 mm2. 
4.2.9 Immunoswitch biodistribution 
Immunoswitch particles were synthesized as described above. Immunoswitch 
particles and a mixture of soluble anti-4-1BB and anti-PD-L1 antibody were labeled with 
IRDye 680RD protein labeled kits from LI-COR Biosciences (Lincoln, Nebraska) 
according to the manufacturer’s protocol.  
Nu/J mice (Jackson Labs; Bar Harbor, ME) were injected with equal protein 
amounts of either IR-labeled soluble antibody or immunoswitch particles subcutaneously 
on the right flank (n=3/group). Dorsal, ventral, right, and left images of the mice were 
taken at 3, 24, 48, and 72 hours post injection. Only right images which show the 
injection area are shown. All images from any individual mouse had matched 
thresholding. Images were analyzed in ImageJ by defining a region of interest (ROI) 
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around the initial injection site which was then duplicated in all images. The mean gray 
value of each ROI was then measured in ImageJ. The mean grey value for an image of an 
individual mouse at time T was then normalized to the mean grey value at 3 hours using 
the following equation: 




This data was then fit to a one phase exponential decay curve using the GraphPad non-
linear regression analysis module (GraphPad Software; La Jolla, CA).   
For organ analysis studies, C57BL/6 mice (n=3/group) were injected 
subcutaneously with B16-SIY cells on day 0. Eight days later, IR-labeled immunoswitch 
particles were injected intratumorally into half of the tumor-bearing mice. 48 hours after 
treatment, the tumor, spleen, tumor draining lymph node, and contralateral lymph node of 
each mouse were dissected and imaged on an IR imager. Images were analyzed in ImageJ 
by defining a region of interest (ROI) around each lymph node which was then duplicated 
in all images. Tumor and spleen ROI were defined for each image independently due to 
their difference in size and shape.  The mean gray value of each ROI was then measured 
in ImageJ and was normalized to the maximum of the sensor. 
4.2.10 Conjugation assay 
2C CD8+ T cells were isolated from naïve splenoctyes and stimulated on days -8 
and -4 with expander beads as previously described. B16-F10 cells were incubated with 
media supplemented with 20 ng/ml recombinant murine IFN-γ (R&D Systems; 
Minneapolis, MN) on day -2 for 48 hours.  
On day 0, CD8 cells and B16-F10 cells were isolated from beads and IFN-γ 
respectively, as previously described. CD8 cell membranes were labeled with the PKH26 
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red fluorescent cell linker kit and B16-F10 cell membranes were labeled with the PKH67 
green fluorescent cell linker kit (Sigma-Aldrich; St. Louis, MO) according to the 
manufacturer’s protocol. Effector and target cells were co-incubated at a 1:1 ratio with 
immunoswitch or isotype particles. After 1 hour, cells were briefly vortexed and fixed. 
For flow cytometry experiments, cells were fixed in 0.5% paraformaldehyde for 20 min 
at room temperature. Cells were then read on a BD FacsCalibur. Conjugate formation 
was measured by first gating on all CD8+ T cells (i.e. red cells), and then on those also 
bound to B16-F10 cells (i.e. also expressing green) using FlowJo (TreeStar). Flow 
cytometry experiments were repeated 3 independent times. For confocal microscopy 
experiments, cells were fixed in 2% paraformaldehyde for 20 min at room temperature. 
Cells were then read on a Zeiss LSM510-Meta laser scanning confocal microscope at 
100x magnification. Two to three non-overlapping images were taken per experiment, 
and the experiment was repeated three independent times. Conjugate formation was 
determined manually by observing red/green overlap/contact using ImageJ. Each image 
was taken as an independent data point. For both flow cytometry and confocal 
microscopy studies, conjugation was measured as the percent of CD8 cells forming 
conjugates with B16-F10 cells divided by the total number of CD8 cells.  
4.2.11 In vivo killing assay 
C57BL/6 mice, five per group, were injected with MC38-OVA tumor and treated 
with immunoswitch particles as in 4.2.8 MC38-OVA in vivo tumor models. On day 28 
post tumor inoculation, immunoswitch-treated mice were categorized by their response 
status—“cured” meaning no palpable tumor, or “not cured” meaning palpable tumor. 
Splenocytes were harvested from naïve C57BL/6 mice and stained with a high or low 
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level of CellTrace Violet (Thermo Fisher Scientific) according to the manufacturer’s 
protocol. Cells with a high level of CellTrace Violet were pulsed with the OVA peptide 
and cells with a low level of CellTrace Violet were pulsed with a non-cognate SIY 
peptide—1 μg of peptide was added per 107 cells and incubated for 1 hour at 37˚C. Cell 
samples were separately washed then mixed at a 1:1 ratio with a total of 108 cells/ml. 
Observation of two separate CellTrace Violet peaks was confirmed by flow cytometry. 
100 μl of the cell mixture was injected into each cured, not cured, and naïve mouse by 
retro-orbital injection.  
Twenty-four hours post injection, mice were sacrificed and splenocytes harvested. 
Lymphocytes were isolated by density centrifugation with Lympholyte Cell Separation 
Media (Cedarlane; Burlington, Ontario, Canada). Lymphocytes were read on flow 
cytometry and number of low and high-stained CellTrace Violet cells were quantified.  
4.2.11 Statistics 
Information on statistical tests are present in all figure legends. One and two-way 
ANOVA were used when making multiple comparisons. Bonferroni posttests were 
performed when comparing all groups, and Dunnett’s posttests were performed when the 
hypotheses being tested involved comparison against a single group. One-tailed and two-
tailed t-tests were used when comparing two groups, as indicated in figure legends. All 
datasets were assumed to fit a normal distribution, and all graphs show mean and error 
bars represent SEM. All n values are present within figure legends. In vivo tumor 
treatment studies were repeated in two independent experiments to ensure adequate 
sample size and reproducibility. Mice with outlier tumor size before the beginning of 
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treatment were removed from the studies. Randomization was performed by cage in all 
animal studies. All statistical analysis was performed using GraphPad Prism software.  
4.3 Results 
4.3.1 Immunoswitch particles activate T cells in vitro 
Immunoswitch particles link checkpoint blockade with T cell costimulation on a 
single nanoparticle platform. The particles are synthesized by conjugating 80 nm iron-
dextran nanoparticles with a 1:1 molar ratio (Figure 4-1) of agonistic antibodies against 
4-1BB (a costimulatory receptor found on the effector T cells) and antagonistic 
antibodies against PD-L1 (found on the cancer cells) (Figure 4-2A – inset). The 
hypothesized mechanism of action of the immunoswitch particles is shown in a schematic 
in Figure 4-2A – the particles target tumor cells expressing PD-L1 and simultaneously 
block access to PD-1 on T cells. Their costimulatory antibody binds to 4-1BB on CD8+ T 
cells, targeting them to the tumor cells and thus switching a negative signal into a co-
stimulatory signal. The clonotypic T cell receptor on the CD8+ T cell receives cognate 





Figure 4-1. Immunoswitch particles combine anti-4-1BB and anti-PD-L1 antibodies on a nanoparticle 
platform. (a) Iron-dextran nanoparticle platform is 80nm in diameter. Unconjugated iron-dextran 
nanoparticle size was measured by nanoparticle tracking analysis. Mean (black) and SEM (red) of 3 
separate captures of a single sample is shown. The mode of the dataset is 81.1 +/- 1.6 nm and the mean of 
the dataset is 96.0 +/- 1.9 nm. (b) Number of anti-4-1BB and anti-PD-L1 molecules per particle, as 
measured by fluorescently labeled secondary antibody. Mean +/- SEM is shown, averaged across 3 
independent experiments. No significant differences in antibody level per each particle type, as measured 




Figure 4-2. Immunoswitch particles link PD-L1 checkpoint blockade with 4-1BB co-stimulation. (a) 
Schematic showing immunoswitch particle interaction with CD8+ T cell and cognate target cell. Inset – 
immunoswitch particles are synthesized by conjugating anti-4-1BB and anti-PD-L1 monoclonal antibodies 
to the surface of 80 nm particles. (b) IFN-γ secretion from PD-1hi 2C CD8 cells co-incubated with PD-L1hi 
cognate B16-SIY cells and immunoswitch particles or soluble antibody. Concentrations refer to total 
antibody in culture. Significance measured by two-way ANOVA with Bonferroni posttest (p=0.0064, 
F1,30=8.607 treatment variation; p<0.0001, F4,30=79.76 concentration variation). (c) IFN-γ secretion from 
PD-1hi CD8 cells co-incubated with PD-L1hi B16-SIY and 9 μg/ml of the indicated particle type. 
Significance measured by one-way ANOVA with Dunnett’s posttest. Comparisons to immunoswitch 
particles are shown. (d) IFN-γ secretion from PD-1hi 2C CD8 cells co-incubated with PD-L1hi cognate 
B16-SIY cells or non-cognate B16-F10 cells and immunoswitch particles. Significant was measured by 
two-tailed t-test (p<0.0001).  Mean +/- SEM of 3 samples is shown for (b-d). (e) Percent specific lysis of 
B16-SIY cells by 2C CD8+ T cells when co-incubated for 4 hours at a 1:1 effector-target ratio in the 
presence of immunoswitch particles and 100 µg/ml anti-Kb blocking mAb or isotype control. Significance 
was measured by two-tailed t-test. (f) PD-1hi 2C CD8 cells and PD-L1hi B16-F10 cells were labeled with a 
red and green membrane dye, respectively. Percent of CD8 cells forming conjugates were counted. Each 
data point represents an independent image taken across three independent experiments. 50 ng of 
immunoswitch particles significantly increased conjugation rate over isotype particles as measured by one-
way ANOVA (p=0.0013) with Dunnett’s posttest. Arrows show conjugate formation. Cell and antibody 
images in (a) are adapted under a Creative Commons License from Servier Medical Art 
(http://www.servier.com/Powerpoint-image-bank). (***p<0.001, **p<0.01, *p<0.05) 
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Immunoswitch particle activity was analyzed in vitro using a model of repetitive 
antigen stimulation known to mimic the tumor microenvironment.195 2C T cell receptor 
transgenic CD8+ T cells, specific for the SIY peptide presented in the context of the H-2 
Kb MHC, were repetitively stimulated with anti-CD3/anti-CD28 expander beads. Murine 
melanoma cells—either non-cognate B16-F10 cells or cognate B16-SIY cells, a 
transfected tumor cell line derived from B16-F10 which expresses the cognate Kb-SIY 
antigen—were treated with 20 ng/ml IFN-γ.  These treatments resulted in upregulation of 
PD-1 and 4-1BB expression on the CD8+ T cells (Figure 4-3A) and upregulation of PD-
L1, but not PD-L2, on the murine melanoma cells (Figure 4-3B,C). Treatment with 
either soluble anti-4-1BB or anti-PD-L1 mAb increased CD8+ T cell activation in a dose 
dependent fashion, demonstrating the ability to study immunoswitch nanoparticle activity 





Figure 4-3. In vitro model results in upregulated inhibitory molecules on CD8 and B16 cells. (a) Flow 
cytometry plots of PD-1 and 4-1BB expression on CD8 cells on day 0 (dotted) and day 8 after expander 
bead stimulation on days 0 and 4 (solid), as compared with isotype (grey, filled). B16 cells were cultured in 
media supplemented with 20 ng/ml IFN-γ for 48 hours, and PD-L1 and PD-L2 expression was assessed by 
flow cytometry. Flow cytometry plot of PD-L1 (b) and PD-L2 (c) expression by B16-SIY (left) and B16-F10 
(right) cells on day 0 (dotted) and 48 hours after IFN-γ treatment (solid), as compared with isotype (grey). 




Figure 4-4. Soluble anti-4-1BB and anti-PD-L1 mAb increase T cell activation when co-incubated with 
target cells. PD-1hi 2C CD8 cells and PD-L1hi cognate B16-SIY cells were co-incubated at a 1:1 ratio in 
the presence of titrating amounts of soluble anti-4-1BB (a) or anti-PD-L1 (b) antibody. IFN-γ secretion by 
CD8 cells was measured by ELISA after 18 hours. Both antibodies induced a significant increase in the 
level of IFN-γ secretion as compared to isotype at concentrations at and above 10 ng/ml. Mean +/- SEM 
are shown of three replicates. Significance measured by one-way ANOVA with Dunnett’s posttest, 
comparing each condition to isotype. (*p<0.05, ***p<0.001) 
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PD-1hi CD8+ T cells and PD-L1hi B16-SIY cells were co-incubated with 
immunoswitch particles, and T cell stimulation was measured by IFN-γ secretion.  
Compared to cultures treated with isotype particles, there was maximally over a 6-fold 
increase in IFN-γ secretion by immunoswitch particle-treated cultures (Figure 4-2B). As 
expected, cultures treated with soluble anti-4-1BB and anti-PD-L1 also increased IFN-γ 
secretion, although only a 2 to 3-fold increase over isotype antibody controls. This data 
shows that the antibodies maintain their functionality even when constrained on 
nanoparticles and in fact potentially have increased T cell stimulatory activity. 
To investigate the requirement for both antibodies on the surface of the nanoparticle, we 
compared CD8+ T cell activation in response to co-incubation with immunoswitch 
particles versus anti-4-1BB mAb only or anti-PD-L1 mAb only particles. The greatest 
IFN-γ secretion, maximally 173±3 ng, was measured in immunoswitch particle treated 
cultures (Figure 4-2C).  In contrast, only 141±18 ng and 107±8 ng of IFN-γ was 
produced by cultures treated with anti-4-1BB and anti-PD-L1 only particles, respectively. 
4.3.2 Enhanced T cell-tumor cell conjugation 
To understand the mechanism of immunoswitch particle activity, we studied their 
cellular interactions. We sought to investigate both their ability to mediate CD8+ T cell-
tumor cell conjugation as well as requirements for cognate peptide-MHC stimulation.  
We investigated the requirement for peptide-MHC recognition by comparing 2C 
CD8+ T cell activation when co-incubated with immunoswitch particles and cognate 
B16-SIY or non-cognate B16-F10 tumor cells.  In the presence of B16-SIY cells, 
immunoswitch particles resulted in robust IFN-γ secretion (Figure 4-2D).  There was no 
IFN-γ secretion in response to immunoswitch particles when 2C CD8+ T cells were 
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stimulated with B16-F10 tumor cells lacking the cognate antigen. We further investigated 
the signal 1 dependence of immunoswitch activation by measuring cytotoxicity of 
cognate tumor cells in vitro. 2C CD8+ T cells were co-incubated with cognate B16-SIY 
cells, immunoswitch particles, and an anti-Kb mAb to block the signal 1 peptide-MHC 
interaction. At a 1:1 effector-target cell ratio, immunoswitch particles resulted in 22.8% 
specific lysis of B16-SIY cells (Figure 4-2E). This was reduced to only 2.16% when an 
anti-Kb mAb was included during the co-incubation. Immunoswitch particle stimulation 
and cytotoxicity is dependent on the CD8+ T cell receiving a cognate signal 1 from the 
tumor cell itself. 
In addition to requiring a cognate tumor cell for CD8+ T cell activation, we also 
investigated the hypothesis that immunoswitch particles increase effector-target cell 
conjugation. 2C CD8+ T cells and B16-F10 melanoma cells were labeled with a red and 
green membrane dye, respectively. Non-cognate B16-F10 cells were chosen to eliminate 
conjugate formation mediated by the T cell receptor-peptide-MHC interaction.  
Labeled 2C CD8+ T cells and B16-F10 cells were co-incubated in the presence of 
immunoswitch or isotype particles. After 1 hour, cells were fixed and conjugate 
formation was measured by confocal microscopy or flow cytometry. Confocal 
microscopy showed an increase in effector-target cell conjugation mediated by 
immunoswitch particles (Figure 4-2F, Figure 4-5A). At a 420 ng/ml total antibody dose, 
immunoswitch particles resulted in significantly higher conjugate formation than isotype 
particles, nearing 30% of CD8+ T cells conjugated to tumor targets. Isotype particles 
resulted in minimal conjugate formation, indicating that PD-1/PD-L1 expression plays 
little to no role in effector-target cell conjugation in this system. These results of confocal 
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microscopy were validated by a flow cytometry-based conjugation assay. 420 ng/ml of 
immunoswitch particles resulted in significantly greater effector-target cell conjugation 
as compared to isotype (Figure 4-5B). These results indicate that immunoswitch particles 




Figure 4-5. Immunoswitch particles increase effector-target cell conjugation. (a) Representative confocal 
images of 2C CD8+ T cells (red) and B16-F10 cells (green) in the presence of immunoswitch or isotype 
particles. Arrows show conjugate formation. (b) Conjugate formation was measured by gating on double 
red and green positive cells by flow cytometry. Each data point represents an independent experiment. 50 
ng of immunoswitch particles significantly increased conjugation rate as measured by two-tailed paired t-
test (p=0.0016). 
 
4.3.3 Immunoswitch particles inhibit tumor growth in vivo  
We investigated the efficacy of immunoswitch nanoparticle treatment in several 
in vivo models. Our first model, based on our in vitro system, was an adoptive transfer of 
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the repetitively stimulated PD-1hi tumor-specific 2C CD8+ T cells into mice with pre-
established B16-SIY melanoma tumors, followed at intervals by immunoswitch particles. 
Adoptively transferred cells were used as a model of exhausted tumor-specific cells that 
would likely be present in a patient’s tumor microenvironment prior to treatment.  
C57BL/6 mice were injected with 1x106 B16-SIY tumor cells on day 0, and 5x105 PD-1hi 
2C CD8+ T cells were adoptively transferred on day 8 (Figure 4-6A, schematic). T cell 
recipients were treated with immunoswitch particles on days 8, 11 and 15, or with various 
controls: 1) PD-1hi 2C CD8+ T cells alone, 2) PD-1hi 2C CD8+ T cells + isotype-
conjugated particles, or 3) PD-1hi 2C CD8+ T cells + soluble anti-4-1BB mAb + soluble 
anti-PD-L1 mAb. All treatment groups received a total of 1.3 ug of antibody per mouse 
per treatment intratumorally, approximately 10-100-fold less than the amount typically 
used for systemic treatment.42,43,45   
Immunoswitch treatment significantly delayed tumor growth compared to all 
other groups (p<0.001). Adoptive cell transfer alone, isotype particles, and soluble 
antibody did not result in significant slowing of tumor growth compared to no treatment 
(Figure 4-6B). This indicates that the particles themselves do not have any effect due to 
the intratumoral injection and that conjugating the antibodies to a rigid nanoparticle is 
necessary for their anti-tumor activity. Additionally, immunoswitch particles were the 
only treatment to significantly extend survival (Figure 4-6C)—mice died later or not at 
all by day 31. Soluble antibody also extended survival in a small number of mice, 




Figure 4-6. Immunoswitch particles inhibits tumor growth in vivo. (a) Schematic showing our in vivo 
model. C57BL/6 mice (n=4 isotype, n=8 all other groups) were injected with 1x106 B16-SIY cells 
subcutaneously (SC) on day 0. 2C CD8 cells were isolated on day 0, stimulated with anti-CD3/anti-CD28 
expander beads on days 0 and 4 as previously described,25  isolated from the beads and injected 
intravenously (IV) on day 8. Particle and antibody treatments were given intratumorally (IT) on days 8, 11, 
and 15. (b) Tumor growth curves show only immunoswitch treatment significantly delayed tumor growth as 
compared to no treatment and all other controls, past day 15. Black arrows indicate treatment days. 
Significance measured by two-way ANOVA with Bonferroni posttest (p<0.001). (c) Immunoswitch 
treatment significantly extended survival as compared to no treatment. Significance measured by log-rank 
test (p=0.0002). Combined results from two independent experiments are shown. (***p<0.001) 
 
In our second in vivo model, we analyzed immunoswitch particle activity in vivo 
in the absence of adoptively transferred T cells in the pre-established B16-SIY model 
(Figure 4-7A, schematic). Controls included no treatment or animals co-injected with a 
mixture of single-coated anti-4-1BB only and anti-PD-L1 only particles. This second 
control was included to investigate the importance of effector-target cell conjugation seen 
in vitro on in vivo activity. If immobilizing the antibodies on a rigid nanoparticle platform 
is sufficient for activity, we would expect both immunoswitch particles and separately 





Figure 4-7. Immunoswitch particles delay tumor growth in the absence of adoptively transferred cells. (a) 
C57BL/6 mice (n=6 separate particle treatment, n=11/other groups) were injected with B16-SIY cells SC 
on day 0. Treatment - either immunoswitch particles or a co-injection of anti-4-1BB and anti-PD-L1 
particles - was injected IT on days 8, 11, and 15. No adoptive transfer of tumor-specific cells was given. (b) 
Immunoswitch particles, but not separate anti-4-1BB and anti-PD-L1 mAb particles, delayed tumor growth 
compared to no treatment at all time points past day 11. Arrows indicate treatment days. Significance was 
measured by two-way ANOVA with Bonferroni posttest (p=0.007). (c) Only immunoswitch particle 
treatment significantly extended survival. Significance was measured by log-rank test (p=0.0066). Results 
from two independent experiments are combined for (a-c). (d) C57BL/6 mice (n=5/group) were injected 
with B16-SIY cells as above, and half were treated with immunoswitch particles IT on days 8 and 11. On 
day 14 tumor-infiltrating lymphocytes and tumor draining lymph nodes were harvested and analyzed. The 
non-treated group had significantly larger tumors (p=0.034) and a lower CD8+ T cell density (p=0.032) 
within the tumor on day 14. Significance was measured by two-tailed t-test. (e) CD8+ cells within the 
tumor draining lymph nodes of immunoswitch-treated mice had higher Kb-SIY (expressed by tumor) 
specificity. Significance was measured by two-tailed t-test (p=0.033). (f) Representative flow plots showing 
Kb-SIY specificity of CD8+ T cells from tumor draining lymph nodes of immunoswitch (left) or non-treated 
(right) mice. (***p<0.001, **p<0.01, *p<0.05) 
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Only immunoswitch treated animals had delayed tumor growth and extended 
survival compared to all other groups (Figure 4-7B,C). By day 18, non-treated and 
separate particle-treated mice had an average tumor size of approximately 176 mm2, 
whereas immunoswitch particle-treated mice had an average tumor size of nearly half, 
approximately 95 mm2. This indicates that immunoswitch particles stimulate the 
polyclonal endogenous repertoire of CD8+ T cells, and that both antibodies must be 
presented by the same nanoparticle for in vivo activity.  
4.3.4 Endogenous T cell activation 
To mechanistically study how immunoswitch particles activate an immune 
response, we analyzed tumor-infiltrating lymphocytes and tumor draining lymph nodes of 
immunoswitch treated animals. C57BL/6 mice were injected with B16-SIY tumor on day 
0.  Immunoswitch particles were administered days 8 and 11 and tumors and tumor 
draining lymph nodes were harvested and analyzed on day 14.  
As expected, immunoswitch treated mice had significantly smaller tumors 
(Figure 4-7D).  The density of CD8+ T cells within the tumor-infiltrating lymphocytes 
compartment more than doubled in the immunoswitch treated group compared to no 
treatment (Figure 4-7D), while CD4+ T cell density remained unchanged (data not 
shown). The impact of immunoswitch treatment on antigen-specific T cells was analyzed 
by determining the Kb-SIY-specific CD8+ T cell response to the B16-SIY tumors. There 
were approximately double the percentage of Kb-SIY positive CD8+ T cells within the 
tumor draining lymph node of immunoswitch treated animals compared to non-treated 
animals—0.49±0.2% and 0.22±0.1%, respectively (Figure 4-7E,F), while no difference 
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in Kb-SIY positive CD8+ T cells were seen within the spleen, peripheral blood (Figure 
4-8), or tumor-infiltrating lymphocytes (Figure 4-9A).  
 
 
Figure 4-8. Tumor specific CD8+ T cells are present in the periphery at the same levels in treated and 
non-treated mice. (a) Flow plots of Kb-SIY staining on CD8+ T cells from the spleens of immunoswitch-
treated and non-treated mice. (b) Percent of Kb-SIY+/CD8+ T cells in the peripheral blood of 











Figure 4-9. A significant portion of the anti-tumor response in the presence and absence of immunoswitch 
treatment is Kb-SIY specific. (a) Representative flow plots of Kb-SIY staining on CD8+ T cells from the 
TILs of immunoswitch-treated and non-treated mice. (b) Expansion protocol used to sequence the Kb-SIY 
specific CD8+ T cell response. Splenocytes from non-tumor bearing C57BL/6 mice were expanded with 
Kb-SIY/anti-CD28 aAPC for 7 days. Kb-SIY+ cells were sorted and sequenced after 7 days. 
 
Since immunoswitch treated mice have significantly delayed tumor growth, we 
hypothesized that treatment may increase the functionality of tumor infiltrating 
lymphocytes. To study the functionality of Kb-SIY+ CD8+ tumor-infiltrating 
lymphocytes following immunoswitch treatment, mice were treated and tumor-
infiltrating lymphocytes harvested on day 14 as above. Tumor-infiltrating lymphocytes 
were re-stimulated in vitro with SIY pulsed RMA-S cells and cytokine and CD107 
production analyzed.  
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Immunoswitch treated animals had more than double the percentage of CD8+ 
tumor-infiltrating lymphocytes expressing CD107, a degranulation marker and indicator 
of the ability of T cells to lyse target tumor cells (Figure 4-10A). CD8+ tumor-
infiltrating lymphocytes also produced more IFN-γ compared to tumor-infiltrating 
lymphocytes from non-treated mice (Figure 4-10B,C). This was seen by both an increase 
in the percent of IFN-γ+ cells (Figure 4-10B) and a 38% increase in the mean 
fluorescence intensity of IFN-γ+ cells, indicating greater per-cell production (Figure 
4-10C). Together, these data indicate that immunoswitch particles stimulate an anti-
tumor CD8+ T cell response by increasing their density, local tumor specificity, and in 




Figure 4-10. Tumor-specific CD8+ tumor-infiltrating lymphocytes of immunoswitch treated mice have 
increased functionality. (a) C57BL/6 mice (n=3/group) were injected with B16-SIY cells SC on day 0. 
Immunoswitch particles were injected IT on days 8 and 11. On day 14 tumor-infiltrating lymphocytes were 
harvested and re-stimulated with SIY pulsed RMA-S cells. Intracellular cytokine staining indicated an 
increased frequency of CD107 producing (a) and IFN-γ producing (b) CD8+ T cells following 
immunoswitch treatment. The mean fluorescence intensity (MFI) of IFN-γ+ cells was increased in treated 





4.3.5 Changes in the T cell receptor repertoire 
To gain a deeper understanding of the mechanism of action of immunoswitch 
particles, we analyzed the T cell receptor repertoire of the tumor infiltrating CD8+ T 
cells.  As described above, tumors were harvested on day 14 and tumor-infiltrating CD8+ 
T cells were sorted and T cell receptors sequenced to determine amino acid sequence of 
the CDR3 region of the T cell receptor beta chains (T cell receptor V-beta). V-beta usage 
by the tumor-infiltrating lymphocytes of each treatment group was compared to usage in 
a naïve C57BL/6 mouse and to a Kb-SIY-specific response obtained by using a 
previously established CD8+ T cell activation protocol194 to expand Kb-SIY-specific 
cells from splenocytes of naïve C57BL/6 mice. After a 7 day stimulation, Kb-SIY+ 
CD8+ T cells were sorted and sequenced (Figure 4-9B). As seen previously by Kb-SIY 
peptide-MHC staining of the tumor-infiltrating lymphocytes, the primary response of 
both immunoswitch-treated and tumor-bearing non-treated mice was dominated by V-
beta 13 which is characteristic of a Kb-SIY response ( 





Figure 4-11. Immunoswitch treatment alters the CD8+ T cell repertoire. (a) T cell receptor V-beta usage 
in CD8+ tumor-infiltrating lymphocytes from immunoswitch-treated, non-treated, non-tumor bearing adult 
B6 mice, or a Kb-SIY-specific CD8+ T cell response. C57BL/6 mice (n=3/group) were injected with B16-
SIY cells SC on day 0. Immunoswitch particles were injected IT into treated mice on days 8 and 11, and 
tumor-infiltrating lymphocytes were isolated on day 14.  Immunoswitch treated and non-treated mice skew 
towards T cell receptor V-beta 13, as is seen in a Kb-SIY specific response. (b) T cell receptor clones 
present in the CD8+ tumor-infiltrating lymphocytes of immunoswitch-treated mice are present at 
significantly higher frequencies than in the tumor-infiltrating lymphocytes of non-treated mice (left). T cell 
receptor clones present in the CD8+ tumor-infiltrating lymphocytes of non-treated mice are present at 
significantly higher frequencies than in the tumor-infiltrating lymphocytes of immunoswitch-treated mice 
(right). Significance measured by two-tailed paired t test (p<0.01). (c) CD8+ T cell receptor clones are 
conserved to a significantly higher extent in immunoswitch-treated mice. Each point represents the percent 
of overlapping clonal response between two mice of the same group. Significance measured by two-tailed t 
test (p<0.01). 
 
Despite the similarity in V-beta usage, the T cell receptor repertoire of these cells 
was significantly altered by immunoswitch treatment. T cell receptor clones, defined by 
the amino acid sequence of the CDR3 region, present in the tumor-infiltrating 
lymphocytes of immunoswitch treated mice appear at significantly lower levels in non-
treated mice ( 
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Figure 4-11B). Similarly, T cell receptor clones present in non-treated mice are 
present at significantly lower levels than in immunoswitch treated mice ( 
Figure 4-11B). This indicates that although a majority of the response both in the 
presence and absence of treatment is specific for the tumor-expressed Kb-SIY model 
antigen, the clones making up this response are changed by immunoswitch therapy.  
Next, we investigated the conservation of this changed CD8+ T cell response after 
immunoswitch treatment. The clones that make up the majority of the response between 
pairs of immunoswitch-treated mice overlap by 44.1±4.3% ( 
Figure 4-11C). This contrasts with only 6.43±6.92% of an overlapping response 
between pairs of non-treated mice. Thus, immunoswitch particle treatment selects for a 
highly conserved anti-tumor response. This indicates that treatment delays tumor growth 
by inducing expansion of a specific population of anti-tumor CD8+ T cells with an 
altered T cell receptor sequence signature. 
4.3.6 Immunoswitch biodistribution 
In addition to altering the immune response, nanoparticles are larger than soluble 
antibody and thus have a different biodistribution.106,196 Therefore, we sought to 
characterize the pharmacokinetics of immunoswitch particle treatment. We hypothesized 
that immunoswitch particles would diffuse from the injection site more slowly than 
soluble antibodies, resulting in a higher average concentration over time.  
Immunoswitch particles or an equivalent amount of soluble antibody were labeled 
with an infrared (IR) dye and injected subcutaneously into nude mice. Mice were imaged 
using a full body IR imager after 3, 24, 48, and 72 hours to quantify biodistribution. 
Soluble antibody was cleared from the injection site significantly more rapidly than 
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immunoswitch particles (Figure 4-12A,B). By 24 hours, approximately 72% of 
immunoswitch particles, but only 26% of soluble antibody remained at the injection site. 
Within 72 hours, this decreased to 60% of immunoswitch particles and 8% of soluble 
antibody. A fit of the data to one-phase decay equations showed a half-life of 15.2 hours 
for soluble antibody compared to 84.5 hours for immunoswitch particles.  
 
 
Figure 4-12. Immunoswitch particles remain at injection site longer than soluble antibody. (a) Nude mice 
(n=3/group) were injected with IR-labeled soluble antibody or immunoswitch particles at t=0 hours. Mice 
were imaged with a full body IR imager at t=3, 24, 48, and 72 hours post injection. (b) Change in mean 
gray value over time in target region of interest. Images from individual mice were normalized to the mean 
gray value at t=3 hours (see Materials and Methods). An immediate decrease is observed after injection 
followed by a consistent clearance rate. Clearance from the injection site is greater for soluble antibodies 
than immunoswitch particles at all time points. t1/2,soluble=15.2 hours and t1/2,immunoswitch=84.5 hours when fit 
to a one phase decay equation. Significance measured by two-way ANOVA with Bonferroni posttest 
(p<0.0001, F1,16=995.7 treatment variation). (c) C57BL/6 mice (n=3) were injected with IR-labeled 
immunoswitch particles 8 days after B16-SIY inoculation. Tumor, spleen, tumor draining lymph node, and 
contralateral lymph node were harvested 48 hours after treatment. Immunoswitch particles are retained 
primarily in the tumor and tumor draining lymph node. Values were recorded relative to the sensor's 





Similarly sized nanoparticles have been shown to drain to the proximal tumor 
draining lymph node following intratumoral injection but not to more distal sites, 
minimizing systemic toxicity.196 We therefore examined the organ biodistribution of 
immunoswitch particles following intratumoral injection. C57BL/6 mice were injected 
with IR-labeled immunoswitch particles 8 days after B16-SIY tumor inoculation. 48 
hours after treatment, the tumor, tumor draining lymph node, contralateral lymph node, 
and spleen were dissected and imaged by an IR imager. Immunoswitch particles were 
found in the tumor and tumor draining lymph node (Figure 4-12C), consistent with our 
finding that tumor-specific CD8+ T cells are present at higher levels in the tumor 
draining lymph node of immunoswitch treated mice. There were little to no detectable 
levels immunoswitch particles in the contralateral lymph node or spleen. Prolonged 
retention of the immunoswitch particles at the tumor site and tumor draining lymph node 
may contribute to their increased efficacy over soluble antibody. This sequestration of 
immunostimulatory ligands in the tumor site is consistent with the findings of others in 
the development of nanocarriers for tumor microenvironment immunomodulation.106,196 
4.3.7 Efficacy in multiple cancer models 
We sought to investigate the broader applicability of immunoswitch particles by 
assessing treatment in additional tumor models, colon cancer and B16-F10, and through 
different injection routes, IV administration. We first studied their efficacy in MC38-
OVA, a murine colon cancer expressing a model foreign antigen, OVA. C57BL/6 mice 
were injected subcutaneously with MC38-OVA tumors on day 0. Mice were treated with 
immunoswitch or isotype particles intratumorally on days 8, 11, 15, and 18 and tumors 
were measured.  
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Immunoswitch treated mice had significantly delayed tumor growth, averaging 19 
mm2 on day 36, as compared to 158 mm2 for non-treated mice and 126 mm2 for isotype 
particle treated mice (Figure 4-13A). 70% of immunoswitch-treated mice survived past 
day 55 as compared with 10% of non-treated mice (Figure 4-13B). These effects were 
even more pronounced than those seen in the B16-SIY model. In 5 of 10 mice, 
immunoswitch particle treatment led to complete regression of palpable MC38-OVA 
tumors. The MC38-OVA cell line also expresses different peptide-MHC from B16-SIY, 
demonstrating the robustness of immunoswitch treatment in the absence of adoptively 
transferred cells. 
 
Figure 4-13. Immunoswitch particles reverse tumor growth and extend survival in multiple tumor models 
and injection routes. (a) C57BL/6 mice (n=6 in isotype, n=10/other groups) were injected with MC38-OVA 
murine colon cancer cells SC on day 0. Treated mice received IT injections on days 8, 11, 15, and 18. Only 
immunoswitch particles significantly delayed and reversed tumor growth as compared with no treatment, 
past day 22. Significance was measured by two-way ANOVA with Bonferroni posttest (p=0.0003). Arrows 
indicate treatment days. (b) Only immunoswitch particles significantly extended survival as compared as 
compared to no treatment, as measured by log-rank test. Combined results from two independent 
experiments are shown. (c) C57BL/6 mice (n=5/group) were injected with B16-F10 cells SC on day 0. 
Treated mice received IT injections on days 8, 11, and 15. Immunoswitch treatment delayed tumor growth 
as compared to no treatment, past day 11. Significance was measured by two-way ANOVA with Bonferroni 
posttest. Arrows indicate treatment days. (d) C57BL/6 mice (n≥5/group) were injected with B16-SIY cells 
SC on day 0. IV immunoswitch particles were administered on days 4, 8, 11, and 15 and days 8, 11, and 15 
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by IT. Immunoswitch particles injected either IT or IV delay tumor growth past day 13 compared to no 
treatment (p<0.01). Soluble injected antibody has no effect on tumor growth. Significance was measured by 
two-way ANOVA with Bonferroni posttest. (**p<0.01, ***p<0.001) 
The tumor models, B16-SIY and MC38-OVA, both express strong model foreign 
antigens. Thus, we next sought to investigate the efficacy of immunoswitch particle 
therapy in a less immunogenic tumor model, B16-F10, which is identical to B16-SIY 
except that it lacks expression of the Kb-SIY model foreign antigen, to demonstrate 
broader therapeutic relevance.  
C57BL/6 mice were injected subcutaneously with B16-F10 tumors on day 0. 
Mice were treated with immunoswitch particles intratumorally on days 8, 11, and 15 and 
tumors were measured. Immunoswitch particle therapy resulted in significantly delayed 
tumor growth compared to non-treated mice (Figure 4-13C). By day 15, the tumor size 
was nearly halved by immunoswitch treatment—tumors averaged 112 mm2 for 
immunoswitch-treated mice compared to 205 mm2 for non-treated mice. Immunoswitch 
particle treatment also resulted in significantly extended survival compared to no 
treatment. This data demonstrates the broader applicability of immunoswitch particle 
therapy to less immunogenic tumor models.  
4.3.8 Efficacy by intravenous immunoswitch injection 
We further investigated the route of administration by studying their effect on 
tumor growth when injected intravenously. C57BL/6 mice were injected subcutaneously 
with B16-SIY tumors and were treated with immunoswitch particles intravenously on 
days 4, 8, 11, and 15. Mice treated with immunoswitch particles intravenously were 
given one additional early dose on day 4, a standard time point used for checkpoint 
inhibition studies in the B16-SIY model.42 Intravenous treatment resulted in similar anti-
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tumor efficacy to our standard intratumoral treatment (Figure 4-13D). In contrast, similar 
doses of IV administered soluble antibody had no effect on tumor growth as was seen 
with intratumoral injection of soluble antibodies.  
4.3.9 Intratumoral treatment results in a systemic memory response 
 Finally, we sought to determine if intratumoral immunoswitch treatment results in 
a systemic memory response. This factor is important for the clinical implications of this 
localized therapeutic. Because immunoswitch treatment was able to cure over 50% of 
mice with palpable MC38-OVA tumors, this model allowed us to study how the systemic 
response differed in cured versus uncured mice, as well as the protection against future 
tumor inoculation in cured mice.  
 C57BL/6 mice were inoculated with MC38-OVA tumors on day 0 and treated 
intratumorally with immunoswitch particles on days 8, 11, 15, and 18. To assess the 
presence of a systemic immune response, mice were injected retro-orbitally with 
differentially fluorescently labeled cognate (OVA) or non-cognate (SIY) peptide-pulsed 
splenocytes on day 28 when tumors were no longer palpable in cured mice. On day 29, 
mice were sacrificed and splenocytes analyzed. There was a significant increase in the in 
vivo killing of OVA-pulsed cells in mice that were cured following immunoswitch 
treatment compared to both naïve, non-tumor bearing mice, and mice treated but not 
cured following immunoswitch treatment (Figure 4-14A). Conversely, there was no 
significant increase of OVA-specific killing in mice treated but not cured from 
immunoswitch treatment. This data indicates that although immunoswitch particles are 






Figure 4-14. Intratumoral immunoswitch treatment results in a systemic memory immune response. (a) 
C57BL/6 mice were inoculated with MC38-OVA tumors on day 0 and treated with immunoswitch particles 
intratumorally. On day 28, cognate (OVA) or non-cognate peptide-pulsed splenocytes were injected retro-
orbitally. Splenocytes were harvested and analyzed on day 29 and specific killing of OVA-pulsed cells 
calculated. Mice cured from immunoswitch treatment had significant killing of OVA-specific cells, over 
50%. Significance measured by one-way ANOVA with Tukey’s post-test. Data combined from two 
independent experiments. (b) C57BL/6 mice were inoculated with MC38-OVA tumors on the right flank on 
day 0 and treated with immunoswitch particles intratumorally. On day 28, cured mice or age-matched 
controls were re-inoculated with MC38-OVA cells on the opposite flank. All naïve mice grew MC38-OVA 
tumors, shown by average tumor size (left) and individual tumor sizes (right), whereas no cured mice 
developed tumors. Tumor growth was significantly inhibited in cured mice (p=0.002) as measured by two-
way ANOVA. (*p<0.05, ***p<0.001) 
 
To assess the presence of a memory response, immunoswitch-cured mice or age-
matched controls were inoculated with MC38-OVA tumors on the opposite flank 28 days 
post-initial tumor inoculation. All naïve age-matched mice developed palpable tumors, 
whereas no cured mice developed tumors over the course of more than 30 days (Figure 
4-14B). Thus, local intratumoral immunoswitch treatment is able to induce a systemic 
memory immune response that protects mice from future tumor re-challenge.  
4.4 Discussion and conclusions 
Combinatorial immunotherapy for cancer treatment has resulted in promising 
success in clinical trials. However, the use of non-specific immunomodulators such as 
checkpoint blockade requires high doses of the drugs and significant off-target side 
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effects, especially when multiple drugs are used in combination.148 There is incentive to 
develop more effective and less toxic treatments.  Sequestering immunotherapeutics on a 
rigid nanoparticle platform alters their biodistribution and may reduce off-target 
toxicities. In this way, Kwong, et. al. have laid the groundwork in the development of 
nanoparticles to deliver and present immunostimulatory ligands, such as anti-4-1BB or 
anti-CD40, to CD8+ T cells and other immune cells.106,196 However, their nanoparticles 
were not designed to target two different cell types in the tumor microenvironment. 
Immunoswitch nanoparticles do this, linking immunomodulators differentially expressed 
on CD8+ T cells and target cells within the tumor and have significant anti-tumor activity 
in vivo. 
We have created an immunoswitch nanoparticle that blocks the 
immunosuppressive PD-L1 pathway while switching on the 4-1BB costimulatory 
pathway of tumor-targeting CD8+ T cells on a single injectable platform. These particles 
utilize spatial constraints to enhance the efficacy of two developing immunotherapies. 
Immunoswitch particles inhibited tumor growth more effectively than equivalent 
amounts of soluble anti-PD-L1 and anti-4-1BB mAb. While tethering the antibodies to a 
rigid particle platform increases avidity for their ligand and may play a role in their 
efficacy, we identified at least two additional mechanisms that explain immunoswitch-
based T cell activation and anti-tumor activity. 
Combining both anti-PD-L1 and anti-4-1BB mAb on a single platform physically 
links the effector and target cells. This was directly shown in vitro by confocal 
microscopy and flow cytometry. The importance of the physical linkage of both 
antibodies to a single nanoparticle was also seen in vivo despite the complexity of the 
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tumor microenvironment; co-injected separately conjugated particles, bearing either anti-
PD-L1 or anti-4-1BB mAb, were ineffective. Additionally, we showed that 
immunoswitch particles diffuse from the injection site more slowly than their soluble 
counterpart. This implies a higher local concentration of the bio-active particles 
integrated over time and consequently a decreased concentration at off-target sites. 
Although soluble antibody and separately conjugated particles had some in vitro activity, 
stimulating IFN-γ secretion, they had no in vivo effect. In contrast, immunoswitch 
treatment had significant anti-tumor activity in vivo. Thus, in vitro IFN-γ secretion may 
not fully explain in vivo activity where other factors such as biodistribution and shaping 
of the endogenous T cell receptor repertoire may play a larger role. 
While the immunoswitch particles led to antigen-independent effector-target cell 
conjugation, target cell recognition and IFN-effector cytokine secretion was signal 1 
dependent. This was demonstrated in vitro when transgenic 2C CD8+ T cells were not 
stimulated by immunoswitch particles in the presence of non-cognate target cells.  
However, a priori knowledge of the tumor antigen is not necessary since signal 1 is 
derived from the tumor cell itself. Thus, immunoswitch particles can activate a diverse 
polyclonal T cell response in vivo and reduce the chance of antigenic escape.197  
Murine melanoma tumor control mediated by immunoswitch particles was 
observed even in the absence of adoptively transferred tumor-specific CD8+ T cells and 
when administered systemically by intravenous treatment. We showed that 
immunoswitch particles exert their effect by increasing the density, specificity, and 
functionality of endogenous tumor-specific CD8+ T cells. Tumor-infiltrating 
lymphocytes of immunoswitch treated mice increased IFN-γ production and CD107 
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expression. In addition, more IFN-γ was made on a per cell basis as seen by an increase 
in IFN-γ MFI after immunoswitch treatment. There was no difference in tumor-specific 
CD8+ T cell levels in the spleen or in circulation, indicating that immune activation is 
concentrated to the tumor site and thus may limit off-target immune-mediated toxicities, 
as supported by the particle biodistribution. Additionally, this approach may be generally 
applicable as tumor control was also evident in an MC38-OVA colon cancer model and 
in a less immunogenic B16-F10 melanoma cancer model lacking a model foreign 
antigen. Despite local intratumoral treatment, immunoswitch particles demonstrated a 
systemic memory immune response that protects mice against future re-challenge. 
However, the data does not prove whether the systemic immune response is a 
consequence of or the cause of immunoswitch-mediated tumor eradication—i.e. the 
elimination of the tumor may cause the tumor-specific CD8+ T cells to enter systemic 
circulation, whereas these tumor-specific cells may be maintained within the tumor 
microenvironment of non-cured mice. Further experiments are required to tease apart this 
cause-effect relationship.  
Finally, sequencing analysis of the tumor-infiltrating lymphocytes revealed that 
the immunoswitch-mediated anti-tumor response is mediated by a change in the T cell 
receptor repertoire. Immunoswitch particle treatment expands a different set of CD8+ T 
cell T cell receptor clones not present at high levels in non-treated mice. This altered T 
cell receptor repertoire is highly conserved, indicating that treatment enables the immune 
system to find the “correct” anti-tumor immune response without switching recognition 
to a different antigen. While many existing therapies induce alterations in the breadth and 
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depth of the T cell response,29,198 we show that immunoswitch particles change the clonal 
composition of the response against a defined tumor antigen. 
Immunoswitch particles are an immunotherapy that utilizes a single, nanoparticle-
based injectable therapeutic. By combining multiple targeting moieties on the surface of a 
single particle, this represents a genre of nanoparticle-based approaches for cancer 
immunotherapy. The increased effectiveness of immunoswitch particles over soluble 
antibody can allow for reduced cost and complexity of a multi-faceted therapeutic. The 
nanoparticle platform also allows for further modifications to optimize biodistribution or 
deliver signals locally. For example, nanoparticle size or shape can be engineered to 
reduce clearance or target specific cell types,58,199 and the core can be designed to release 
an immune-stimulant such as IL-2.97 Additionally, we have shown proof of concept of a 
“signal-switching” approach that links two signaling pathways. This can be extended to 
other parts of the cancer-immunity cycle, including other inhibitory and/or co-stimulatory 
pathways, such as Lag-3, CTLA-4, or CD28, in addition to pathways relevant in 
autoimmunity and other disease states. Thus, immunoswitch particles are a nanoparticle-
based combination therapy and build a framework for further mechanistic and 





Chapter 5. Separating T Cell Targeting Components 
onto Magnetically-Clustered Nanoparticles Boosts 
Activation2 
5.1 Introduction 
Decades of research have built a framework for understanding T cell signaling 
and have led to protocols for the in vivo and in vitro activation of T cells for basic science 
studies as well as immunotherapeutic applications. However, it has become evident that 
current platforms are not optimized for effective T cell stimulation. T cell activation is 
sensitive to the composition and organization of a large family of signaling molecules, 
many of which are often absent or difficult to optimize using the current methods of 
synthetic or modified antigen-presenting cells. 
Minimally, T cells require two signals for activation—signal 1, specific peptide-
MHC (pMHC), and signal 2, a co-stimulatory signal such as the B7 interaction with 
CD28. During endogenous T cell activation, signal 1 and 2 co-cluster in the immune 
synapse, a dynamic microcluster of signaling molecules at the interface of the T cell and 
antigen presenting cell.15 This co-clustering is necessary, as micropatterned surfaces that 
separate signal 1 and signal 2 by several microns eliminate activation.18  
Although the B7/CD28 interaction is thought of as the “prototypical” signal 2, 
dozens of different molecules can serve as co-stimulation for CD8+ T cell activation, 
                                                          
2 Sections of this chapter are reprinted (adapted) with permission from “Kosmides, A., Necochea, K., 
Hickey, J.W., and Schneck, J.P. Separating T Cell Targeting Components onto Magnetically Clustered 




among them 4-1BB, CD27, and OX40, and each plays a different role in the activation 
process.4–8 The specificity and phenotype of activated T cells is sensitive to co-
stimulatory molecule composition6,7,9–13 and affects the ability to stimulate a long-lived 
memory population able to kill virally infected or tumor cells.  Even simply changing the 
ratio of co-stimulatory molecules or their timing during stimulation alters T cell 
functionality.9,10   
One reductionist approach for CD8+ T cell stimulation utilizes artificial antigen 
presenting cells (aAPCs), three-dimensional platforms that minimally present the two 
signals necessary for T cell activation—signal 1, specific peptide-MHC (pMHC), and 
signal 2, such as B7/anti-CD28 monoclonal antibody (mAb).200,201 In contrast to cell-
based methods such as K562-based antigen presentation,6 cell-free aAPC provide an 
engineered, more cost-effective off-the-shelf therapeutic. These particles can be used to 
activate and expand a patient’s CD8+ and CD4+ T cells against tumor antigens for 
adoptive cell therapy (ACT).68,84,202–205 The signaling molecules are often randomly 
conjugated to the surface of the aAPC53,200,201 which leaves little control over the 
nanoscale organization of the molecules, despite this showing importance 
empirically.15,47 When length scales have been more systematically investigated, it has 
been performed on flat substrates which lack the properties of three-dimensional 
activation structures.47,48 Progress in understanding the dynamics of T cell activation 
requires methods of such analyses on three dimensional platforms that can be 
systematically manipulated. 
Initially, traditional aAPCs were micron sized and thus have radii larger than the 
necessary degree of co-clustering. This necessitates that all signaling molecules be 
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conjugated to the surface of the same aAPC. Thus, for each type of co-stimulation 
condition studied, new aAPC must be synthesized which limits the ability to study large 
numbers of co-stimulatory conditions and increases time spent on quality controlling and 
potential for error.206 Nano-aAPC with length scales closer to that required for signal 
clustering during T cell activation could allow for more control over signal distribution. 
Our previous work has demonstrated the ability to increase the effectiveness of nano-
aAPC which normally are not capable of activating a robust T cell response.60 By 
constructing aAPC on paramagnetic iron-dextran nanoparticles, the aAPC can be 
clustered on the T cell surface using an external magnetic field to more closely mimic the 
clustering required for endogenous T cell activation. Because of the small length scales of 
these nano-aAPC, we hypothesized that we could use this approach to separate the 
signaling components onto distinct particles. 
Here, we develop and validate a reductionist T cell stimulation platform with each 
type of signaling molecule on separate paramagnetic nanoparticles. Previously, T cell 
signaling components could not be isolated on distinct particles unless embedded into a 
solid substrate or nanomatrix.207 However, with the paramagnetic nanoparticle platform, 
the separately conjugated particles can be co-clustered on the cell surface in the presence 
of a magnetic field60 to mimic the signal microcluster and activate T cells. This new 
system provides a streamlined approach to T cell activation where a small number of 
homogenous particles to be easily synthesized and added into culture at different times, 
ratios, and amounts to customize stimulatory conditions. This platform can also be 
utilized to study biophysical aspects of T cell activation. We demonstrate that by altering 
nanoparticle size and composition, the separate particle platform can be used to assess the 
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optimal degree of clustering between signaling molecules. This platform outperforms 
traditional methods to expand endogenous CD8+ T cell populations by enabling greater 
initial enrichment of the cells of interest, and can be used to systematically study the 
biophysical effects of signal clustering on the cell surface.  
5.2 Methods 
5.2.1 Mice 
PMEL TCR/Thy1a Rag-/- transgenic mice were a gift from Nicholas Restifo 
(National Institutes of Health, Bethesda, MD, USA) and maintained as homozygotes. 
C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). All 
mice used were 6-8 weeks of age and were maintained according to Johns Hopkins 
University's Institutional Review Board. 
5.2.2 Reagents and Cell Lines 
Kb-Ig and Db-Ig soluble MHC-Ig dimer were prepared and loaded with peptides 
as described.208 Briefly, Kb-Ig and Db-Ig producing hybridoma cell lines were expanded 
in hybridoma serum free media (Thermo Fisher Scientific; Waltham, MA) supplemented 
with L-glutamine. After one to two weeks, the supernatant was harvested and run over an 
NP sepharose column. Dimer was then eluted from the column with NIP-e-Aminocaproic 
acid and concentrated by membrane ultrafiltration with a Vivaspin 20 50 kDa MWCO 
(GE Healthcare, Little Chalfont, Buckinghamshire, UK). Concentration and molecular 
weight were measured by a Nanodrop ND-1000 Spectrophotometer and SCL-10A 
Shimadzu HPLC. Dimers were biotinylated with EZ-Link Sulfo-NHS-Biotinylation 
(Thermo Fisher Scientific) according to the manufacturer’s protocol, adding 20x molar 
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excess biotin. Loading of Db-Ig with gp100 peptide was performed by first denaturing 
the dimer with an acidic (pH=6.5) buffer, adding 50x molar excess gp100 peptide 
(GenScript, Piscataway, NJ) and incubating at 37⁰ C for 1 hour. Two-fold molar excess of 
human beta 2 microglobulin (Bio-Rad Laboratories, Hercules, CA) was added and 
solution was brought back to neutral pH (pH=7.4) and allowed to refold at 4⁰ C for 24 
hours. Excess peptide was removed by washing 3X with PBS using membrane 
ultrafiltration with a Vivaspin 20 50 kDa MWCO (GE Healthcare). Loading of Kb-Ig 
with trp2 peptide was performed by first denaturing the dimer with a basic (pH=11.5) 
buffer, equilibrating at room temperature for 15 min, and adding 50x molar excess trp2 
peptide (GenScript) and bringing back to neutral pH (pH=7.4). Loaded dimer was 
allowed to refold at 4⁰ C for 48 hours, and excess peptide was removed as above.  
Anti-CD28 clone 37.51 and anti-4-1BB clone 3H3 were purchased from 
BioXCell (West Lebanon, NH). Biotinylated anti-CD28 antibody clone 37.51 and anti-
CD27 antibody clone LG.3A10 were purchased from BD Biosciences (San Jose, CA). 
Fluorescently labeled monoclonal antibodies were purchased from BioLegend (San 
Diego, CA, USA). B16-F10 was a gift from Charles Drake (Johns Hopkins University, 
MD, USA). RMA-S cells were a gift from Michael Edidin (Johns Hopkins University, 
MD, USA). 
5.2.3 Particle synthesis and characterization 
For transgenic CD8+ T cell stimulation studies, anti-biotin coated 100 nm iron-
dextran nanoparticles were purchased from Miltenyi Biotec (Cologne, Germany). A two-
fold excess of biotinylated MHC-Ig dimers and co-stimulatory molecules were allowed to 
conjugate to particles in PBS overnight at 4⁰ C, and excess unbound antibody was 
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removed by washing with PBS over an MS column (Miltenyi Biotec, Cologne, 
Germany). 100 nm streptavidin-coated polystyrene particles were purchased from 
Micromod (Rostock, Germany) and conjugated as above. Excess unbound antibody was 
removed by washing with PBS 3x for 20 min at 22,000xg at 4⁰ C.  
For different sized particles and endogenous expansion experiments, antibodies 
were directly conjugated to amine-functionalized iron-oxide particles according to the 
manufacturer’s protocol (Micromod, Rostock, Germany). Briefly, antibodies of interest 
were thiolated with Traut’s reagent (Sigma-Aldrich, St. Louis, MO) in a PBS-EDTA 
buffer at pH 7.6. Excess Traut’s reagent was removed by running the antibody sample 
over a PD10 column (GE Healthcare) and concentration was measured by a Nanodrop 
ND-1000 Spectrophotometer. Particles were functionalized with maleimide by incubating 
particles in 10x PBS with a Sulfo-SMCC crosslinker (ProteoChem, Hurricane, UT) for 
one hour at room temperature with continuous mixing. Excess Sulfo-SMCC was removed 
by washing the particles over an LS column (Miltenyi Biotech) according to the 
manufacturer’s protocol. Maleimide functionalized particles were mixed with thiolated 
proteins in a PBS-EDTA buffer at room temperature overnight. Excess unbound antibody 
was removed by washing with PBS over an LS column (Miltenyi Biotec) or by using an 
EasySep Magnet (STEMCELL Technologies, Vancouver, Canada). 
Particle size was determined by nanoparticle tracking analysis using a Nanosight 
LM10. To characterize protein conjugation, a standard curve relating absorbance to 
particle concentration was first made using a Beckman Coulter AD340 plate reader and 
Nanosight LM10. Briefly, a serial dilution of each particle size at a known concentration 
from the manufacturer was made, and absorbance was read for each sample (Figure 5-1). 
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A standard curve relating absorbance to particle concentration was made for each size. 
Particles were then subsequently measured for absorbance to determine concentration 
based on the standard curve. The amount of specific antibody per particle was determined 
by staining the particles with fluorescently-labeled secondary monoclonal antibodies 
against the antibody of interest. Excess antibody was removed by running the particles 
over an MS column (Miltenyi Biotec), and antibody concentration was measured by 
comparing particle fluorescence to a standard curve and correlating with the total bead 
concentration.  
 
Figure 5-1. Standard curves relate absorbance to particle concentration of nanoparticles. Serial dilutions 
were made for each particle size at known concentrations as specified by the manufacturer, and 
absorbance was measured. Standard curves relating absorbance to particle concentration were made for 




5.2.4 CD8+ T cell aAPC stimulation 
PMEL or C57BL/6 CD8+ T cells were isolated from naïve spleens by negative 
selection with the Miltenyi CD8a+ isolation kit IIa following the manufacturer’s protocol 
(Miltenyi Biotec). For transgenic studies and polyclonal C57BL/6 studies, CD44lo CD8+ 
T cells were isolated by including anti-CD44-biotin during CD8+ negative selection. For 
endogenous stimulation, CD8+ T cells were enriched prior to expansion with signal 1 
only or traditional aAPC, as specified, using a previously established protocol.194 Briefly, 
CD8+ T cells were incubated with the particles of interest at 4⁰ C for 1 hour. Cells bound 
to particles were then isolated by positive selection using an MS column (Miltenyi 
Biotec) and only the positive fraction was then plated for expansion. This “enrichment” 
step was nor performed for the studies described in Fig. 3c where non-paramagnetic 
nanoparticles were used—the complete un-enriched endogenous CD8+ T cell repertoire 
was expanded.  
For expansion, CD8+ T cells isolated from either of the above methods were 
mixed with the particles of interest and cultured in 24-well or 96-well culture plates in 
RPMI supplemented with L-glutamine, non-essential amino acids, vitamin solution, 
sodium pyruvate, β-mercaptoethanol, 10% FBS, ciproflaxin, and a cocktail of T cell 
growth factors. To produce a magnetic field, culture plates were fixed between two 1/2 
in. neodymium N52 disk magnets and placed at 4⁰ C for 1 hour, followed by 37⁰ C for the 
first three days of culture. CFSE fluorescence was measured on day three using a BD 
FacsCalibur flow cytometer and analyzed using FlowJo (TreeStar). Fold expansion was 
measured by using a trypan blue exclusion test to exclude dead cells and counting cells 
seven days after stimulation. In endogenous cell stimulation studies, cells were stained 
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with a biotinylated MHC-Ig dimer and other fluoresecently labeled antibodies of interest 
seven days after activation followed by a fluorescently labeled streptavidin and read on a 
BD FacsCalibur.  
5.2.5 Specific lysis assay 
PMEL CD8+ T cells were stimulated with the particles indicated. After seven 
days, cells were harvested and incubated with cognate B16-F10 cells at the indicated T 
cell-target cell ratio in a 96-well plate for four hours at 37⁰ C. Lysis was measured using a 
CytoTox-Glo Cytotoxicity Assay kit (Promega, Madison, WI) according to the 
manufacturer’s protocol. Luminescence was read on a Tropix TR717 Microplate 
Luminometer (Applied Biosystems, Bedford, MA).  
5.2.6 Particle clustering analysis 
Anti-PE and anti-APC nanoparticles (Miltenyi Biotec) were conjugated with PE-
labeled and APC-labeled MHC-Ig Db-gp100 dimer and anti-CD28 mAb, respectively. 
MHC-Ig Db-gp100 dimer and anti-CD28 mAb were fluorescently labeled with a PE/R-
Phycoerythrin and APC Conjugation kit (Abcam), respectively, according to the 
manufacturer’s protocol. Particles were incubated with naïve CD44lo PMEL CD8+ T 
cells for one hour at 4⁰ C followed by one hour at 37⁰ C in a magnetic field. Cells were 
fixed with 2% PFA at room temperature for 20 minutes then imaged on a Zeiss LSM510-
Meta laser scanning confocal microscope at 100X magnification.  To measure clustering 
of signal 1 and signal 2 particles, confocal images were analyzed in Matlab.  
For cluster number and size analysis, nanoparticles ranging from 30-500 nm were 
conjugated with Kb-SIY as described in Particle synthesis and characterization. Particles 
were incubated with cognate 2C CD8+ T cells for one hour at 4⁰ C followed by one hour 
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in a magnetic field. For confocal imaging, cells were stained with fluorescently labeled 
antibodies against CD8 and the MHC-Ig dimer on the nanoparticles, fixed, and read by 
confocal microscopy. Cluster analysis was performed in ImageJ (National Institutes of 
Health) using the build-in particle analyzer. 15-25 cells were analyzed per condition. 
Cells were also imaged by SEM. 
5.2.7 Matlab clustering analysis 
LSM images were imported into Matlab. For each image, the cell borders were 
first detected. To do so, the gradient was calculated for the white color image, 
normalized, and thresholded. The image was then morphologically closed. Cell borders 
were identified using the function imfindcircles in the image processing toolbox using the 
Hough transform method.   
For each identified cell, its border was expanded internally and externally by 
35%, and then divided equally into 150 voxels. A cell was only included in the analysis if 
it was fully visual within the field of view of the image and expressed red and green 
levels above background. For each voxel, the average red and green value was calculated 
and normalized to the maximum. Co-localization score for each cell was calculated by 
multiplying the normalized red and green values in each voxel, summing over the entire 
cell border, and dividing by the Euclidian distance of the normalized red and green 
values. For no magnetic field, 47 total cells were analyzed. For magnetic field, 58 total 
cells were analyzed.  
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5.2.8 Fold-enrichment studies 
CD8+ T cells were isolated from Thy1.1+ PMEL and Thy1.2+ C57BL/6 spleens 
by negative isolation. PMEL CD8+ T cells were doped into Thy1.2+ wild type C57BL/6 
CD8+ T cells at a 1:1000 ratio. Cell mixture was enriched with signal 1 only Db-gp100 
particles, signal 1/2 Db-gp100/anti-CD28 aAPC, or noncognate aAPC, as above. 
Enriched fraction was stained with a fluorescently labeled Thy1.1 monoclonal antibody 
and read on a BD FacsCalibur.  
5.2.9 Endogenous CD8+ T cell cytokine functionality 
To assess functionality of expanded cells, CD8+ T cells were isolated on day 7 
post expansion. CD8+ T cells were co-cultured with cognate and non-cognate peptide-
pulsed RMA-S cells with anti-CD107a-FITC, GolgiStop, and GolgiPlug for five hours. 
Cells were then stained for surface markers, then fixed and permeabilized with BD 
Cytofix/Cytoperm and stained with fluorescently labeled antibodies against intracellular 
cytokines according to the manufacturer’s protocol. Labeled cells were read on an LSR II 
and analyzed with FlowJo.  
5.2.10 In vivo adoptive transfer studies 
CD8+ T cells were isolated from Thy1.2+ C57BL/6 mice on day -7. CD8+ T cells 
were split into three groups and stimulated with either 1) traditional Kb-trp2/anti-CD28 
aAPC, 2) Kb-trp2 particles and anti-CD28 particles using the separate particle platform, 
or 3) Kb-trp2 particles, anti-CD28 particles, and anti-4-1BB particles at a 75/25% anti-
CD28/anti-4-1BB ratio. All stimulations were done as in 5.2.4 CD8+ T cell aAPC 
stimulation and were normalized by the total amount of co-stimulation. 107 CD8+ T cells 
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from host mice were stimulated via the enrichment and expansion protocol per 1 donor 
mouse.  
On day -1, all Thy1.1+ C57BL/6 host mice were irradiated with 500 cGy 
sublethal dose of irradiation. On day 0, expanded cells were harvested and injected via 
retro-orbital injection into host mice. 30,000 U IL-2/mouse were injected into all host 
mice via intraperitoneal injection on days 0 and 1. Mice were sacrificed and organs 
harvested on day 21. Cells were stained with a fluorescently labeled antibody against 
Thy1.2 to detect transferred cells and read on an LSR II.  
5.3 Results 
5.3.1 Separate particle platform activates CD8 cells 
To study the impact of altering composition and ratio of costimulatory signals, we 
developed a separate paramagnetic nanoparticle platform. The separate particle platform 
enables T cell activation by using an external magnetic field to cluster paramagnetic 
nanoparticles separately conjugated with signal 1 or signal 2. The separate particles are 
then added to culture at defined combinations and ratios to optimize T cell stimulation 







Figure 5-2. CD8+ T cells are activated by nanoparticles separately expressing signal 1 and signal 2 when 
particles are clustered within a magnetic field. (a) Schematic comparing standard aAPC co-expressing 
stimulatory signals on the same nanoparticle, and separate signal 1 + 2 particle platform with each 
stimulatory signal conjugated to distinct nanoparticles. (b) TCR transgenic PMEL CD8+ T cells were 
stimulated with signal 1 only Db-gp100 dimer particles in the presence (black) or absence (grey) of signal 
2 only anti-CD28 particles. CFSE dilution was measured after three days. Decreased fluorescence 
indicates increased proliferation. Cells proliferate when signal 1 and signal 2 are presented on separate 
particles, only when clustered within a magnetic field. (c) PMEL CD8+ T cells were stimulated with anti-
CD28 signal 2 (s2) only particles, standard signal 1/2 aAPC (aAPC) expressing Db-gp100, or signal 1 (s1) 
only Db-gp100 particles with 0-8X molar ratio of signal 2 only anti-CD28 particles. Significance measured 
by two-way ANOVA with Bonferroni post-test. Signal 2 only particles and s1+8X s2 particles induce 
significantly different expansion compared to traditional aAPC within a magnetic field. (d) PMEL CD8+ T 
cells were incubated with signal 1 only particles, signal 1 and 2 expressed on separate particles (s1 + s2), 
or traditional signal 1/2 aAPC with 12 ng total signal 1. On day seven post stimulation, cells were isolated 
and co-incubated with cognate B16-F10 tumor cells for 4 hours. Cytotoxicity was measured. Significance 
measured by two-way ANOVA with Bonferroni post-test. (*p<0.05, **p<0.01) 
 
One hundred nanometer paramagnetic iron-dextran particles were chosen as the 
base of the separate particle platform which we previously showed can be clustered on 
the T cell surface by an external magnetic field.60 Thus, nanoparticles separately 
conjugated with T cell stimulatory signals can be brought into the close proximity 
required for T cell activation. Though signal 1 and signal 2 separated onto distinct 
stimulatory complexes cannot activate T cells,209,210 clustering of paramagnetic particles 
mimics stimulation by a single, larger signal 1 and signal 2 complex.  
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We first demonstrated proof-of-principle of the system using separately 
conjugated signal 1 and signal 2 nanoparticles in the PMEL TCR transgenic murine 
model. While transgenic T cells may be less sensitive to changes in co-stimulation, the 
large numbers of identical T cell receptors provide an ideal system for validation. Anti-
CD28 was chosen as the co-stimulatory molecule and Db-gp100 pMHC as the initial 
signal 1 to stimulate TCR transgenic PMEL CD8+ T cells, all of which are specific for 
the gp100 peptide presented by Db MHC I.  
Separately conjugated Db-gp100 dimer only and anti-CD28 mAb only particles 
were incubated with naïve PMEL CD8+ T cells at a 1:1 molar ratio in the presence or 
absence of a magnetic field. There was significant expansion of the cells by the separate 
particle platform in the presence of a magnetic field (p<0.001) which increased in a dose 
dependent fashion with increasing signal 2:signal 1 ratio (slope=0.2±0.09, p=0.02). In 
contrast, in the absence of a magnetic field, there was little to no CD8+ T cell 
proliferation in the presence of low or high doses of signal 1 and regardless of whether 
signal 2 was present. This was seen by both CFSE dilution (Figure 5-2B) and day 7 cell 
counts (Figure 5-2C). As expected, signal 2 alone did not cause T cell expansion, 
indicating that the magnetic field clustering alone does not non-specifically activate the 
cells.  
CD8+ T cells stimulated with the separate particle platform had equivalent 
cytotoxicity to those stimulated with traditional aAPC, maximally ~40% specific lysis 
(Figure 5-2D). Signal 1 only activated cells had significantly less cytotoxic activity as 
expected, as signal 1 alone has been demonstrated previously to produce anergic cells211. 
Thus, the separate particle platform stimulates CD8+ T cells equivalently to traditional 
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aAPC and maintains the requirement for signal 2, recapitulating the natural biology of T 
cell stimulation.  
5.3.2 Dependence of particle size 
Based on data that T cell signaling starts on a nanoscale level,53 we hypothesized 
that increasing the particle size would limit the activity of the separate particle platform 
because this would intrinsically limit the co-clustering of the individual molecules. Thus, 
we next sought to evaluate the working parameters of particle diameter using the separate 
particle platform.   
We synthesized signal 1 and signal 2 only particles ranging in diameter from 30 
nm to 4500 nm. Naïve PMEL CD8+ T cells were stimulated with each pair of matching 
diameter signal 1 and signal 2 only particles within a magnetic field, normalized to total 
signal 1 amount, and fold expansion was measured after seven days. Standard aAPC 
based activation (i.e. signal 1 and 2 on the same particle, in the absence of a magnetic 
field) results in increasing CD8+ T cell activation with increasing particle diameter 
(Figure 5-3). This is a well-documented phenomena due to the higher radius of curvature 
of larger particles and thus higher surface area of contact between the T cell and 
aAPC.59,65 In contrast, the opposite effect is seen with the separate particle platform—
particles with a diameter of 30 nm resulted in the greatest expansion over the course of 
one week, almost three times more than expansion by 4500 nm particles (Figure 5-4A). 
Magnetic clustering had no effect on activation by particles with diameters of 500 nm and 
above (Figure 5-4B), whereas smaller diameter particles only stimulated a CD8+ T cell 
response when clustered within a magnetic field. This effect was not correlated with 
cluster size or the number of clusters on the cell surface (Figure 5-5A,C). 100 nm and 
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300 nm particles resulted in significantly fewer numbers of clusters per cell than 30 nm 
or 500 nm particles despite producing intermediate levels of T cell activation. Similarly, 
cluster size did not vary significantly based on particle size, although 300 nm trended 
toward the largest diameter clusters (Figure 5-5B,C). SEM imaging further confirmed 
the consistency of cluster size (Figure 5-5D,E). This data indicates that the signaling 
molecules must be presented on particles less than 500 nm in diameter to enable signal 1 
and 2 co-clustering at sufficiently small length scales. Particles with diameters smaller 
than 500 nm enable the signaling molecules to cluster within the nanoscale proximity 
required for activation. 
 
 
Figure 5-3. Traditional aAPC activate a more robust T cell response at larger particle sizes. TCR 
transgenic PMEL CD8+ T cells were stimulated with traditional Db-gp100/anti-CD28 aAPC varying in 
diameter from 30 nm to 4500 nm with 18 ng total signal 1. Cell counts were taken on day seven and fold 
expansion calculated. Maximal expansion occurred when cells were stimulated with 4500 nm aAPC. 
Significance measured by one-way ANOVA with Tukey’s post-test. Data combined from three independent 




Figure 5-4. Separate particle platform requires particles on the nanometer size scale for efficient CD8+ T 
cell stimulation. (a) TCR transgenic PMEL CD8+ T cells were stimulated with different size Db-gp100 and 
anti-CD28 particles presented on separate particles within a magnetic field. Cell counts were taken on day 
seven and fold expansion calculated. Maximal expansion occurred when cells were stimulated with 30 nm 
separately conjugated particles. Significance measured by one-way ANOVA with Tukey’s post-test. (b) 
CFSE labeled PMEL CD8+ T cells were stimulated with different size Db-gp100 and anti-CD28 particles 
presented on separate particles in the presence (black) or absence (grey) of a magnetic field. CFSE 






Figure 5-5. Number of nanoparticle clusters per cell is affected by particle size. (a) 100 nm and 300 nm 
particles produce significantly fewer numbers of clusters per cell than 30 nm particles. (b) 300 nm particles 
trend toward a larger average cluster size per cell. Significance for (a,b) measured by one-way ANOVA 
with Tukey’s post-test. (c) Representative confocal images show CD8 (red), nanoparticles (NP; green), and 
cluster identification for each size nanoparticle. 15-25 cells per condition were analyzed. SEM Imaging 




5.3.3 Dependence of signal co-clustering 
To study the importance of clustering both signal 1 and signal 2, we synthesized 
nanoparticles from paramagnetic or non-paramagnetic materials to control which 
particles, and thus which signals, co-cluster when a magnetic field is applied. While it is 
known that during endogenous T cell activation the signal 1 and CD28 molecules co-
localize within the immune synapse,212,213 since our platform utilizes external forces to 
co-cluster the molecules it may intrinsically change the properties of activation and alter 
the requirement for co-clustering of signal 1 and signal 2 molecules.  
Db-gp100 dimer and anti-CD28 mAb were separately conjugated to the surface of 
100 nm paramagnetic iron-dextran particles, or 100 nm non-paramagnetic polystyrene 
particles (Figure 5-6). Each type of signal 1 only and signal 2 only particle were 
combined with PMEL CD8+ T cells within a magnetic field to produce co-clustering of 
the signaling molecules, signal 1 or 2 only clustering, or no clustering of either signaling 
molecule (Figure 5-7A, schematic).  
 
 
Figure 5-6. Polystyrene and iron-dextran nanoparticles have similar protein densities. 100 nm diameter 
polystyrene particles had the same or greater amounts of signal 1 pMHC dimer (a) and signal 2 anti-CD28 
mAb (b) conjugated to their surface as 100 nm diameter iron-dextran particles. Analysis performed on 





Figure 5-7. Signal 1 and signal 2 only nanoparticles must be co-clustered on the cell surface for efficient 
CD8+ T cell activation. (a) Schematic of stimulatory conditions and subsequent CD8+ T cell activation 
measured in (b). (b) PMEL CD8+ T cells were stimulated with signal 1 only Db-gp100 and signal 2 only 
anti-CD28 nanoparticles with either an iron or polystyrene (PS) core. Cells were counted after seven days. 
The greatest proliferation was measured when both signal 1 and signal 2 were presented on paramagnetic 
iron-dextran particles. Significance measured by two-way ANOVA with Bonferroni post-test. (c) C57BL/6 
CD8+ T cells were stimulated with separately conjugated Kb-trp2 signal 1 only and anti-CD28 signal 2 
only particles with an iron or polystyrene core. Cells were stained for CD8 and Kb-trp2 cognate dimer 
after seven days. When both signals were presented on iron-dextran particles, there was a maximum of 
42.3% Kb-trp2+ CD8+ T cells. (d) Naïve PMEL CD8+ T cells were incubated with fluorescently labeled 
Db-gp100 signal 1 only (red) and anti-CD28 signal 2 only (green) nanoparticles for 60 min +/- a magnetic 
field. Representative confocal images are shown. (e) Cells incubated +/- magnetic field were analyzed and 
each given a colocalization score quantifying the colocalization between signal 1 and signal 2 particles 
(see Materials and Methods). Cells incubated within a magnetic field had significantly higher 
colocalization between signal 1 and signal 2 measured by a Mann-Whitney test (p=0.0401). (*p<0.05, 
**p<0.01, ***p<0.001) 
 
Optimal expansion occurred when both signals were co-clustered on the surface 
of iron-dextran particles and decreased when either signal was presented on non-
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paramagnetic polystyrene particles (Figure 5-7B). Clustering of signal 1 alone decreased 
cell expansion by approximately 17% and clustering of signal 2 alone decreased cell 
expansion by approximately 33%. All conditions resulted in little to no expansion in the 
absence of magnet-induced clustering.  
While transgenic T cells provide an important tool for proof-of-principle 
validation studies, they do not fully recapitulate endogenous naïve T cell activation. 
Thus, we sought to assess the clustering of signal 1 and signal 2 on the separate 
nanoparticle platform to expand endogenous T cell populations from naïve wild-type 
mice. To study this, we conjugated the Kb-trp2 pMHC dimer or anti-CD28 mAb to the 
surface of iron-dextran or polystyrene 100 nm particles, as above. CD8+ T cells were 
expanded over the course of one week with each combination of paramagnetic and non-
paramagnetic signal 1 and signal 2 only particles in a magnetic field. 
After seven days of stimulation, CD8+ T cells were harvested and analyzed 
(Figure 5-7C). When both signal 1 and 2 were clustered on iron-dextran particles, over 
40% of cells were specific for Kb-trp2. This is an increase in specificity of up to 400,000-
fold, as the estimated pre-curser frequency for Kb-trp2 is approximately 10-100 cells per 
10 million, or 0.001-0.0001%.214 This decreased to less than 12%, a greater than one third 
reduction, when signal 1 and/or 2 was not clustered on polystyrene particles, indicating 
the necessity for co-clustering of the signals in endogenous CD8+ T cell expansion. 
Next, we sought to visualize and quantify the co-clustering of signal 1 and signal 
2 particles in the presence and absence of a magnetic field. Fluorescently labeled Db-
gp100 (red) and anti-CD28 (green) particles were co-incubated with naïve PMEL CD8+ 
T cells for one hour in the presence or absence of a magnetic field. Cells were then fixed 
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and analyzed by confocal microscopy. Visually, it was evident that the two types of 
particles were co-clustered when incubated within a magnetic field (Figure 5-7D). Co-
clustering was quantified in Matlab by assigning each cell from each condition a co-
localization score that indicates the level of clustering between the two particle types at 
the cell level, with a higher co-localization score indicating increased clustering (see 
5.2.7 Matlab clustering analysis). The median co-localization score for cells within a 
magnetic field was more than double that for cells in the absence of a magnetic field—
0.560 and 0.271, respectively—and the two groups differed significantly by a Mann-
Whitney test (Figure 5-7E).  
5.3.4 Increased expansion of antigen-specific endogenous CD8 cells 
We have shown previously that paramagnetic nano-aAPC can be used to enrich 
for clonal populations of CD8+ T cells from an endogenous repertoire on a magnetic 
column prior to in vitro expansion.194 Enrichment prior to expansion reduces the 
competition for cytokines and MHC binding and has been shown to increase the 
expansion of cognate CD8+ T cells greater than 10-fold over non-enriched cells.194 
However, traditional aAPC are conjugated with anti-CD28 mAb in addition to the 
cognate signal 1 molecule and thus may lead to non-specific binding and decreased 
enrichment potential. We hypothesized that since we can separate signal 1 and signal 2 
on the nanoparticle platform, the separate particle platform could be utilized to obtain 
more highly enriched cells with the use of signal 1 only particles, followed by the 
addition of signal 2 particles to stimulate expansion.  
We first modeled the difference in enrichment potential of traditional aAPC 
versus signal 1 only particles in PMEL CD8+ T cells. To study this, fluorescently labeled 
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naïve PMEL CD8+ T cells were doped into CD8+ T cells from a naïve C57BL/6 mouse 
at a 1:1000 ratio. aAPC expressing both Db-gp100 and anti-CD28 or Db-gp100 alone 
were then used to enrich for the cognate PMEL CD8+ T cells, normalized by the total 
amount of Db-gp100. Signal 1-only particles resulted in a final purity of 1% PMEL 
CD8+ T cells, a 10-fold enrichment over the original cell mixture (Figure 5-8A). 
Traditional aAPC enriched PMEL CD8+ T cells to a final purity of only 0.5%, 50% less 
than signal 1 alone. Non-cognate particles did not enrich for PMEL CD8+ T cells. Both 
signal 1 alone and traditional aAPC resulted in approximately 80% or more recovered 
PMEL CD8+ T cells (Figure 5-9). 
 
Figure 5-8. Separate particle platform results in greater expansion of functional cognate CD8+ T cells. (a) 
Thy1.1+ TCR transgenic PMEL CD8+ T cells were doped into Thy1.2+ wild type C57BL/6 CD8+ T cells 
at a 1:1000 ratio. Cell mixture was enriched with signal 1 only Db-gp100 particles, signal 1/2 Db-
gp100/anti-CD28 aAPC, or noncognate aAPC. Signal 1 only enrichment resulted in a final purity of 
approximately 1% cognate PMEL cells, while signal 1/2 aAPC had a final purity of approximately 0.5%. 
Noncognate cells did not enrich for PMEL cells. Significance measured by one-way ANOVA with Tukey’s 
post-test. (b) C57BL/6 cells were enriched and expanded with Kb-trp2 signal 1 dimer presented on 
traditional aAPC or the separate particle platform within a magnetic field. Representative staining shows 
that separate particle platform increases the percentage of expanded cognate cells from an endogenous 
response after seven days. (c) Percent of cognate dimer positive cells seven days post enrichment and 
expansion. (d) Number of Kb-trp2+ CD8+ T cells seven days post enrichment per one million expanded 





Figure 5-9. Percent recovery of cognate T cells is equivalent with aAPC and separate particle platform. 
Enrichment with signal 1 only or traditional signal 1/2 aAPC recovered a similar amount of total PMEL 
CD8+ T cells, approximately 70-80%. Significance measured by one-way ANOVA with Tukey’s post-test. 
Data combined from three independent experiments. (*p<0.05, **p<0.01) 
 
Next, we sought to determine if the increased enrichment by signal 1 only 
particles corresponds with a greater expansion of endogenous CD8+ T cell populations 
from naïve C57BL/6 mice by the separate particle platform compared to traditional 
aAPC. CD8+ T cells isolated from naïve C57BL/6 mice were enriched with either 
traditional aAPC or signal 1 only Kb-trp2 particles. Anti-CD28 mAb signal 2 only 
particles were added to cells enriched with signal 1 only Kb-trp2 particles, and both 
traditional aAPC and separate signal 1 and 2 particle cultures were expanded in a 
magnetic field for one week. All cultures were normalized by the total amount of signal 1 
and 2 which were present at an approximate 1:1 molar ratio.   
After one week, cells were harvested, counted, and stained with Kb-trp2. Cells 
enriched with signal 1 only particles then expanded with signal 1 and signal 2 only 
particles contained 35.8% Kb-trp2+ cells, more than double that of traditional aAPC, 
15.6% (Figure 5-8B). This effect was consistent in multiple independently repeated 
experiments (Figure 5-8C) as well as with different signal 1 peptides (Figure 5-10). The 
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total number of Kb-trp2+ cells also increased nearly 2-fold when enriched and expanded 
with the separate particle platform (Figure 5-8D). 
 
 
Figure 5-10. Separate particle platform improves T cell expansion against various antigens. Endogenous 
C57BL/6 CD8+ T cells were enriched and expanded with Kb-SIY signal 1 dimer presented on traditional 
s1/2 aAPC or the separate particle platform within a magnetic field. Representative staining shows that the 
separate particle platform approximately doubles the percentage of expanded Kb-SIY+ cognate cells from 
an endogenous response after seven days. 
 
The functionality of the cells expanded by the separate particle platform was 
assessed by measuring cytokine secretion and degranulation markers. Seven days after 
stimulation, the cells were harvested and re-stimulated with trp2-pulsed RMA-S cells and 
cytokine secretion and CD107 expression, a degranulation marker, was measured. Cells 
expanded with the separate particle platform secreted the same or higher level of all 
cytokines measured—IFN-γ, IL-2, and TNF-α—and had equivalent expression of CD107 
(Figure 5-11). Thus, the separate particle platform results in greater expansion of highly 






Figure 5-11. Separate particle platform results in greater or equal T cell cytokine secretion. Shown is the 
percent of cognate dimer positive cells secreting cytokines after seven day enrichment and expansion with 
traditional s1/2 aAPC or separate particle platform (s1 + s2). Separate particle platform results in 
significantly greater TNF-α secretion and equivalent secretion of all other cytokines as compared with 
traditional aAPC. Data combined from three independent experiments. (*p<0.05) 
 
5.3.5 High throughput co-stimulatory molecule customization 
A valuable goal of the development of this platform is the ability to easily 
customize the type, combination, and specific ratios of co-stimulatory signal 2 molecules 
during CD8+ T cell expansion. We thus sought to use the separate particle platform to 
investigate how altering co-stimulatory molecule type and ratio affects endogenous CD8+ 
T cell expansion and phenotype. Four stock particle types were synthesized expressing 
anti-CD3, anti-CD28, anti-4-1BB, or anti-CD27 mAb. Anti-CD3 bypasses the pMHC-
TCR recognition and was used as the signal 1 to stimulate endogenous polyclonal CD8+ 
T cells.  
CD8+ T cells were isolated from C57BL/6 mice on day 0 and incubated with 
signal 1 particles and a constant total amount, but varied ratio, of anti-CD28 and anti-4-
1BB mAb signal 2 particles within a magnetic field. After seven days, total cell counts 
were recorded. Despite the total amount of signal 2 in all stimulatory conditions being 
equivalent, changing the ratio of signal 2 molecules significantly impacted CD8+ T cell 
proliferation (Figure 5-12A). All combinations of anti-CD28 and anti-4-1BB resulted in 
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equivalent or greater CD8+ T cell expansion than either signal 2 molecule alone. At a 
75/25% ratio of anti-CD28/anti-4-1BB, CD8+ T cells reached nearly 13-fold expansion, 
approximately 50% more proliferation than anti-CD28 alone and 95% more than anti-4-
1BB alone. Also of note, signal 1 alone induced little to no cell proliferation of 
endogenous antigen-specific CD8+ T cells. Similarly, we showed how the separate 
particle platform allows for streamlined signal 2 customization by also testing various 
combinations of anti-CD28 and anti-CD27 mAb during a seven day activation. 
Interestingly, at a 50/50% ratio of anti-CD28/anti-CD27 mAb, there was a significant 
increase in the number of CD8+ T cells with a memory phenotype despite no significant 
difference in total CD8+ T cell expansion (Figure 5-13). This data indicates that altering 
signal 2 composition can impact skewing toward specific T cell subsets in addition to 
overall expansion.  
 
Figure 5-12. Separate particle platform allows for manipulation of co-stimulatory signal 2 composition. 
(a) Naïve CD44lo CD8+ T cells from C57BL/6 mice were stimulated for seven days with separate particle 
platform. Anti-CD3 mAb was used as signal 1, and anti-CD28 and/or anti-4-1BB mAb were used as signal 
2. Total signal 2 amount remained constant, only ratio varied. A 75/25% anti-CD28/anti-4-1BB ratio 
significantly increased expansion over either signal 2 alone. (b) C57BL/6 cells were enriched and 
expanded with Kb-trp2 signal 1 dimer presented on the separate particle platform within a magnetic field. 
Signal 2 ratio varied as in (a). On day seven, cells were harvested and stained for Kb-trp2 and CD127. The 
addition of anti-4-1BB significantly increased the percent of Kb-trp2+ cells expressing CD127. 





Figure 5-13. Separate particle platform enables customization of co-stimulation. (a) CD8+ T cells from 
C57BL/6 mice were stimulated for seven days with separate particle platform. Anti-CD3 mAb was used as 
signal 1, and anti-CD28 and/or anti-CD27 mAb were used as signal 2. Total signal 2 amount remained 
constant, only ratio varied. Significance measured by one-way ANOVA with Dunnett’s post-test. (b) 
Resultant CD8+ T cells were stained for CD62L and CD44 on day seven post activation. The percentage of 
memory (CD44hiCD62Lhi) CD8+ T cell responders were assessed. At a 50/50% ratio of anti-CD28/anti-
CD27 mAb, there is a significant increase in the number of memory CD8+ T cells. Significance to anti-
CD28 alone is measured by one-way ANOVA with Dunnett’s post-test. Data from three independent 
experiments combined. (*p<0.05, ***p<0.001) 
 
Finally, we assessed the ability to use the separate particle platform to study how 
different signal 2 ratios change T cell phenotype when expanding endogenous antigen-
specific CD8+ T cells. C57BL/6 mice were enriched with signal 1 only Kb-trp2 particles, 
and different ratios of anti-CD28 and anti-4-1BB mAb signal 2 only particles were added 
during expansion, as above.  
Both a 25/75% and 75/25% ratio of anti-CD28 and anti-4-1BB mAb increased the 
expression of CD127, the IL-7Rα chain, on Kb-trp2+ CD8+ T cells compared to anti-
CD28 alone (Figure 5-12B). Signaling CD8+ T cells through 4-1BB has previously been 
shown to increase CD127 expression in CD8+ T cells and may be indicative of cells with 
a memory rather than exhausted phenotype.215 Thus, the separate particle platform 
presents a streamlined method to customize stimulatory conditions to optimize the 
phenotype of T cells for immunotherapeutic applications.    
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5.3.6 Co-stimulatory molecule selection impacts memory formation in vivo 
 Our in vitro data indicated that a 75/25% ratio of CD28/4-1BB co-stimulation 
improves the expansion and skews toward a memory phenotype of CD8+ T cells. Thus, 
we sought to assess the ability of the separate particle platform to extend the persistence 
of adoptively transferred antigen-specific CD8+ T cells in vivo and demonstrate a 
therapeutic use case.  
 CD8+ T cells were isolated from Thy1.2+ C57BL/6 mice and stimulated in vitro 
with Kb-trp2/anti-CD28 traditional aAPC, identical signals on the separate particle 
platform, or the separate particle platform with a 75/25% ratio of anti-CD28/anti-4-1BB. 
After one week, expanded cells were injected retro-orbitally into Thy1.1+ C57BL/6 mice 
and mice were treated with IL-2 on the day of and day after transfer. Short-term and 
long-term persistence of the cells were analyzed by sacrificing mice 7 and 21 days post-
adoptive transfer and staining for Th1.2+ cells.  
 At twenty-one days after adoptive transfer, cells stimulated with the optimal anti-
CD28/anti-4-1BB signals were detected at significantly higher levels than either other 
stimulus (Figure 5-14). The frequency of the transferred cells was approximately 5-fold 
higher in the spleen and 10-fold higher in the lymph node than traditional aAPC or the 
separate particle platform with anti-CD28 alone. There were no significant differences in 
the blood on day 21, or in any organs on days 3 or 7 (data not shown). Thus, the separate 





Figure 5-14. Separate particle platform activates optimal CD8+ T cells for adoptive cell transfer. CD8+ T 
cells from Thy1.2+ C57BL/6 mice were activated in vitro with Kb-trp2/anti-CD28 traditional aAPC 
(aAPC), separate particle platform (s1+s2), or separate particle platform with a 75/25% ratio of anti-
CD28/anti-4-1BB. After seven days, expanded cells were injected retro-orbitally into Thy1.1+ C57BL/6 
mice. Adoptively transferred cells activated with anti-4-1BB on the separate particle platform were present 
at significantly higher frequencies than either other stimulus on day 21 post transfer. Significance in each 
organ was analyzed by a one-way ANOVA with Tukey’s post-test (**p<0.01, ***p<0.001). 
 
5.4 Discussion and conclusions 
Here, we have developed and validated a system that can combine high 
throughput synthesis of single-molecule paramagnetic “aAPC” with magnetic fields to 
demonstrate a reductionist platform capable of studying and optimizing T cell activation. 
While upcoming cancer immunotherapies such as adoptive cell transfer are promising for 
generating patient-specific cytotoxic T cell responses, approaches that use homogenous 
microscale aAPC cannot take full advantage of the nanoscale organization and co-
stimulus diversity that has demonstrated importance in generating long-lived functional T 
cell populations. Additionally, few platforms exist that enable the more fundamental 
study of T cell co-stimulus clustering in a three-dimensional system. We show proof of 
concept for this platform to easily customize co-stimulatory signals, study the clustering 
of signaling molecule clustering during activation, and isolate and activate higher purity 
endogenous T cell populations.  
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Various recent studies have shown the impact of the composition of co-
stimulatory molecules on the expansion and phenotype of activated T cells. Simply 
changing the ratio of co-stimulatory molecules without altering the total amount of signal 
on aAPC can impact the expansion of T cells.10 The previous approach to study co-
stimulus composition on three dimensional platforms involves synthesizing new aAPC 
for each condition.6,10 This limits throughput and can present difficulty in accurately 
studying such effects as it has been documented that unexpected experimental artifacts in 
the preparation of aAPC with defined ratios of molecules are common.206 The separate 
particle platform simplifies nanoparticle synthesis and quality control assessment while 
maintaining a similar, if not higher, level of T cell activation. The importance of co-
stimulatory signal medication was further emphasized in vivo where the separate particle 
platform with a specific anti-CD28/anti-4-1BB ratio significantly extended the 
persistence of adoptively transferred CD8+ T cells.  
This platform allowed us to easily investigate ten different co-stimulatory 
conditions, whereas previous reports have investigated five or fewer.6,10 We demonstrated 
proof of concept for ability to alter the frequency and phenotype of CD8+ T cells by 
incorporating anti-4-1BB and anti-CD27 mAbs at defined ratios, although it could easily 
be extended to study additional conditions. This platform also provides a technique to 
customize co-stimulation on a case-by-case basis. For example, it can be hypothesized 
that in the future of adoptive cell therapy, one may wish to co-stimulate with molecules 
that synergize with checkpoint blockade5 in some patients, but molecules that improve 
expansion and function in the presence of signal 1 alone in others.6,7 Information gained 
about co-stimulatory requirements using this approach may also help to guide 
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optimization of approved therapies such as CAR T cells in terms of which co-stimuli to 
incorporate. 
In addition to providing a mechanism for high-throughput co-stimulus 
customization, by design, this platform also enables the three-dimensional study of signal 
co-clustering. Prior studies that manipulate signal clustering at the nanoscale often utilize 
two dimensional platforms that poorly simulate endogenous activation.18,48 By 
incorporating the separate signaling molecules on different sized paramagnetic and non-
paramagnetic particles, we showed that pMHC and anti-CD28 require co-clustering at 
length scales smaller than 500 nm. This size-dependent effect did not seem to be 
associated with a change in cluster size, as 30 nm particles did not result in any 
significant change in cluster size or number as compared to 500 nm particles. However, 
all particles resulted in cluster sizes that average 1 µm2 or greater, correlating with a 
cluster radius greater than 500 nm. It is likely that the magnetic field-induced clustering 
decreases the degree of particle internalization by the T cells and thus prolongs 
extracellular activation time, especially of the 30-100 nm particles, as it has been shown 
that particles with diameters of 40-60 nm have the shortest internalization time.216  
Likewise, this approach can be used to investigate clustering requirements for less 
studied co-stimulatory or co-inhibitory molecules. While some previous reports analyzed 
4-1BB co-localization at the immune synapse during T cell activation,217 little to no 
information is known about the clustering of other co-stimulatory molecules such as 
CD27, CD40L, and OX40.  
Finally, the separate particle platform results in greater expansion of specific T 
cell clones from an endogenous repertoire. Previous work from our lab established an 
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Enrichment and Expansion protocol to enrich for specific CD8+ T cell clones using 
paramagnetic aAPC prior to expansion.194 The success of enrichment prior to expansion 
was demonstrated to be due to reduced competition for growth factors and pMHC 
binding and results in approximately a 10-40-fold increase in frequency after one week 
compared to expansion alone. Likewise, we showed that by further increasing enrichment 
using particles that only have cognate signal 1 molecule followed by the addition of co-
stimulatory particles for expansion, we further doubled the frequency and total number of 
activated cognate CD8+ T cells. This is especially relevant as next generation expansion 
protocols could incorporate other co-stimulatory molecules that are not specific to the T 
cells of interest and would decrease enrichment. This platform enables a mechanism to 
eliminate that obstacle.    
Because magnetic clustering is required to stimulate T cells with this platform, it 
is likely that this approach would be limited to in vitro stimulation protocols. This may 
include serving as a tool for assessing T cell activation conditions or customizing 
conditions for adoptive cell transfer where ex vivo stimulation is required. We have 
demonstrated the ability of this platform to activate all T cells or specific T cell subsets 
depending on the type of signal 1 stimulation. For adoptive cell therapy, this separate 
particle approach could be used to activate specific T cell populations using an MHC-Ig 
dimer loaded with a specific tumor peptide, or could be used in combination with anti-
CD3-coated particles to non-specifically activate T cells in a more high-throughput 
manner. Additionally, we have only studied how changes in co-stimulation composition 
and clustering impact murine T cell activation. It is likely that co-stimulatory 
composition differentially affects expansion of murine and human T cells, and the 
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efficacy of this approach for stimulating human T cells needs to be investigated. Finally, 
it is important to note that in contrast to other methods, this separate particle approach 
creates homogenous single signal “islands” which may not directly translate to a 
homogenous distribution of the molecules. Further studies need to be performed to 
investigate how these too approaches compare in the context of T cell activation. 
We have developed a reductionist T cell activation platform that simplifies and 
streamlines customized co-stimulatory conditions. This platform is a robust tool for the 
study of the composition and clustering of signaling molecules for T cell activation by 
altering particle size, material, and molecules conjugated to their surface. This will allow 
for further study of T cell signal clustering and composition to better understand the 
signaling pathways as well as optimize activation for cell-based immunotherapies such as 









Chapter 6. Improving the Efficacy of Biodegradable 
Artificial Antigen Presenting Cell Platforms3 
6.1 Introduction 
Biomimetic materials that target the immune system hold promise for cancer 
immunotherapy.218 Synthetic immunotherapies can be designed with defined 
characteristics and therefore often outperform their cell-based counterparts. These 
platforms can be engineered in terms of biodegradability,87 controlled release of immuno-
modulators,219 and physical parameters including shape and size.65 Biomimetic materials 
can be customized to incorporate combination therapies in an all-in-one therapeutic and 
are therefore an exciting platform for the future of cancer immunotherapy. Despite their 
potential, current development of combinatorial immunotherapies utilizing biomaterials 
has been limited as their interaction with other existing therapeutics must first be 
understood. 
Synthetic artificial antigen presenting cells (aAPC), a biomaterial-based 
immunotherapy, have shown success in generating an anti-tumor immune response in 
vitro and in vivo.70,75,205,220 aAPC are three-dimensional platforms that minimally express 
the two signals required for T cell activation – a signal 1, peptide-MHC (pMHC) to 
provide T cell receptor (TCR) specificity, and a signal 2, such as anti-CD28 monoclonal 
antibody (mAb) to provide the co-stimulatory “go” signal. aAPC can be functionalized 
                                                          
3 Sections of this chapter reprinted (adapted) from “Kosmides, A.K.*, Meyer, R.A.*, Hickey, J.W., Aje, K., 
Cheung, K.N., Green, J.J., and Schneck, J.P. Biomimetic Biodegradable Artificial Antigen Presenting Cells 
Synergize with PD-1 Blockade to Treat Melanoma. Biomaterials 2017, 118, 16-26.”  
*authors contributed equally 
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with tumor-specific pMHC to activate a patient’s immune system against cancer antigens 
and mediate tumor rejection.71,72,221 They can be utilized in adoptive cell transfer (ACT) 
of ex vivo activated autologous T cells68,71,222 or directly administered intravenously (IV) 
for in vivo anti-tumor T cell activation.200,223 Synthetic aAPC platforms have distinct 
advantages over cellular systems in terms of long-term storage and the ability to optimize 
T cell activation and biocompatibility.224 Unlike biological antigen presenting cells used 
as cellular therapy, biomaterial-based aAPC have the advantage of being able to maintain 
an “always on” state that cannot be down-regulated by the microenvironment as well as 
flexibility for manufacturing as an acellular product.  Compared to poly(lactic-co-
glycolic acid) (PLGA)-based drug delivery particles for cancer therapy, the anti-cancer 
drugs must reach and destroy every cancer cell to ultimately be effective.  In contrast, 
PLGA-based aAPC particles for immunotherapy need only reach tumor specific T cells 
that can recognize the tumor antigen for the aAPC to then be able to direct a robust 
systemic immunotherapy response against the cancer cells. Biomimetic modifications of 
PLGA-based aAPC materials that greatly enhance their effector capacity, including 
controlling the shape of the aAPC65,66 or slowly releasing pro-inflammatory cytokines 
from their core,54,97 have demonstrated the benefit of bringing novel materials 
engineering concepts to the development of immunotherapeutics.  
In addition to amplifying positive regulators of the immune system, inhibiting 
negative regulators has also shown success in generating anti-tumor immune responses. 
Checkpoint molecules, including programmed death 1 (PD-1) and CTLA-4, are negative 
regulators of T cell function. These molecules are upregulated on tumor infiltrating 
lymphocytes and on activated T cells expanded during ACT, being described as a 
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rheostat of the immune system.39 PD-1 signaling inhibits CD8+ T cell effector function 
upon ligation with its ligand, programmed death ligand 1 (PD-L1), and is one of the 
methods by which tumors escape immune surveillance. Checkpoint blockade with 
monoclonal antibodies against PD-1 and PD-L1 delay tumor growth in murine tumor 
models,168,187 and FDA approved monoclonal anti-PD-1 and anti-CTLA-4 antibodies 
have shown significant overall response rates and long-term survival benefits. However, 
clinical responses only reach approximately 30%41,189–191 indicating that there is a 
necessity for improvement. 
Single-targeted approaches have limited efficacy because cancerous cells utilize 
multiple mechanisms to avoid immune surveillance and the immune system internally 
suppresses prolonged strong activation.28 The combination of checkpoint inhibitors with 
other immunotherapies that boost T cell effector functions or promote cancer cell 
recognition by the immune system have potential to increase anti-tumor effectiveness. 
Checkpoint blockade in conjunction with T cell costimulatory antibodies resulted in 
tumor regression in multiple murine tumor models43,44,170 and increased effector functions 
of exhausted CD8+ T cells by forcing them out of quiescence.5 These studies suggest that 
checkpoint blockade can boost the effects of other immune-stimulatory approaches, 
although their interaction with biomaterial-based antigen-specific T cell stimulation has 
not been studied.  
Here, we investigate the synergy between a biomimetic material, biodegradable 
PLGA-based aAPC, and anti-PD-1 monoclonal antibody treatment for the activation of 
tumor-specific CD8+ T cells. Combinatorial treatment enhances CD8+ T cell effector 
functions in vitro and significantly delays tumor growth in vivo. These results 
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demonstrate the effectiveness of PLGA-based aAPC in combination immunotherapy, and 
identify a molecule that could potentially be incorporated and released from polymeric 
aAPC for increased effectiveness.  
6.2 Methods 
6.2.1 Artificial antigen presenting cell synthesis and characterization 
PLGA artificial antigen presenting cells were synthesized in a two-step core 
particle formation and functionalization.  Particles cores were synthesized from poly 
(lactic-co-glycolic acid) (PLGA 50:50 lactic acid to glycolic acid ratio, MW 34,000-
58,000 Da) that was purchased commercially (Sigma Aldrich; St. Louis, MO).  For a 
typical microparticle synthesis, 100 mg of PLGA was dissolved in 5 mL dichloromethane 
and homogenized into a 50 mL, 1% poly vinyl alcohol (PVA) solution by an T-25 digital 
ULTRA-TURRAX IKA tissue homogenizer at a speed of 5,000 rpm (IKA Works; 
Wilmington, NC).  The resulting microparticle emulsification was then added to 100 mL 
of 0.5% PVA solution.  The dichloromethane was then allowed to evaporate over the 
course of 4 hrs.  After particle hardening, the particles were washed three times in water 
through centrifugation at 3000 g for 5 min.  The washed microparticle solution was flash 
frozen in liquid nitrogen and lyophilized for 1 day prior to characterization and use. 
PBAE/PLGA aAPC were synthesized by mixing PLGA and PBAE at defined 
ratios during the emulsion process. Briefly, PBAEs were synthesized by polymerizing a 
base chain diacrylate group and a hydroxyl amine in solvent free conditions at 90 °C.  
The terminal acrylate groups on the resulting PBAE were end capped with an amine 
coupled functional group to enhance the PBAE efficacy. PLGA was purchased at a 50:50 
wt/wt ratio of monomers. PLGA/PBAE particles were synthesized by single emulsion at 
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a 3:1 PLGA:PBAE ratio with or without a fluorescent dye. After particle hardening, the 
particles were washed three times in water through centrifugation at 3000 g for 5 min.  
The washed microparticle solution was flash frozen in liquid nitrogen and lyophilized for 
1 day prior to characterization and use. 
Functionalization of both PLGA aAPC and PLGA/PBAE aAPC was achieved 
through EDC/NHS chemistry to conjugate carboxylic acid terminated PLGA to amines 
on the proteins of interest.  Lyophilized particles were dissolved in 0.1 M MES buffer at 
pH 6.0 at a concentration of 2 mg/mL.  100 µL of EDC/NHS (Sigma Aldrich; St. Louis, 
MO) stock solution at 40 mg/mL and 48 mg/mL respectively were added to each sample 
and the particles were activated for 30 min.  The resulting surface activated particles were 
washed in PBS through centrifugation at 5,000 g for 5 min.  The particles were 
resuspended in PBS at 2 mg/mL.  8 µg MHC IgG dimer loaded with the antigen of choice 
and 10 µg anti-CD28 monoclonal antibody (mAb) (BD Biosciences; San Jose, CA) was 
added to each sample and the particles were allowed to react with the proteins overnight 
at 4 ºC.  The resulting aAPC were washed 3x in PBS through centrifugation at 5,000 g 
and then dissolved in 400 µL of 100 mg/mL endotoxin free sucrose.  The resulting 
suspension was then lyophilized overnight. 
Particle imaging was conducted with a Leo FESEM scanning electron 
microscope.  To prepare samples for analysis, lyophilized particles were mounted onto 
carbon tape (Nisshin EM Co.; Tokyo, Japan) and placed upon aluminum tacks (Electron 
Microscopy Services; Hatfield, PA).  The excess particles were removed by blowing air 
across the surface of the tack and the sample was then sputter coated with a 20 nm thick 
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layer of gold-palladium.  The samples were then loaded into the microscope and imaged.  
The images were processed in ImageJ to obtain size information. 
To determine the amount of protein on the surface, conjugated aAPC 
microparticles were stained with Alexa Fluor 647 goat anti-mouse IgG for the dimer and 
Alexa Fluor 546 goat anti-hamster IgG for the anti-CD28 (Life Technologies; Grand 
Island, NY) for 1 hour at 4 °C. The particles were subsequently washed with PBS three 
times and fluorescence readings of particles were evaluated for fluorescence with a 
BioTek Synergy 2 plate reader (Biotek; Winooski, VT).  The mass of protein on the 
particle was calculated to evaluate conjugation efficiency. Conjugation efficiency was 
calculated as (Protein Calculated on Particles)/(Protein Added to Conjugation Media) 
*100%.   
6.2.2 Anti-PD1 monoclonal antibody synthesis 
Anti-PD-1 mAb clone G4 was grown from the G4 hybridoma cell line. 
Hybridoma cells were grown in hybridoma serum free media supplemented with L-
glutamine. After one week, the supernatant was harvested and run over a HiTrap protein 
G column (GE Healthcare, Little Chalfont, Buckinghamshire, UK), then eluted according 
to the manufacturer’s protocol. G4 mAb was concentrated by membrane ultrafiltration 
with a Vivaspin 20 50 kDa MWCO (GE Healthcare) and concentration was measured by 
Nanodrop ND-1000 Spectrophotometer. 
6.2.3 In vitro artificial antigen presenting cell T cell stimulation 
To determine the effectiveness of the aAPC at stimulating antigen specific T cells, 
we used primary CD8+ T cells isolated from PMEL or 2C mouse splenocytes. All mice 
were maintained according to Johns Hopkins University’s Institutional Review Board. 
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The mice were sacrificed and then the spleen was dissected out and homogenized through 
a cell strainer.  The CD8+ T cells were then isolated using the Miltenyi CD8a+ Isolation 
Kit (Miltenyi; Auburn, CA).  The cells were then stained with Vybrant Cell Tracker 
carboxyfluorescein succinyl ester (CFSE) (Life Technologies; Grand Island, NY) dye 
following the manufacturer’s protocol.  CFSE stained cells were incubated with the 
particle bearing the antigen of choice at a concentration of 1 mg, 0.1 mg, or 0.01 mg 
aAPC (polymer weight)/100,000 CD8+ T cells in RPMI supplemented with L-glutamine, 
non-essential amino acids, vitamin solution, sodium pyruvate, β-mercaptoethanol, 10% 
FBS, ciproflaxin, and a cocktail of T cell growth factors.  CFSE dilution was then 
assessed after three days of incubation through flow cytometry analysis on a BD 
FACSCalibur. Each generation is defined as a distinct peak of the flow cytometry CFSE 
histogram, as the CFSE dye is diluted in half with each cell division. Generational 
analysis was assessed using the built in function in FlowJo (TreeStar). Total proliferation 
after seven days was assessed by cell counting on a hemocytometer and using a trypan 
blue exclusion test to exclude dead cells.    
6.2.4 In vitro anti-PD-1 mAb functionality assay 
To evaluate the functional effectiveness of the synthesized anti-PD-1 mAb, we 
utilized an in vitro assay of repeated CD8+ T cell stimulation to upregulate PD-1 
expression, as PD-1 expression is low on naïve CD8+ T cells. On day 0, primary 
splenocytes were isolated from naïve 2C transgenic mouse (Jackson Labs; Bar Harbor, 
ME) spleens through cell straining. Cells were treated with 4 mL of ACK lysis buffer for 
1 minute to lyse red blood cells. CD8+ T cells were isolated by negative selection with 
the Miltenyi CD8a+ Isolation Kit following the manufacturer’s protocol (Miltenyi; 
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Auburn, CA). Micro anti-CD3 (145.2C11)/anti-CD28 (37.51) aAPC were synthesized on 
4.5μm M-450 Epoxy Dynabeads (Life Technologies; Grand Island, NY) at a 1:1 protein 
ratio, following manufacturer’s protocol. Anti-CD3 and anti-CD28 antibodies were 
purchased from BioXCell (West Lebanon, NH). 2C CD8+ T cells were mixed with micro 
aAPC at a 1:1 ratio and cultured in RPMI supplemented with L-glutamine, non-essential 
amino acids, vitamin solution, sodium pyruvate, β-mercaptoethanol, 10% FBS, 
ciproflaxin, and a cocktail of T cell growth factors. On day 4, additional T cell growth 
factors and anti-CD3/anti-CD28 beads were added at a 2:1 bead:cell ratio. On day 6, 
B16-SIY and B16-F10 cells were cultured in RPMI supplemented with L-glutamine, non-
essential amino acids, vitamin solution, sodium pyruvate, β-mercaptoethanol, 10% FBS, 
ciproflaxin, and 20 ng/ml recombinant murine IFN-γ (R&D Systems, Minneapolis, MN) 
to upregulate PD-L1 expression. 
On day 8, B16-F10 and B16-SIY were harvested and washed three times to 
remove all IFN-γ, as confirmed by ELISA. CD8+ T cells were also harvested, washed 
three times, and aAPC were removed with a magnet. PD-1 and PD-L1 expression was 
confirmed on CD8 and B16 cells by flow cytometry using fluorescently labeled anti-PD-
1 and anti-PD-L1 antibodies (Biolegend).  CD8+ T cells and B16-SIY or B16-F10 cells 
were mixed at a 1:1 effector target ratio in the presence of 10 µg/ml anti-PD-1 mAb or 
Armenian hamster IgG isotype control antibody. The cells were co-incubated for 18 
hours at 37 ˚C, then supernatants were collected. IFN-γ was measured by ELISA using 
the ebioscience murine IFN-γ Ready-SET-Go! Kit (San Diego, CA).  
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6.2.5 In vitro anti-PD-1 mAb and aAPC assay 
To evaluate the synergistic effect of aAPC and anti-PD-1 mAb treatment, we 
utilized an in vitro T cell and tumor cell co-incubation assay. CD8+ T cells were 
stimulated at a single earlier time-point prior to the start of the assay to allow for resting 
time before the secondary stimulation. On day -5, primary splenocytes were isolated from 
naïve 2C transgenic mouse (Jackson Labs; Bar Harbor, ME) spleens through cell 
straining, and incubated with a 1:1 ratio of anti-CD3/anti-CD28 microbeads as above. 
Additional T cell growth factors and media were added on day -2. On day -2, B16-SIY 
and B16-F10 cells were cultured in the presence of 20 ng/ml IFN-γ, as above. On day 0, 
B16-F10 and B16-SIY were harvested and washed three times to remove all IFN-γ, as 
confirmed by ELISA. 2C cells were also harvested, washed three times, and aAPC were 
removed with a magnet. Cells were stained with PE anti-PD-1, PE anti-PD-L1, PE anti-
PD-L2, and isotype control antibody (Biolegend) and read on a BD FacsCalibur to 
confirm expression. CD8+ T cells and B16-SIY or B16-F10 cells were mixed at a 1:1 
effector target ratio, and anti-PD-1 mAb and PLGA aAPC were added into culture at 
titrating amounts. The cells were incubated for 18 hours at 37˚, then supernatants were 
collected. IFN-γ was measured by ELISA using the ebioscience murine IFN-γ Ready-
SET-Go! Kit (San Diego, CA).  
6.2.6 In vivo particle and cell biodistribution study 
To evaluate the influence of the combination of adoptively transferred cells on the 
biodistribution of our aAPC, we used near infrared (IR) fluorescence to track the aAPC 
upon intravenous administration.  The particles and aAPC were synthesized as previously 
described except that 1 mg of a custom synthesized hydrophobic dye from LI-COR 
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biotechnologies fluorophore (LICOR Biosciences; Lincoln, NE) was added to the 
dichloromethane mixture to be encapsulated into the particles.  Labeled aAPC were split 
up into two different treatment groups. For group 1, Thy 1.2+ C57BL/6 mice (Jackson 
Laboratories; Bar Harbor, ME) received intravenously 2 mg of the IR labeled aAPC 
alone. For group 2, Thy 1.2+ C57BL/6 mice received intravenously 2 mg of IR labeled 
aAPC with 1x106 Thy1.1+ PMEL CD8+ T cells that had been pre-incubated for 1 hour at 
4 °C. Blood was collected retroorbitally at 10, 20, 30, and 40 min post injection to 
monitor elimination from the bloodstream and was imaged in the LI-COR Pearl Impulse. 
At 24 hours, mice were sacrificed and the liver, kidney, spleen, heart, and lung were 
dissected out and imaged in the LI-COR Pearl Impulse (LICOR Biosciences; Lincoln, 
NE) to determine biodistribution of the particles over 24 hrs.  All fluorescence was 
quantified by ImageJ for normalized measurements of particle concentration.  For 
retroorbital bleeds, the data for each mouse was normalized to the fluorescence value of 
the initial time point collected.  This data was then fit to a single exponential decay curve 
using the GraphPad non-linear regression analysis module (GraphPad Software; La Jolla, 
CA).  For organ distribution, the fluorescence readings were normalized to the sum of the 
fluorescence values across all organs to get a percent distribution across the organs 
analyzed.   
6.2.7 In vivo tumor treatment study 
To evaluate the efficacy of dual treatment in vivo we utilized an adoptive 
immunotherapy murine melanoma treatment model.  Thy 1.2+ C57BL/6 mice (Jackson 
Laboratories; Bar Harbor, ME) were inoculated subcutaneously on the right flank with 
3x105 B16-F10 melanoma cells four days prior to treatment.  One day prior to treatment, 
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the mice were irradiated with a central dose of 500 cGy, a sublethal dose to induce 
transient lymphopenia as per standard approaches to adoptive immunotherapy.225  On the 
day of treatment, mice were subdivided into four groups randomly by cage: 1) no 
treatment, 2) CD8 adoptive transfer + anti-PD-1 mAb, 3) CD8 adoptive transfer + aAPC, 
or 4) CD8+ T cell adoptive transfer + anti-PD-1 mAb + aAPC.  All injection volumes 
were 100 µL. All injections were completed intravenously, and group 1 received mock 
injections of PBS, labeled as no treatment control. Group 2 received an injection of 1x106 
Thy 1.1+ PMEL CD8+ T cells and 200 µg of anti-PD-1 antibody intraperitoneally.  
Group 3 received an injection of 1x106 Thy 1.1+ PMEL CD8+ T cells that had been pre-
incubated with 2 mg of PLGA aAPC particles for one hour at 4˚C.  Group 4 received an 
injection of 1x106 Thy 1.1+ PMEL CD8+ T cells that had been pre-incubated with 2 mg 
of PLGA aAPC particles as well as 200 µg of anti-PD-1 antibody intraperatoneally.  One 
day post treatment, Groups 2 and 4 received an additional 100 µg of anti-PD-1 antibody 
intraperitoneally.  At six, ten, and thirteen days post treatment, the mice were bled 
retroorbitally to analyze peripheral blood.  Red blood cells were lysed with 4 min of 
treatment in ACK lysis buffer and then the remaining white blood cells were stained with 
anti-CD8a-APC (BD Biosciences; San Jose, CA) and anti-Thy1.1-Alexa Fluor 488 
(BioLegend).  The cells were then analyzed by flow cytometry on a BD FACSCalibur to 
evaluate the percentage of antigen specific Thy1.1+ CD8+ T cells in the periphery at the 
indicated time points.  Beginning seven days after treatment, all tumor areas were 
measured by multiplying the length of the longest dimension by the length of the 




To evaluate the efficacy of PLGA/PBAE hybrid particles in vivo, wild type 
C57BL/6 mice (n=6/group) were injected with 3x105 B16-F10 cells subcutaneously on 
day 0. On days 4, 11, and 18, half of the mice were treated with 2 mg aAPC 
intravenously. All mice, including the non-treated group, received 200 ug and 100 ug of 
anti-PD-1 monoclonal antibody on days 4 and 5, respectively. Beginning on day 7, all 
tumor areas were measured by multiplying the length of the longest dimension by the 
length of the perpendicular dimension.  The mice were sacrificed once tumor size 
progressed past 200 mm2.  
6.2.8 In vivo CD8+ T cell harvest and analysis 
To further probe the effect of treatment on CD8+ T cells, we used the same in 
vivo set up as used in Section 2.7. However, at day 11 post treatment tumor size was 
measured. Also on day 15 mice were sacrificed and spleen and tumors were harvested 
and homogenized through a cell strainer.  Tumor infiltrating lymphocytes (TILs) were 
isolated by a density separation technique, using Lympholyte-M (Cedarlane; Burlington, 
Ontario, Canada) according to the manufacturer’s protocol. Splenocytes were treated with 
4 mL of ACK lysis buffer for 1 minute to lyse red blood cells. Total immune cells were 
measured from the spleen and TILs with manual counting on a hemocytometer and a 
Trypan blue exclusion test to exclude dead cells. Immune cells were stained with surface 
staining antibodies anti-PD-1-PE/Cy7, anti-Thy1.1-APC, anti-CD8-
APC/Cy7(Biolegend); Live/Dead-FITC (Life Technologies; Carlsbad, CA) for 30 
minutes at 4 °C. No more than 200,000 cells were used for any given condition. One 
sample per treatment group per organ was stained with anti-PD-1 mAb isotype antibody 
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anti-RIgG2a-PE/Cy7. All samples were then washed and analyzed by flow cytometry on 
a BD FACSCalibur.   
To look at the stimulatory potential of CD8+ T cells isolated from tumor-bearing 
animals of this in vivo experiment, we stimulated splenocytes isolated with micro-aAPC. 
Techniques previously described in 2.3. In Vitro Artificial Antigen Presenting Cell T-Cell 
Stimulation were followed with minor modifications. Briefly, micro Db-GP100/anti-
CD28 mAb (37.51) aAPC on 4.5μm M-450 Epoxy Dynabeads (Life Technologies) were 
made at a 1:1 protein ratio, following manufacturer’s protocol. Anti-CD28 monoclonal 
antibody was purchased from BioXCell (West Lebanon, NH). Splenocytes were stained 
with CFSE and Db-GP100/anti-CD28 mAb micro aAPC were added to isolated 
splenocytes at a 1:1 ratio. Total dilution was assessed after three days of incubation by 
flow cytometry. Percent of diluted CD8+ T cells was measured by comparing flow 
cytometry histograms to non-stimulated controls for each condition studied.  
6.3 Results 
6.3.1 PLGA-based aAPC synthesis and characterization 
 PLGA-based aAPC were made as recently described.65 Briefly, the core PLGA 
particle was synthesized by a single emulsion technique.  The particles were subsequently 
functionalized by EDC/NHS chemistry with two proteins to mimic the surface of the 
natural APC which relays two critical signals to CD8+ T cells.65  We used a soluble 
major histocompatibility complex (MHC) Class I-Ig fusion protein to mimic signal 1 in 
the aAPC/CD8+ T cell interaction, and an agonistic monoclonal anti-CD28 antibody to 
serve as a costimulatory molecule to mimic signal 2.66 In this way, the aAPC were able to 
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activate only a particular cognate CD8+ T cell that recognizes the specific MHC with 
loaded melanoma antigen peptide as signal 1. 
Initially we evaluated the physical and chemical properties of the PLGA-based 
aAPC by imaging lyophilized particles by scanning electron microscopy (SEM) to 
determine particle morphology and size (Figure 6-1A).  SEM images revealed that the 
conjugated particles were spherical in nature. Image analysis determined an average 
particle size of 4.42 µm with a standard deviation of 1.45 µm (Figure 6-1B).  We 
designed the aAPC to be approximately 4-5 µm in size as this is large enough to mimic 
the length scale of biological antigen presenting cells and also small enough to avoid 
pulmonary embolism following systemic injection. To evaluate the surface protein 
content, we stained the particles with fluorescent monoclonal antibodies for the 
conjugated proteins, and measured the effect of incubation time of activated particle and 
protein on conjugation efficiency over a 48 hour period (Figure 6-1C).  There is a clear 
increase in both pMHC and anti-CD28 mAb content at longer incubation times, 
maximally approximately 10% and 3% at 48 hours, respectively. Thus, we synthesized 





Figure 6-1.  aAPC characterization and functional assessment. (a) SEM micrographs of conjugated aAPC 
microparticles. (b) Particle size distribution of conjugated aAPC microparticles as evaluated by image 
analysis of SEM micrographs. (c) Particle protein content on aAPC microparticles as evaluated by 
fluorescent antibody staining of the particles and measured by a fluorescent plate reader. Conjugation 
efficiency is defined in Materials and Methods. (d) Antigen specific CD8+ T cell stimulation capabilities of 
aAPC microparticles.  CFSE dilution of CD8+ T cells from either PMEL or 2C TCR transgenic mice 
incubated for 3 days with indicated dose of particles (1 mg, 0.1 mg, 0.01 mg) functionalized with the 
indicated antigen, GP100 or SIY peptide. (e) Generation analysis of CFSE dilution data in (d) indicates 
antigen specific proliferation of PMEL and 2C CD8+ T cells in response to stimulation by Db-GP100 (left) 
or Kb-SIY (right) aAPC microparticles. (f) Fold proliferation calculated by day 7 cell counts after 
stimulation with the Db-GP100 (left) or Kb-SIY (right) aAPC microparticles indicates antigen specific 
proliferation of CD8+ T cells.  Error bars are SEM of n=3 replicates.  
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6.3.2 aAPC stimulate peptide-specific CD8+ T cells 
 Biologically, one of the most important properties of an aAPC is the capability to 
specifically stimulate T cells of interest. To that end we evaluated the ability of our aAPC 
to specifically stimulate CD8+ T cells from two primary transgenic mice (PMEL or 2C) 
whose CD8+ T cells are all specific for the same peptide-MHC.  The particles were 
functionalized with either Db-GP100 (cognate to PMEL CD8+ T cells) or Kb-SIY 
(cognate to 2C CD8+ T cells) peptide-MHC and an anti-CD28 co-stimulatory 
monoclonal antibody. CD8+ T cell activation was quantified by two measurements of 
cell proliferation – CFSE dilution and day 7 cell counts.  
Each particle type was separately incubated with CFSE-labeled 2C or PMEL 
CD8+ T cells, and CFSE dilution was analyzed by flow cytometry after three days. In 
this assay, if the CD8+ T cells are stimulated by the aAPC, they rapidly divide, diluting 
the CFSE dye between daughter cells following each division.  Effective stimulation of 
CD8+ T cells occurred only in the case of a cognate antigen/CD8+ T cell match as seen 
by CFSE dilution (Figure 6-1D). Nearly all CD8+ T cells divided one or more times at 
the highest 1 mg dose of aAPC. CD8+ T cell expansion was dose dependent as evidenced 
by CD8+ T cell generation analysis of CFSE data (Figure 6-1D,E). Nearly 80% of 
PMEL CD8+ T cells divided 4 or more times at a 1 mg particle dose as compared to only 
15% at a 0.01 mg dose. For 2C CD8+ T cells, which have a lower activation threshold, 
robust proliferation was seen across all doses studied (Figure 6-1D,E).   
Cell counts after 7 days of stimulation confirmed the dose-dependence of aAPC-
based activation in both transgenic systems (Figure 6-1F). At the highest aAPC particle 
dose of 1 mg, PMEL CD8+ T cells reached approximately 30-fold expansion and 2C 
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CD8+ T cells reached approximately 20-fold expansion which is similar to our previously 
reported proliferation levels for spherical PLGA aAPCs.65  
6.3.3 Anti-PD-1 mAb and aAPC activate cognate CD8 cells in vitro 
We hypothesized that simultaneous PD-1 blockade would further enhance 
activation of cognate cells for adoptive cell transfer. To investigate this, we first 
developed an in vitro system to mimic some of the major immunosuppressive 
characteristics of the tumor microenvironment. We utilized PD-L1hi target tumor cells 
and pre-activated CD8+ T cells that express PD-1 (Figure 6-2A, schematic).  
To establish the in vitro system, 2C CD8+ T cells were stimulated with cognate 
aAPC on days 0 and 4 to upregulate PD-1 expression. This resulted in elevated PD-1 
expression by day 8 compared to naïve cells (Figure 6-2B). B16-SIY murine melanoma 
cells which express the cognate Kb-SIY pMHC, and noncognate B16-F10 murine 
melanoma cells, were treated with IFN-γ for 48 hours to upregulate PD-L1 expression 
(Figure 6-2C). All IFN-γ was removed from B16-SIY cells from prior treatment, as 





Figure 6-2. aAPC and anti-PD-1 mAb show greater CD8+ T cell activation in combination. (a) Schematic 
of in vitro tumor microenvironment model system. 2C CD8+ T cells were isolated and stimulated with a 
1:1 cell:aAPC ratio and B16-SIY and B16-F10 cells were incubated with 20 ng/ml IFN-γ. Activated 2C 
CD8+ T cells and B16 cells were purified from aAPC and IFN-γ, respectively, and combined at a 1:1 
effector to target ratio with additional aAPC in the presence or absence of anti-PD-1 mAb. IFN-γ release 
was measured by ELISA after 18 hours. (b) CD8+ T cells are PD-1hi after dual aAPC activation (black), 
compared to expression on naive cells (dotted) and isotype (grey). (c) B16-SIY (left) and B16-F10 (right) 
are PD-L1hi after IFN-γ treatment (black) as compared to untreated cells (dotted) and isotype (grey). (d) 
PD-1hi 2C CD8+ T cells and target PD-L1hi B16-SIY (cognate; cog) or B16-F10 (noncognate; noncog) 
were co-incubated at a 1:1 ratio in the presence of 10 ug/ml anti-PD1 mAb or isotype control (iso). Anti-
PD-1 mAb increased CD8+ T cell IFN-γ release as compared to isotype. No IFN-γ release was measured 
in response to CD8+ T cells and noncognate B16-F10 cells incubated with anti-PD-1 mAb. Significance 
was measured by one-way ANOVA with Dunnett’s post-test. (e) CD8+ T cells secrete more IFN-γ in 
response to increasing doses of both aAPC and anti-PD-1 mAb.  Error bars represent SEM, and 
significance compared to no treatment (i.e. no aAPC, anti-PD-1) is shown (* = p<0.05, ** = p<0.01, *** 
= p<0.001). Both aAPC and anti-PD-1 significantly affect IFN- γ (p<0.001; F3,40=226.4 and F3,40=88.32, 
respectively) by two-way ANOVA. 
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To validate that the resultant cell phenotypes can model the effect of PD-1 
blockade in vitro, we first assessed IFN-γ release from CD8+ T cells in response to anti-
PD-1 mAb alone. 8-day activated PD-1hi 2C CD8+ T cells and 48 hour treated PD-L1hi 
B16-SIY cells were co-incubated at a 1:1 ratio in the presence or absence of 10 μg/ml 
anti-PD-1 mAb or isotype control antibody. IFN-γ secretion, a marker of T cell 
activation, was 2.5-fold higher in the presence of anti-PD-1 mAb (Figure 6-2D). 
Importantly, anti-PD-1 mAb did not stimulate CD8+ T cells in the absence of a cognate 
signal 1, indicated by co-incubation with noncognate B16-F10 cells. These results 
demonstrate that this model can assess synergy between anti-PD-1 mAb and aAPC-based 
CD8+ T cell activation in vitro. 
Next, we sought to investigate the combinatorial power of aAPC and anti-PD-1 
mAb treatment in vitro. We hypothesized that this two-hit approach would disrupt the 
inhibitory PD-1/PD-L1 pathway which is upregulated during stimulation and therefore 
lead to greater CD8+ T cell activation by aAPC. 2C CD8+ T cells were stimulated for 
five days with cognate aAPC and B16-SIY cells were primed with IFN-γ as previously 
described. CD8+ T cells and B16 cells were co-incubated at a 1:1 ratio in the presence of 
titrating amounts of cognate PLGA aAPC and anti-PD-1 mAb alone or in combination, 
and response was quantified by IFN-γ release (Figure 6-2A, schematic). While CD8+ T 
cells secreted minimal levels of IFN-γ with no aAPC or anti-PD-1 mAb treatment, and 
either treatment alone increased activation in a dose-responsive manner (Figure 6-2E), 
the combination of aAPC and anti-PD-1 mAb resulted in the greatest activation – over 
3.5-fold more IFN-γ secretion over no treatment. No further increase in IFN-γ release 




6.3.4 PLGA aAPC biodistribution 
We next sought to demonstrate the biodistribution of aAPC with and without 
adoptively transferred CD8+ T cells. PLGA aAPC particles encapsulating a near infrared 
dye were injected intravenously into C57BL/6 mice.  Particles were injected either alone 
or after a co-incubation with cognate CD8+ T cells to assess their impact on particle 
distribution.  We serially collected blood and imaged the samples to track fluorescence of 
the particles (Figure 6-3A).  There was a noticeably faster elimination of the particles in 
the presence of cells compared to particles alone.  A single exponential decay curve was 
fit to each data set, and it was determined that the effective half-life of the aAPC alone 
was 11.6 min and aAPC in the presence of cells was 2.8 min.  At 30 and 40 minutes post 
injection, there were significantly more aAPC particles still in circulation when particles 
were injected alone as compared to particles co-injected with cells. 
 
Figure 6-3. Co-administration of aAPC with CD8+ T cells impacts aAPC biodistribution.  (a) Blood was 
collected retroorbitally following intravenous administration of IR fluorescence labeled particles alone or 
incubated with cells.  Blood was imaged and fluorescence was quantified and normalized to the first time 
point collected. Asterisk indicates time points at which normalized data was significantly different between 
the two groups.  Lines through the points denote first order exponential decay curves fit to the data.  In the 
presence of cells, the aAPC particles are eliminated faster than without cells.  (b) At 24 hrs post-aAPC 
administration, the organs were dissected out, imaged, and quantified for fluorescence.  In the presence of 
cells, the aAPC particles resist getting trapped in the lungs (p<0.05) or the heart (p<0.01), and trend 





24 hours post administration, the animals were sacrificed and the spleen, liver, 
kidney, heart, and lung were harvested for fluorescence quantification (Figure 6-3B).  In 
both the aAPC alone and the aAPC with cells groups the major organs for accumulation 
were the spleen and the liver.  The aAPC in the presence of cells potentially had 60.1% 
greater accumulation in the spleen than the aAPC alone.  With regard to the lung 
(p<0.05) and heart (p<0.01) it was concluded that there were fewer aAPC particles 
trapped in these tissues when the aAPC were in the presence of cells compared to aAPC 
alone.   
This biodistribution study also demonstrated that systemic injection of the aAPC 
particles with or without cells did not cause an acute safety risk such as embolism.  
Systemic injection of these micron-scale biomimetic aAPC is a new administration route 
as we have previously used similar aAPC particles only sub-cutaneously.65  We found the 
intravenous injections to be well tolerated in all animals.  This approach used for the 
biodistribution studies also highlights another potential advantage of these particular 
PLGA aAPC biomaterials as it validates that they are capable of co-encapsulating 
imaging or other agents internally, while orthogonally allowing presentation of 
biomolecules from their surfaces. 
6.3.5 Combination therapy delays tumor growth and extend survival 
 To evaluate the therapeutic potential of combination biodegradable aAPC and 
anti-PD-1 mAb therapies, we assessed their efficacy alone or in combination in an 
adoptive immunotherapy melanoma tumor treatment model.  Thy1.2+ C5BL/6 mice were 
inoculated subcutaneously in the right flank with B16-F10 murine melanoma cells 
(Figure 6-4A, schematic).  Three days later, all mice were irradiated with a sub-lethal 
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dose of radiation to induce transient lymphopenia.  On the following day, naïve cognate 
Thy1.1+ PMEL CD8+ T cells alone or co-incubated with PLGA aAPC were injected 
intravenously into treated mice. Anti-PD-1 mAb was given intraperitoneally on the same 
day and the day after aAPC and CD8+ T cell treatment, as per standard anti-PD-1 mAb 
treatment.  Peripheral blood samples were taken from the mice to evaluate antigen 
specific CD8+ T cell proliferation of the adoptively transferred cells, and tumor size was 
measured every other day.  
Analysis of the circulating CD8+ T cell population revealed a proliferative 
advantage of the adoptively transferred cells in the dual treatment group (Figure 6-4B). 
Significantly higher percentages of Thy1.1+ antigen specific CD8+ T cells were seen in 
the periphery of mice treated with the combined aAPC and anti-PD-1 mAb treatment as 
opposed to aAPC or anti-PD-1 mAb alone.  There was on average a 3-4 fold increase in 
proliferation of CD8+ T cells in the combination treatment group over the anti-PD-1 
mAb alone group and a 2-3 fold proliferative advantage of the combination treatment 




Figure 6-4. Anti-PD1 mAb and aAPC synergize to mediate anti-tumor activity in vivo. (a) Schematic of the 
adoptive transfer experiment. Blue arrows indicate anti-PD-1 mAb treatment, green arrows indicate blood 
sampling days. (b) Percent of CD8+ T cells in peripheral blood that are Thy1.1+.  Anti-PD1 mAb and 
aAPC dual therapy mediated the best proliferation of antigen-specific CD8+ T cells in vivo. Significance 
evaluated with two-way ANOVA with Bonferroni post-test. (c) Tumor measurements indicate an anti-tumor 
response was mediated by the dual therapy group. Significance measured by two-way ANOVA with 
Bonferroni post-test. (d) Kaplan-Meier survival plots indicate that dual therapy mediates the best survival. 
Only combination treatment resulted in significantly extended survival compared to no treatment by Log-
rank test (p<0.01). (e) Survival distributions illustrate a statistically significant survival advantage of the 
dual therapy regimen compared to no treatment and anti PD-1 mAb alone. Significance measured by one-
way ANOVA with Dunnett’s post-test. Error bars represent the standard error of n=4-6 mice/group. 
Results from one representative experiment are shown. Experiment was repeated with the same overall 




 A therapeutic benefit of the combination treatment was also seen as determined 
by inhibition of tumor growth and prolonged survival (Figure 6-4C-E). There was a 
statistically significant reduction in tumor burden for the combination treatment group 
compared to no treatment, whereas either treatment alone had no effect (Figure 6-4C). 
By day 17, the combination treatment group had an average tumor size of 111 mm2 – 
over a 50% reduction in tumor size from the no treatment and single treatment groups 
with all p values being less than 0.01.  Additionally, the survival of the animals was 
extended only in the combination treatment group (Figure 6-4D), with the median 
survival increasing 24% from 17 days for no treatment and all single treatment groups to 
21 days for the combination therapy (Figure 6-4E).  This survival advantage was 
statistically significant compared to the no treatment and anti-PD-1 mAb treatment 
groups.  
6.3.6 Combination therapy increases T cell functionality 
To understand mechanistically how the combination of aAPC and anti-PD-1 mAb 
treatment affects tumor-specific CD8+ T cells in vivo, we analyzed phenotypic and 
functional changes in adoptively transferred CD8+ T cells in the various treatment 
groups. Thy1.2+ C5BL/6 mice were inoculated subcutaneously in the right flank with 
B16-F10 murine melanoma cells and sublethally irradiated after three days. Mice 
received either Thy1.1+ PMEL CD8+ T cells alone or co-incubated with aAPC, and were 
treated with anti-PD-1 mAb as described above. Eleven days after treatment, tumor 
infiltrating lymphocytes (TILs) and splenocytes were harvested and adoptively 
transferred cells were identified by the presence of Thy1.1+ on the cell surface.  
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Thy1.1+ CD8+ adoptively transferred PMEL T cells in the TILs expressed 
significantly higher levels of the immunosuppressive PD-1 molecule in the absence of 
anti-PD-1 treatment (Figure 6-5A). A similar trend was evident in the spleen, where 
adoptively transferred cells expressed higher PD-1 levels in the absence of any additional 
treatment (Figure 6-5B). Additionally, there was about half the percentage of Thy1.1+ 
CD8+ T cells in the spleen of mice lacking aAPC treatment as compared to dual treated 







Figure 6-5. Anti-PD1 mAb and aAPC combination therapy decreases PD-1 expression and increases 
expansion of tumor-specific CD8+ T cells. C57BL/6 mice were inoculated with B16-F10 tumors on day -4 
and sublethally irradiated on day -1. On day 0, mice received an IV injection of PMEL Thy1.1+ CD8+ T 
cells either alone or co-incubated with cognate aAPC. Two of the groups also received an IP injection of 
anti-PD-1 mAb on days 0 and 1. Splenocytes and TILs were harvested on day 11. (a) Thy1.1+ TILs of mice 
not treated with anti-PD-1 mAb had significantly elevated PD-1 expression as compared to dual treated 
mice. (b) Thy1.1+ cells in the spleen of non-treated mice also had significantly elevated PD-1 expression 
as compared to dual treatment. (c) CD8+ T cells within the spleen of mice not treated with aAPC had a 
significantly lower percentage of Thy1.1+ tumor-specific cells as compared to dual treatment. (d) 
Splenocytes were CFSE stained and re-stimulated with Db-GP100/anti-CD28 mAb aAPC, and CFSE 
dilution was assessed after 3 days. There was significantly less expansion of tumor-specific CD8+ T cells 
in mice not treated with aAPC. Significance measured by one-way ANOVA with Dunnett’s post-test 
comparing all groups to dual treatment (*p<0.05, **p<0.01, ***p<0.001). 
 
To investigate the functional capacity of the tumor-specific cells, we studied their 
ability to expand in response to re-stimulation. Isolated splenocytes from each mouse 
were stained with a CFSE dye and re-stimulated in vitro with aAPC expressing cognate 
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Db-GP100 pMHC and anti-CD28 mAb to expand only tumor-specific cells. After three 
days, CFSE dilution was assessed by flow cytometry and expanded cells identified. 
CD8+ T cells from dual treated mice expanded about 2-3 fold more in response to 
antigen-specific re-stimulation than compared to non-treated and anti-PD-1 mAb only 
treated mice (Figure 6-5D). Together, this data shows that dual aAPC and anti-PD-1 
mAb treatment leads to a change in expression of checkpoint molecules and increases the 
proliferative capacity of CD8+ T cells both within the tumor microenvironment and 
secondary lymphoid tissue. PD-1 blockade reduces CD8+ T cell PD-1 expression and 
aAPC treatment increases tumor-specific CD8+ T cell expansion and re-activation 
potential. Thus, combination therapy leads to a superior CD8+ T cell population by 
facilitating both lower expression of the immunosuppressive PD-1 molecule and 
increased proliferative and functional capacity. 
6.3.7 PLGA/PBAE hybrid aAPC outperforms traditional PLGA 
 Next, we sought to develop an aAPC with greater efficacy that could further 
increase the anti-tumor effect, activate an endogenous anti-tumor T cell response, and 
potentially eliminate established tumors upon combination with checkpoint blockade. 
Particle material has been shown to affect the ability to activate a T cell response because 
of changes in protein density, shape, surface charge, size, and stiffness among other 
factors. Particle material can also enable further modifications such as the ability to 
encapsulate drugs or deliver gene-modifying agents. Thus, we assessed the changes in T 
cell activation by aAPC synthesized with polymeric materials demonstrated in other drug 
delivery fields to enable surface protein conjugation, drug encapsulation, and gene 
delivery. The success of this new type of aAPC would allow for exciting combination 
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therapies in future iterations, such as siRNA-mediated knock-down of checkpoint 
molecules that is restricted to antigen-specific T cell populations or paracrine delivery of 
inflammatory cytokines.  
 A blend of PLGA and a poly(beta-amino ester) (PBAE) was chosen as the base 
material for particle synthesis. PLGA enables conjugation of proteins to the surface, 
whereas PBAEs have demonstrated the ability to delivery siRNA intracellular in other 
cell types.226,227 PLGA/PBAE or PLGA only aAPC, each approximately 1 µm in 
diameter, were synthesized by single emulsion and subsequently characterized. SEM 
analysis showed that morphologically the particles we identical in surface features and 
spherical shape (Figure 6-6A-B).  We assessed size via ImageJ analysis of the collected 
SEM micrographs and found the size to be statistically similar after counting 100 
particles each (Figure 6-6C).  In addition, the size distributions were essentially identical 
between the two particle populations (Figure 6-6D). 
PLGA/PBAE hybrid or PLGA aAPC were conjugated with Kb-SIY dimer signal 
1 and anti-CD28 mAb signal 2 via EDC/NHC chemistry. To characterize the amount of 
protein immobilized on the surface of the particles, we used signal 1 and signal 2 proteins 
pre-conjugated to fluorophores and assessed fluorescent content of the particles after 
protein conjugation (Figure 6-6E).  Interestingly, we found that the PLGA/PBAE 
particle immobilized a significantly higher amount of protein after the conjugation 
compared to the PLGA particles and that a large fraction of the protein was bound non-
specifically in the absence of conjugation reagents. PLGA/PBAE aAPC thus increase the 
maximum achievable signal density on the particle surface, a characteristic shown to be 




Figure 6-6. PLGA/PBAE and PLGA particle characterization.  SEM images of (a) PLGA and (b) 
PLGA/PBAE microparticles synthesized by single emulsion. (c) Average size and standard error of 100 
representative particles for both materials. (d) Size distributions for particles for both materials. (e) 
Protein conjugation efficacy for PLGA and PLGA/PBAE particles with and without EDC/NHS conjugation 
reagents. 
 
To assess the stimulatory potential of the PLGA/PBAE hybrid particles, PLGA or 
PLGA/PBAE particles were incubated with cognate 2C transgenic CD8+ T cells at 
titrating doses. All CD8+ T cells from a 2C transgenic mouse recognize the Kb-SIY 
peptide MHC complex making it a useful system for studying CD8+ T cell activation 
potential in vitro. PLGA/PBAE aAPC resulted in equivalent expansion of 2C CD8+ T 
cells as their PLGA counterparts at 100X lower doses (Figure 6-7A-B). We then studied 
how changing the length of the carbon chain in the PBAE backbone affects the 
stimulatory potential of the hybrid particles. Our standard PBAE has a 4 carbon length 
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chain, and we studied the effect of 3 and 5 carbon length chains. Interestingly, this had no 
effect on CD8+ T cell activation across three doses–all PLGA/PBAE hybrid aAPC 
stimulated cells to a greater extent than PLGA aAPC (data not shown). The effect of 
PBAE ratio in the hybrid particles was also investigated as it affects T cell activation. 
This is important to study, as the PBAE ratio alters the biodegradation rate as well as 
siRNA encapsulation ability. It may therefore be necessary to slightly alter the PBAE 
ratio to optimize future plans for siRNA encapsulation and in vivo kinetics. The standard 
hybrid particles contain 25% PBAE and were compared to particles containing 15% 
PBAE. Again, this resulted in no difference in CD8+ T cell stimulatory potential (data 
not shown). Thus, PLGA/PBAE hybrid particles are robust stimulators of a cognate 
CD8+ T cell response and are relatively insensitive to PBAE construct and concentration. 
 
 
Figure 6-7. PLGA/PBAE hybrid particles activate cognate CD8+ T cells. (a) Fold expansion of 2C CD8+ 
T cells incubated with Kb-SIY/anti-CD28 PLGA or PLGA/PBAE aAPC, normalized to 1 mg PLGA. 
Significant by two-way ANOVA (p<0.05). (b) Representative total expansion of 2C CD8+ T cells incubated 
with PLGA or PLGA/PBAE aAPC. 
 
For optimal activity of the hybrid particles, it is important for the aAPC to have 
high specificity for cognate cells expressing the correct signal 1. Thus, to further study 
how the PLGA/PBAE particles interact with the cells of interest, we performed confocal 
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microscopy and flow cytometry with aAPC encapsulating a fluorescent dye. Confocal 
microscopy showed that the PLGA/PBAE aAPC bound cognate but not non-cognate 
CD8+ T cells, as expected (Figure 6-8A). Additionally, PLGA/PBAE aAPC bound 
cognate cells at a higher frequency than PLGA only aAPC, as shown by 2D and 3D 
reconstructed images (Figure 6-8B). The higher binding capacity was further confirmed 
by flow cytometry. Neither aAPC showed significant binding to non-cognate cells. 
However, the hybrid aAPC bound more cells and at a higher level than the traditional 
PLGA aAPC (Figure 6-8C).  
 
 
Figure 6-8. PLGA/PBAE bind cognate cells at a higher level than PLGA aAPC. (a) Confocal images show 
PLGA/PBAE aAPC (red) bind cognate cells (green) at a higher frequency than PLGA aAPC (red). (b) 3D 
reconstruction of confocal image. (c) Flow cytometry showing higher binding of PLBA/PBAE aAPC to 
cognate cells than PLGA aAPC. 
 
Finally, we assessed the ability of our PLGA/PBAE aAPC to inhibit tumor 
growth in vivo. We investigated this in a tumor treatment study without any adoptive 
transfer of tumor-specific cells. PLGA/PBAE aAPC were synthesized as above, and 
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conjugated with Kb-trp2 and Db-gp100 signal 1, and anti-CD28 mAb signal 2. Wild type 
C57BL/6 mice (n=6/group) were injected with 3x105 B16-F10 cells, which express Kb-
trp2 and Db-gp100, subcutaneously on day 0. On days 4, 11, and 18, half of the mice 
were treated with 2 mg aAPC intravenously. All mice, including the non-treated group, 
received 200 ug and 100 ug of anti-PD-1 monoclonal antibody on days 4 and 5, 
respectively, a dose we have shown to have no effect on tumor growth when given as a 
monotherapy (data not shown). Mice that received aAPC injection had significantly 
delayed tumor growth (Figure 6-9A). Additionally, treated mice lived significantly 
longer – non-treated mice died on day 13 on average, while aAPC treatment extended 
this until day 16 (Figure 6-9B). 
 
 
Figure 6-9. PLGA/PBAE aAPC inhibit tumor growth. C57BL/6 mice were inoculated with B16-F10 tumors 
on day 0. Mice were treated with anti-PD-1 mAb +/- PLGA/PBAE aAPC expressing Db-gp100 and Kb-
trp2. (a) PLGA/PBAE aAPC treatment inhibits growth of established B16-F10 tumors. (b) Treatment also 
extends survival. 
 
6.4 Discussion and conclusions 
Stimulating a tumor-specific cytotoxic CD8+ T cell response is a promising 
approach in cancer immunotherapy, although several hurdles still exist in generating a 
population of cells that is both optimally effective and persistent. Often, very large 
numbers of activated T cells, up to 1011,68 are necessary for an objective response. 
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Advancements in biomimetic and biodegradable aAPC have made robust activation for 
clinical therapy possible, although strong activation upregulates immunosuppressive 
surface molecules on the CD8+ T cells such as PD-1. As progress is made in the field of 
biomaterials for robust T cell activation, it is likewise necessary to understand their 
interaction with other conventional immunotherapeutics, including new clinical standards 
of care, to counterbalance the resultant inhibitory phenotype. 
Here, we have characterized the synergistic interaction between biodegradable 
PLGA aAPC and PD-1 checkpoint blockade for murine tumor control in an adoptive 
transfer model. PLGA-based aAPC were chosen as they are effective T cell stimulators, 
and, due to well-known experience with PLGA particles in the body, offer translational 
potential for tumor-specific CD8+ T cell expansion in vivo. We showed antigen-specific 
stimulation of CD8+ T cells in response to PLGA aAPC conjugated with two different 
peptide-MHC complexes. The aAPC are able to induce robust expansion in each of the 
tested cell types.   
However, the immune system has developed ways to self-regulate itself by 
upregulating immunosuppressive molecules in response to activation. In this nature, 
activated CD8+ T cells express high levels of PD-1 which is important biologically to 
control autoimmunity, but detrimental in cancer immunotherapy where a strong anti-
tumor response is desired. Tumors take advantage of this biological process and express 
the ligand for PD-1, PD-L1, to inhibit an anti-tumor CD8+ T cell response. Our in vitro 
model of PD-1hi CD8+ T cells and PD-L1hi tumor cells, mimicking those that would be 
found within the tumor microenvironment of a patient, showed increased CD8+ T cell 
activation in response to the combination of aAPC stimulation and PD-1 blockade. While 
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both therapeutics alone increased activation, the combination was able to stimulate CD8+ 
T cells while turning off their “rheostat” and led to a further enhanced antigen-specific 
response.  
We also sought to study the effectiveness of combination treatment in vivo since 
the dynamics of the tumor microenvironment can play a significant role in the response. 
The aAPC were first demonstrated to circulate systemically, both with and without a co-
injection of cognate CD8+ T cells. When aAPC were co-injected with CD8+ T cells, they 
spent less time in circulation and accumulated less in off-target sites such as the lung and 
heart. This comparison is both interesting and important, as the intrinsic honing 
capabilities of CD8+ T cells may cause accumulation of aAPC in immune-dense sites. 
Indeed, we did see a trend towards higher aAPC accumulation in secondary lymphoid 
tissue - the spleen. While this >50% change in distribution was not significant under the 
conditions studied, it may help to explain the statistically shorter circulation half-life of 
particles co-injected with cells along with the greater accumulation of tumor-specific 
CD8+ T cells in the spleens of mice treated with particles and cells in vivo.  
Combination of aAPC expressing tumor antigens and anti-PD-1 mAb treatment 
resulted in delayed tumor growth and extended survival in vivo in an adoptive transfer 
model. Importantly, this is the first time this PLGA aAPC-based therapeutic was effective 
in a therapeutic rather than prophylactic tumor model as well as the first time that it has 
been evaluated following systemic administration.65 The therapeutic effect was shown to 
be due to increased proliferation of the adoptively transferred tumor-specific cells both in 
the peripheral blood and spleen in response to aAPC transfer, as well as decreased PD-1 
expression by these cells in the spleen and tumor in response to anti-PD-1 mAb 
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treatment. Importantly, this strong stimulation of the tumor-specific CD8+ T cells did not 
lead to unresponsiveness—CD8+ T cells from the spleen of the dual treatment group also 
expanded the greatest amount upon re-stimulation ex vivo.  
Finally, we synthesized and characterized a new hybrid material that increases the 
activation potential of aAPC. These PLGA/PBAE aAPC demonstrated maximal T cell 
proliferation at doses 100x less than PLGA alone. The data suggests that this is due to 
significantly enhanced protein conjugation, leading to a higher signal density and 
increased binding to cognate T cells. This new aAPC material is exciting not only 
because of the improved activation that could potentially further increase anti-tumor 
activity when combined with anti-PD-1 mAb, but also because of the doors it opens for 
next generation aAPC. PBAE-based particles have been shown to efficiently deliver 
intracellular genetic material to cells and can be used to create a dual-functioning aAPC 
in future work. For example, siRNA that knocks down expression of inhibitory molecules 
like PD-1 could be encapsulated within the aAPC and activate clonal T cell populations 
on an extracellular (i.e. aAPC) and intracellular (i.e. siRNA delivery) level. This may 
lead to a new therapeutic capable of eradicating established tumors and decreasing side 
effects experienced with systemic immune activation. 
In summary, anti-PD-1 immunotherapy unleashes more of the aAPC-activated 
CD8+ T cells to perform effector function whereas without anti-PD-1 mAb therapy more 
aAPC-activated CD8+ T cells were ineffective due to the immunosuppressive tumor cells 
expressing PD-L1. Furthermore, aAPC activate and increase the number of CD8+ T cells 
that anti-PD1 therapy can target and affect. CD8+ T cells not activated by aAPC do not 
proliferate as much or upregulate PD1, thus decreasing the total effect of the checkpoint 
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blockade immunotherapy. Therefore, both therapies complement and synergize to 
provide a more potent tumor immunotherapy. 
 Here we have developed a biomaterial-based combinatorial cancer 
immunotherapy.  This therapeutic simultaneously activates cytotoxic CD8+ T cells while 
reducing the immune dampening effects of the tumor microenvironment.  We have 
developed a biomimetic PLGA-based aAPC that can, in an antigen specific fashion, 
stimulate cancer-targeting CD8+ T cells and synergize with PD-1 checkpoint blockade.  
The aAPC particles generate a cytotoxic response against melanoma cells in vitro and, for 
the first time, these aAPC have been shown effective in an in vivo tumor treatment model 
following a single intravenous injection. The combined therapy was able to mediate a 
reduction in tumor burden and increase median survival time. As the aAPC are composed 
of PLGA, a biodegradable material that has a track-record of safe use in the clinic with 
related technologies, these advanced immunostimulatory materials may be promising for 










Chapter 7. Conclusions 
7.1  Summary of work 
Cancer immunotherapies aim to increase the ability of a patient’s immune system 
to recognize and eliminate cancerous cells. The immune system is complex and involves 
both antigen-specific recognition, such as the case of the T cell receptor on T cells, as 
well as non-antigen-specific modulators, including co-stimulatory molecules, co-
inhibitory checkpoint molecules, and cytokines. Current immunotherapies target one or 
more of these various pathways with the goal of stimulating the most robust anti-tumor 
response with minimal systemic effects.  
Artificial antigen presenting cells, aAPC, are one of the most common approaches 
for antigen-specific T cell stimulation. These synthetic particles present a tumor antigen 
in the context of an MHC molecule along with the necessary co-stimulatory signals. 
Synthetic aAPC have many advantages over cell-based APC because of their ability to be 
engineered to explicit specifications and reduced cost and extended shelf-life. However, 
aAPC have been limited by their ability to induce a sufficiently persistent and robust anti-
tumor T cell response capable of eliminating established tumors.  
Due to the complexities of the nano- and micro-scale interactions necessary for T 
cell activation, aAPC that are several microns in diameter are the most effective at 
stimulating T cells. However, their reduced biocompatibility makes micron-scale 
particles infeasible for in vivo because of their rapid clearance and poor bioavailibility. In 
this dissertation, I described how aAPC efficacy can be improved through combination 
therapies and by altering particle material and surface protein composition. Chapter 6 
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showed how simply modifying the material of the aAPC platform can increase activation 
up to 100x. Previous work from our lab demonstrated how magnetic field-induced 
clustering could increase T cell activation induced by nano-aAPC. In Chapter 5, I 
described how this type of approach could be further improved to more than double the 
stimulatory potential of nano-aAPC. No previous aAPC platforms were optimized to take 
advantage of the diversity of co-stimulatory molecules that affect T cell phenotype and 
function. However, the importance of this was demonstrated by the fact that the 
incorporation of additional co-stimulation significantly extended T cell persistence in 
vivo following adoptive transfer. Additionally, due to the nature of the approach, it also 
provides a mechanism for analyzing the necessity of nano-and micro-scale clustering of T 
cell signaling molecules or signal clustering on other types of immune or non-immune 
cells. This information could be further used to improve more biocompatible aAPC.  
In addition to directly increasing T cell stimulation through the modification of 
the aAPC platform, Chapter 6 demonstrated how direct aAPC-induced T cell stimulation 
can be improved through combination immunotherapy. Biodegradable aAPC were shown 
to synergize with anti-PD-1 mAb checkpoint blockade and delay tumor growth at doses 
where neither treatment alone had any effect. These studies begin to bring nano-aAPC 
into the playing field for adoptive cell transfer. The data also indicates that improvements 
in aAPC-based activation can take the form of engineering enhancements or 
combinations with therapies that target activation through non-overlapping pathways.  
aAPC have the advantage of targeting antigen-specific T cells. However, this 
requires a priori selection of a tumor antigen which can be difficult, expensive, and allow 
for antigen-escape. The opposing approach is to target pathways that are utilized by all T 
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cells, the downside being that non-specific immune activation may lead to off-target 
toxicities. Thus, I described in Chapter 4 how nanoparticles can both increase the synergy 
between combination non-specific immunotherapies, as well as target the drug delivery to 
the tumor site to decrease off-target effects. I demonstrated how these immunoswitch 
particles can reverse or eliminate tumor growth as a standalone therapy to stimulate a 
polyclonal anti-tumor immune response that forms a memory response.  
Together, these approaches demonstrate the various ways by which 
nanotechnology can be used to improve immunotherapies and study T cell activation. 
Many of the studies also utilize combination immunotherapy, combining T cell activation 
with checkpoint blockade, which has been shown by others as well to significantly 
improve the anti-tumor immune response.  
7.2  Future directions 
 Much of the work presented here is primarily proof-of-concept studies with 
various interesting future directions. In terms of the immunoswitch particles described in 
Chapter 4, next steps include further optimization of the platform and analysis of the 
mechanism of action. For example, the particles were constructed with a 1:1 anti-PD-1 to 
anti-4-1BB mAb ratio on 100 nm particles, but other ratios or other particle sizes may 
prove to be more efficacious. Altering the relative antibody densities may affect their cell 
targeting abilities or biodistribution in vivo. Likewise, we predict that the size of the 
particle will have an impact on efficacy. Smaller particles may be preferential in terms of 
the resultant intercellular distance, but may have conflicting effects compared to the size-
induced change in biodistribution or avidity. Immunoswitch particles may also have 
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further increased efficacy if pre-coated on tumor-specific CD8+ T cells prior to adoptive 
cell transfer.  
It will also be important to perform immunohistochemistry experiments and in 
vivo imaging to assess immunoswitch particle interactions within the tumor 
microenvironment. The data presented here indicates that primarily a CD8+ T cell 
response is induced, although it does not prove that the response is caused by a direct 
interaction with immunoswitch particles and tumor cells in vivo. Other immune cell types 
express both PD-L1 and 4-1BB including dendritic cells and CD4+ T cells and the 
interaction of immunoswitch particles with these other cell types may also play a role. 
Finally, TCR sequencing analysis demonstrated that immunoswitch particles select for 
the expansion of a single T cell clone in the B16-SIY murine melanoma model. 
Experiments to determine if this type of response is preserved against other tumors 
lacking a dominant antigen and the impact of this monoclonal-skewed response would be 
interesting and important.  
The T cell stimulation platform described in Chapter 5 showed how this approach 
can be used to manipulate various aspects of activation. I demonstrated how altering the 
size or material of particles can alter the clustering of different signaling molecules. It 
would be interesting to use this approach to study the impact of clustering of other less-
studied co-stimulatory molecules such as OX40 or CD40L, or on other immune or non-
immune cell types. I also demonstrated how this platform can be used to customize the 
ratio and combination of co-stimulation and how this affects T cell phenotype. Future 
studies that utilize this platform to further investigate the importance of additional co-
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stimulatory combinations would be interesting and important to the future of adoptive 
immunotherapy.  
Chapter 6 demonstrated how checkpoint blockade synergizes with micro-scale 
aAPC. Further studies to investigate if this synergy is maintained with more 
biocompatible nano-aAPC would be important to the field. Additionally, the polymeric 
particles could potentially have anti-PD-1 mAb secreted from their core to localize the 
delivery of checkpoint blockade to cognate T cells. Further optimization should also be 
conducted for the PLGA/PBAE hybrid aAPC. This particle formulation was originally 
chosen due to its potential ability to encapsulate and deliver genetic material in other cell 
types. Interesting future work would explore the potential to encapsulate siRNA to 
selectively give cognate T cells a proliferative advantage, such as an siRNA to turn off 
PD-1 expression. The polymeric aAPC could then be used to both activate cognate T 
cells at a cell membrane level, as well as genetically modify the T cells to reduce the 
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